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Abstract 
 
Many cancers, including melanoma and breast cancer, metastasize via the lymphatic 
system, a mono-directional network of vessels and nodes that parallels the circulatory system.  
Accurate determination of the lymph nodes involved in the early lymphatic spread of the primary 
tumor is paramount for survival of the patient.  Melanoma and breast cancer, when detected early 
offer promising 5-year survival rates of more than 90%; however, once the metastases have 
spread beyond the lymph node basin draining the primary tumor, the typical first metastatic site, 
to successive lymph nodes or organs, the 5-year survival dramatically drops to less than 20%.  
However, conventional systemic chemotherapy offers limited penetration into the lymphatic to 
treat lymphatic metastases, and often the dose limiting toxicities associated with systemic 
chemotherapy limit the dose to below that needed for effective treatment.  Therefore, there is a 
great need to develop localized treatment and imaging agents for the delivery and identification 
of the tumor lymphatics and metastases, which can offer enhanced detection and improved 
efficacy and reduced toxicity over systemic therapy.  Specific targeting of the lymphatics is 
possible by utilizing the natural structure of the lymphatic capillaries by tailoring the size and 
charge of the carriers to 10 to 100 nm in diameter and modifying the surface charge to be neutral 
to anionic in nature.    
 Herein this dissertation focuses on the development and optimization of two different 
polymeric platforms for enhanced lymphatic uptake by tailoring the size and degree of anionic 
charge, utilizing hyaluronan and star polymers, respectively, as intralymphatic delivery platforms 
for the use in imaging and treatment of lymphatically metastatic cancers, such as melanoma and 
breast cancer.  Further, the development of a geldanamycin-polymer conjugate utilizing the 
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optimized star polymer and evaluation of its efficacy in three orthotopic tumor models for 
melanoma and breast cancer will also be discussed. 
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Chapter 1.  Introduction 
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1.1  Objectives and Thesis Overview 
The objectives of this work are to develop and optimize the size and charge of polymeric 
nano-carriers for localized lymphatic imaging and drug delivery, and to develop a intralymphatic 
chemotherapy using one of the optimized polymeric nano-carriers for the treatment of 
lymphatically metastatic cancers, such as melanoma and breast cancer.  This work can be divided 
into three parts:  1) Development of hyaluronan (HA)-fluorescent dye conjugates and the 
molecular weight optimization of the HA-dye conjugates for intralymphatic delivery utilizing 
whole body fluorescent imaging; 2) Development of star polymer-fluorescent dye conjugates and 
the optimization of the degree of negative charge required for intralymphatic delivery utilizing 
whole body fluorescent imaging; and 3) Development of a star polymer-geldanamycin conjugate 
(Star-GA) for the intralymphatic delivery and determination of the in vitro and in vivo efficacy of 
Star-GA in melanoma and breast cancer. 
The following chapter will provide a brief background on the physiology of the 
lymphatic system and how cancers metastasize, followed by examples of clinical and preclinical 
lymphatic imaging and drug delivery platforms that exploit the physiology of the lymphatics and 
the natural lymphatic progression of cancer allowing for the specific lymphatic targeting for 
medical diagnosis, imaging, and drug delivery.  Both of which lay the foundation for purpose of 
this work of developing and optimizing two different lymphatic imaging and drug delivery 
carriers, and the evaluation of their use as a lymphatic drug delivery carrier for the treatment of 
melanoma and breast cancer.   
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1.2  Introduction 
Many cancers, including melanoma, breast, colon, lung, and ovarian, spread or 
metastasize via the lymphatic system, a mono-directional network of vessels and nodes that 
parallels the circulatory system [1,2].  Accurate determination of the lymph nodes involved in the 
early lymphatic spread of the primary tumor is paramount for survival of the patient.  In 
melanoma and breast cancer, the first metastatic site is usually the lymph node basin draining the 
primary tumor [3,4].  It is possible to specifically target the lymphatics utilizing the natural 
structure of the lymphatic capillaries, which have pores of approximately 100 nm in diameter, by 
tailoring the size of bimodal imaging and drug carriers to be 10 to 100 nm in diameter.  By 
exploiting the physiology of the lymphatics along with the pathology of cancer spread, we can 
localize imaging agents and chemotherapeutics to the lymphatics, where the metastases reside.  
Localized lymphatic delivery of multimodal imaging and drug carriers will allow the accurate 
identification of the diseased nodes and along with treating the primary tumor and metastases.  In 
addition, this approach will minimize toxicities associated with systemic administration of 
cytotoxic chemotherapeutics and maximize the localized dose to the affected tissues, with the 
potential to significantly increase the treatment efficacy.  
 
1.3  Lymphatic System and its Role in Drug Delivery 
 
1.3.1  Physiology of the Lymphatic System 
The lymphatic system is a unidirectional network of capillaries, vessels, and nodes that 
parallel the systemic circulation.  Lymphatics are found virtually everywhere in the body where 
blood vessels are present, with the exception of the central nervous system.  The propulsion of 
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the lymph is mainly driven by muscle contractions and relaxations, although increased muscular 
activity will increase the interstitial pressure resulting in an increase in the lymph flow.  The 
presence of one-way valves throughout the lymphatic vessels prevents backflow and assists in 
the lymph propulsion.  The primary function of the lymphatic system is to maintain fluid balance 
and absorption of plasma proteins and cellular waste materials from the extracellular space and 
returning them to the systemic circulation [5-8].   
The interstitium is the space between the capillary walls and the cells in the tissue.  Its 
structure is similar to that of tissue, in that it is a fibrous network of collagen and reticular fibers 
embedded in a gel-like ground substance.  The fibrous network provides physical support for the 
interstitium.  The ground substance is composed of glycosaminoglycans (GAGs), salts, and 
plasma proteins [5,9].  The GAGs are polyanionic, unbranched, polysaccharides consisting of 
disaccharide units of an amino sugar and an uronic acid [9,10].  With the exception of 
hyaluronan (HA), the GAGs are covalently bound to a protein and are referred to as 
proteoglycans.  However, the major GAG in the skin is HA, which accounts for approximately 
two thirds of the total GAG content [9].  Further, about one half of the total HA in the body is 
found in the dermis and epidermis [9,11].  The GAGs are ionized at physiological pH resulting in 
a net negative charge of the ground substance.  Within the interstitium, there are areas of 
aggregated and disaggregated polysaccharides forming narrow aqueous channels with diameters 
of 100 nm [5]. 
The interstitial fluid that drains from the interstitium through the lymphatics is referred to 
as lymph.  The lymph and plasma components are essentially the same, but are present at 
different concentrations, which may vary based on their location.  Some of the major 
components in both the plasma and lymph are:  proteins, enzymes, lipids, and electrolytes.  The 
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proteins found in the plasma are also in the lymph, but at a lower concentration; for example, the 
protein concentration in the thoracic duct lymph is approximately 60% of that found in the serum.  
Similarly, most of the enzymes found in the plasma are also present in the lymph.  However, in 
the tissues that produce the enzymes, their concentrations are higher in the lymph than in the 
plasma, suggesting that the primary route of these enzymes entering the plasma is through the 
lymphatics.  The lipid concentration in the lymph is also lower than that of the plasma, with the 
exception of the intestinal lymph.  Finally, the concentration of the electrolytes is similar in both 
the lymph and plasma, however, the cation (Na+, Ca2+, K+, and Mg2+) concentration is slightly 
lower, and the anion (Cl- and HCO3-) concentration is slightly higher in the lymph than the 
plasma [5,7]. 
The physiology and size of the lymphatic capillaries and vessels vary along the course of 
the lymphatic network.  The initial or terminal lymphatic capillaries are the smallest in nature (10 
to 60 µm), but unlike blood capillaries, lymphatic capillaries consist of a single layer of non-
fenestrated endothelial cells and lack a continuous basal lamina [5-7].  Anchoring filaments 
between the outer portion of the plasma membrane of the endothelial cells and the interstitium, 
provide the structural support of the capillaries.  Along the initial lymphatics, there is a 
considerable amount of overlap of the endothelial cells and gaps within the intercellular 
junctions, leading to the formation of clefts and pores along the capillary wall.  When the 
interstitial pressure exceeds the intraluminal lymphatic pressure, these clefts and pores are 
“opened” allowing for the passage of macromolecules into the lymphatic capillaries [5-7].  This 
is an important property of the lymphatic capillaries that leads to the ability to natural “recycling” 
of extracellular proteins, fluids, and lipids, to the systemic circulation via the lymphatics.  
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 The initial lymphatics merge into the collecting lymphatics, which drain to the lymph 
nodes.  The collecting lymphatic capillaries are larger in size (0.5 to 0.75 mm in diameter) [6,8], 
also the emergence of thicker walls and valves distinguish the collecting lymphatics from their 
predecessors.  This increase in wall thickness is due to the appearance of a connective tissue and 
smooth muscle, and they eventually progress to having a trilaminar structure, resembling more 
that of blood vessels.  In addition to fewer open junctions, the basal lamina is continuous.  
Because lymphatic system lacks a “pump”, the presence of the smooth muscle allows for vessel 
contractions to help propel the lymph.  Additionally, to prevent back-flow, there are valves, 
usually unicuspid or bicuspid in nature, at regular intervals along the lymphatic vessels [5-7].   
The afferent lymphatic vessels are the collecting lymphatics from the peripheral tissue 
that drain into the lymph nodes through the subcapsular sinus of the node.  The efferent 
lymphatic vessels, vessels from the lymph nodes, upon exiting from the hilum of the node merge 
to form post-nodal vessels, which either lead to the successive lymph nodes or larger lymphatic 
vessels.  These vessels have a similar structure to that of the collecting lymphatics, but are 
equipped with thicker walls, larger lumina, and tricuspid valves.  These larger lymphatic vessels 
combine with the lymphatic trunks, which eventually drain into the thoracic duct and the right 
lymphatic ducts that return the lymph to the systemic circulation through the internal jugular and 
right subclavian veins, respectively [5,7].   
The lymph nodes are kidney bean shaped dense masses of tissues located throughout the 
lymphatic system, they are highly compartmentalized and are usually found in principal groups 
near the blood vessels for which there are named.  In the average adult, there are anywhere from 
500 to 1000 lymph nodes of 1 mm to 1 cm in diameter [7].  The two main functions of the lymph 
nodes are:  1) to serve as a filter for the lymph, and 2) carry out immunological functions [5,7].  
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The lymph enters the node through the afferent lymphatics into the subcapsular sinus, 
progressing through the cortical and then the medullary sinuses, finally exiting the node through 
the hilum to the efferent lymphatics [5,7].  The sinuses are lined with fixed or stationary 
macrophages along with having mobile macrophages that can act as both antigen presenting cells 
and as a filter for the removal of antigens and non-!antigenic particulates [5]. 
 
1.3.2  Lymphatic Spread of Cancer 
 Cancer cells can metastasize via the lymphatics, circulatory system, or by invading local 
tissues; however, many cancers, including melanoma and breast cancer, metastasize 
preferentially via the lymphatics [2-4].  As early as the late nineteenth century, Halstead 
theorized that breast cancer is a localized disease that metastasizes through the lymphatics to the 
regional lymph nodes (RLN).  Today it is well-established that cancers can progress 
lymphatically without systemic involvement [1].  The process of lymphatic metastasis follows a 
stepwise progression from the primary tumor to the regional lymph nodes through the 
intervening lymphatic vessels.  Once metastases are established in the sentinel lymph node 
(SLN), the further metastatic progression can continue through the draining lymphatics and 
eventually enter the systemic circulation to form distant metastases.  However, direct 
hematological metastasis can proceed without SLN involvement; though, we are primarily 
interested in the lymphatic route of metastasis and treatment.   
 The general metastatic pathway via the lymphatics is thought to be similar in all 
vertebrates.  Once the primary tumor growth reaches a critical mass [4], it secretes 
lymphangiogenic cytokines to induce the formation of new lymphatic capillaries, also known as 
lymphangiogenesis [1].  Invading tumor cells can then enter the extracellular matrix (ECM), 
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where they can then enter the new lymphatic vessels with the lymph due to the increase in 
interstitial pressure.  Further, as the tumor grows, the intratumoral interstitial fluid pressure 
increases, resulting in an increase in the interstitial fluid volume, thus causing the anchoring 
filaments to widen the lymphatic lumen and open the intercellular junctions; allowing for uptake 
of fluid and cells into the lymphatics [1].  Although many cancers are reported to have non-
functional intratumoral lymphatics, functional lymphatics have been identified within the tumor 
margin (<100 µm from the tumor edge) [2,12,13].  Once the cancer cells enter the lumen of the 
lymphatic capillaries, single cell or clustered embolisms, “in-transit” metastases, are formed in 
the draining lymphatics to the RLNs.  The surviving “in-transit” metastases can either adhere to 
the lymphatic endothelium, proliferate, and invade the surrounding tissue, or enter the afferent 
lymphatics of the SLN.  Once the “in-transit” metastasis has entered the SLN, the cells can 
invade the LN cortex forming a lymph node metastasis or continue through the lymphatics to the 
subsequent LNs [1]. 
 In both breast cancer and melanoma, the first site of metastasis is usually the regional 
lymph node basin [3,4].  Further, lymphatic vessel growth within the tumor has been shown to 
have a positive correlation with the metastatic spread of melanoma, breast and head and neck 
cancers [14].  The use of sentinel lymph node biopsies, discussed in the next section, has been 
used for the clinical staging of melanoma and breast cancer since the early 1990s [15].  Where 
the lymph nodes that test positive for micrometastases by pathology are identified and removed, 
potentially saving the patient from a complete lymphadenectomy of unaffected nodes or a radical 
mastectomy.  In spite of this, nanometastases are often overlooked leading to relapse. 
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1.4  Lymphatic Imaging and Drug Delivery 
Imaging of the lymphatics plays a role in disease discovery and diagnosis, as many 
cancers metastasize via the lymphatic system, including:  melanoma, breast, colon, lung, and 
ovarian cancers [1,2]; accurate determination of the lymph nodes involved in the early lymphatic 
spread of the primary tumor is paramount for survival of the patient.  In melanoma for example, 
the five year survival rates are >90%, 40-60%, and 15-20%, if the primary tumor is small (<1-2 
mm thick) and completely localized, has spread locally only around the primary tumor with 1-3 
local lymph node involvement, or any distant spread including distant lymph nodes and organs, 
respectively [16]. 
 
1.4.1  Requirements for Lymphatic Targeting  
Uptake of particulates into the lymphatic capillaries after subcutaneous administration is 
dependent on several factors, including:  size, charge, and hydrophobicity; however, size is the 
predominantly governing factor in the absence of macrophage interactions [17,18].  Due to the 
natural structure of the clefts and pores along the lymphatic capillaries and the presence of 
aqueous channels (100 nm in diameter) within the interstitium [19], particles with sizes of 10 to 
100 nm are preferentially taken up by the lymphatics [18,20]. Whereas particles >100 nm largely 
remain at the injection site as a depot, and particles <10 nm are reabsorbed by the blood 
capillaries.  Though it is generally recognized that the pores in the blood capillaries in the skin 
are ca. 5 nm in diameter and non-fenestrated, it was found that the capillaries of rodent footpads 
are fenestrated with pores of 6 to 12 nm [21-23], thus the use of the 10 nm cutoff rather than 5 
nm for lymphatic targeting.  
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It has been reported that negatively charged particles are more readily taken up by the 
lymphatics compared to neutrally to positively charged particles [24-26].  In part due to the 
electrostatic repulsions between the negatively charged particle and the extracellular matrix [18] 
that is primarily negatively charged [5,17,18].  Also, negatively charged particles have been 
shown to have longer lymph node retention due to the activation of macrophages [18].  However, 
little research has been conducted into the extent of negative charge needed for optimal 
lymphatic uptake.  Further, hydrophilic particles have increased lymphatic uptake and decreased 
nodal retention compared to hydrophobic particles [18,27]. 
 
1.4.2  Clinical Methods for Lymphatic Imaging 
 Conventional imaging for the diagnosis of lymphadenopathy and lymph node metastases 
rely on the identification of enlarged lymph nodes using computed tomography (CT) and 
magnetic resonance imaging (MRI).  These methods are susceptible to errors in that they rely on 
the identification of enlarged lymph nodes, which may be due to metastases, infection, or an 
autoimmune disease, leading to false-positives.  Further, these techniques are not very sensitive 
in that the lymph nodes have to be significantly enlarged for identification; for CT a lymph node 
with a short axis diameter of !1cm is considered to have metastases.  These techniques are not 
able to identify the SLN or micro-metastases, mainly found with breast cancer, where these 
nodes are usually “normal” in size and shape [28,29]. 
 
1.4.2.1  Sentinel Lymph Node Biopsy (SLNB) 
The clinical method for determining the SLN, the first draining lymph node, has not 
changed significantly since its first use in the 1960s.  Currently, sentinel lymph node biopsies are 
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used for the clinical staging of melanoma and breast cancer [15,30-33].  The SLN mapping 
consists of an injection proximal to the primary tumor of a blue dye (isosulfan blue, patent blue, 
or methylene blue) or 99mTc-sulfur colloid, used singly, or in combination, is performed prior to 
the sentinel lymph node biopsy (SLNB).  Both the dye and colloid drain to the regional 
lymphatic vessels, sentinel lymph node, and regional nodes, which is observed visually (dyes) or 
with a gamma camera (99mTc colloids).  Both methods have their own disadvantages; including, 
rapid dispersion and lack of localization to only the SLN (dye), risk of anaphylaxis (dye), 
propensity for long term staining of skin (dye), low resolution (99mTc), and radiative isotopes 
(99mTc) [15,29,34].  Further, the two injections do not occur simultaneously, thus causing the 
differing distribution and clearance kinetics of the two substances.  In order to overcome this 
issue and simplify the presurgical injection procedure, the kit was developed by combining the 
isosulfan blue dye with the 99mTc labeled liposomes. 
In 2002, Plut et al. developed a formulation kit by chemically combining a pyrogen-free 
low molecular weight isosulfan blue dye solution and 99mTc labeled liposomes, producing a 
radioactive blue liposomal formulation for pre-surgical injections [35]. This formulation avoids 
the non-synchronized distribution and clearance kinetics of the small molecular weight dye and 
the radioactive liposomes when they are administered separately.  Because of the importance in 
SLN staging and the disadvantages in the current clinical methods, there is a great need for new 
imaging and targeted drug delivery vehicles to the lymphatics.   
 
1.4.2.2  Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) could become another useful tool for imaging the 
lymphatic system.  MRI can overcome the poor resolution of 99mTc, but lymphcentric contrast 
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agents are required to provide clinically useful imaging of the lymphatic system.  Fujimoto et al. 
developed gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) labeled liposomes using 
long-circulating palmityl-D-glucuronide liposomes [36].  After a subcutaneous injection of the 
liposomal formulation into the hind feet of rabbits, the popliteal lymph nodes as well as the deep 
retroperitoneal lymph node were detected.  The enhanced lymphatic liposomal accumulation was 
likely due to the trapping of liposomes by the macrophages [36-38].  Rapid clearance post 
injection is the major drawback of liposomal formulations; therefore, a liposomal drug delivery 
system with prolonged retention is of high interest to physicians.  More recently, the Kobayashi 
group at the NCI has investigated dendrimer-Gd conjugates for lymphatic imaging, discussed 
further in the dendrimer section [39-41]. 
 
1.4.3  Immerging Platforms for Lymphatic Imaging and Drug Delivery 
 
 
1.4.3.1  Liposomes 
 Liposomes have probably been the most widely studied platform for the use in lymphatic 
delivery, and most of the early work developing optimized lymphatic carriers used liposomes 
[25,42-45].  In a study of negatively, neutrally, and positively charged 99mTc and 125I labeled 
poly(vinyl pyrrolidone) liposomes, Patel et al. determined that negatively charged liposomes are 
localized in the lymph nodes more than positively and neutrally charged liposomes after s.c. 
administration in the rat footpads [25]. Further, using liposomes, it was found that the size cutoff 
for lymphatic uptake is approximately 100 nm for neutral liposomes [46]. 
Liposomal formulations can encapsulate anti-cancer drugs for intravenous infusion for 
the treatment of various types of cancers.  The primary advantages of systemic liposomal 
chemotherapy encompass reduced side effects compared to the standard i.v. therapy, and inhibit 
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the anti-cancer drug from enzymatic digestion in the systemic circulation.  Early i.v. liposomal 
delivery formulations had short circulatory half-life due to the rapid clearance by the 
reticuloendothelial system (RES).  In addition, these formulations were unstable in the plasma 
and gastrointestinal tract resulting in lipid degradation and drug leakage [47].  PEGylation of 
liposomes is one method for prolonging the systemic retention and decreasing the volume of 
distribution and clearance [48] by protecting the liposomes from opsonization and subsequent 
macrophage uptake by Kupffer cells in the liver [49]. The increased systemic circulation allows 
for an increase in liposomal tumor accumulation through the enhanced permeability and 
retention (EPR) effect [48]. As the lymphatic system is difficult to target via the intravenous 
route, due to the separation from systemic vasculature and the unidirectional flow [50], local 
parenteral administration, such as subcutaneous, intraperitoneal (for intestinal delivery), and 
intramuscular injections, is more extensively investigated for lymphatic delivery via liposomal 
carriers.  Another characteristic of pegylated liposomes is that their size can be adjusted through 
the modification of the PEG chains or lipid bilayer core of the carrier, promoting its potential use 
as a drug delivery vehicle to the lymphatics after subcutaneous injection [51]. 
Doxil!, a pegylated liposomal doxorubicin chemotherapy formulation, is widely used as 
first-line therapy of AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other 
solid tumors [48,52-55].  Intravenous liposomal doxorubicin (i.e. Doxil!) has substantially 
improved pharmacokinetics of the drug compared to standard i.v. doxorubicin therapy, including 
increased AUC and half life. Multiple clinical trials with i.v. Doxil! alone or in combination 
with other chemotherapeutics, such as paclitaxel and other taxanes, cyclophophamide, docetaxel, 
and gemcitabine, have been conducted since the mid-1990s [56] for various different cancers.   
In a randomized Phase III clinical trial of patients with stage IIIB or IV metastatic breast cancer, 
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509 women with normal cardiac function were treated with either pegylated liposomal 
doxorubicin HCl (PLD) (50 mg/m2, every 4 weeks) or i.v. doxorubicin (DOX) (60 mg/m2, every 
three weeks) [57].  Although the PLD formulation exhibited a significant reduction in the 
cardiotoxicity (DOX to PLD hazard ratio = 3.16, p<0.001), myelosuppression, vomiting, and 
alopecia, it did not exhibit increased efficacy compared to conventional i.v. DOX (21 vs. 22 
month mean survival, 23% response rate).  In addition, the PLD formulation increased the 
incidence of palmar-plantar erythrodysesthesia (PPE, hand-foot syndrome) (48% vs. 2%), 
stomatitis (22% vs. 15%), and mucositis (23% vs. 13%) compared to i.v. DOX [57]. 
Keller et al. conducted a randomized Phase III trial with 301 women with taxane-
refractory advanced breast cancer [58].  Following previous failure with first- or second-line 
treatment regimens with taxanes, patients were treated with PLD (50 mg/m2, every 28 days, 
n=150), vinorelbine (5 mg/m2, weekly, n=129) or mitomycin C (10 mg/m2, day 1 and every 28 
days) plus vinblastine (5 mg/m2, days 1, 14, 28, and 42) (n=22), as a comparison for salvage 
regimens.  In patients with taxane-refractory breast cancer, treatment with vinorelbine or the 
combination of mitomycin C and vinblastine are common salvage treatment regimens 
(comparator).  Patients receiving PLD exhibited comparable progression free survival (PFS) and 
overall survival (OS) efficacy compared to the comparator [2.9 vs. 2.5 months (PFS) and 11.0 
and 9.0 months (OS), for the PLD and comparator, respectively].  PLD was hematologically 
safer than the comparator, with a grade 3 to 4 decrease in the leukocytes of 20% for PLD, 54% 
for vinorelbine, and 30% for mitomycin C – vinblastine.  The commonly reported adverse effects 
of nausea, vomiting, and fatigue, were comparable amongst all of the treatment groups.  
However, PPE was the most common reported treatment related adverse event with 37% of 
patients experiencing grade 3 and one patient experiencing grade 4.  Further PLD treatment 
! 15!
increased the incidence of stomatisis from 4% to 22%, for treatment with vinorelbine compared 
to PLD, respectively.  
Although i.v. Doxil! reduces cardiotoxicity compared to conventional i.v. DOX, along 
with improved pharmacokinetics, it does not exhibit an increase in efficacy over conventional 
treatment in the aforementioned clinical trials.  However, Doxil! liposomes are approximately 
90 nm in size [59], thus they could be potentially be delivered lymphatically and have increased 
efficacy compared to i.v. administration.  Ling et al. compared subcutaneous administration of 
liposomal doxorubicin with the standard intravenous doxorubicin treatment in a rabbit breast 
cancer model [60].  Female New Zealand rabbits were inoculated with VX2 carcinomas and 
treated three times with 1-mg/kg (doxorubicin equivalent) of subcutaneous liposomal 
doxorubicin, intravenous adriamycin, or saline, once the axillary lymph nodes reached 5 mm in 
diameter. Two days after the completion of the treatment, the nodal volume was measured and 
compared between different treatment groups.  Data revealed that the liposomal doxorubicin 
treatment and intravenous doxorubicin decreased the nodal volume by 57% and 27%, 
respectively, and increased the number of apoptotic cells by 3.2- and 2.0-fold, respectively, 
compared to the saline control.  The subcutaneous administration of doxorubicin demonstrated a 
more robust inhibitory effect relative to systemic doxorubicin, with a p value equal to 0.002 
between the two treatment groups.  Site inflammation including allergy and skin ulceration was 
not observed, likely due to the low dose of the drug administered, as well as the relatively short 
treatment period.  In summary, the liposomal doxorubicin treatment exhibited effective 
inhibition of tumor progression and induction of apoptosis of metastatic cells, which may be a 
promising method for the treatment of node-positive advanced breast cancer. 
Harrington et al. reported improved delivery of anticancer drugs to tumors using 
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PEGylated liposomes as vehicles for intratumoral and subcutaneous injection [51].  The authors 
compared the pharmacokinetics and tissue distribution, of subcutaneously or intratumorally 
injected pegylated liposome-encapsulated 111In-labeled diethylenetriaminepentaacetic acid 
(IDLPL) with the unencapsulated IDLPL.  The encapsulated form increased the carrier residence 
time and concentration in the head and neck tumors and their nodal metastases (both inguinal 
and axillary lymph nodes) in a nude mouse xenograft model, yielding a 11.6-fold increase in the 
area-under-the-curve (AUC) (96 h).  Although the addition of PEG to liposomes increases the 
systemic retention after i.v. administration in comparison to uncoated liposomes or the free drug, 
for subcutaneous administration, the addition of PEG to liposomes only slightly increases the 
lymphatic absorption and retention compared to non-PEG coated liposomes [61].  
Melphalan is a nitrogen mustard alkylating agent with high systemic toxicity but 
extremely poor stability at physiological conditions (half-life < 1 h) owing to its rapid hydrolysis 
resulting in the inactive form of the drug. Melphalan was encapsulated into liposomes made of 
egg phosphatidylcholine (PC) and cholesterol with average entrapment efficiency of 8.1% [62]. 
The release study in PBS at 37°C indicated the rapid release of melphalan during the first 4 h    
(> 70%) and only 20% remained after 24 h.  After subcutaneous injection of free melphalan into 
left leg of rats, different melphalan concentrations were seen between ipsilateral and contralateral 
nodes at 0.5 h, but no differences were observed at subsequent time points.  In the liposomal 
melphalan group, the liposome concentration in the ipsilateral lymph nodes was 200- and 100-
fold higher than that in the plasma and contralateral nodes, respectively. The encapsulated 
melphalan demonstrated a sustained release from the liposome in vivo.  At 24 h post dose, the 
melphalan level in the ipsilateral nodes was 20- and 10-fold greater than in the plasma and the 
contralateral nodes, respectively.  In the tumor-bearing rats (mammary adenocarcinoma 13762), 
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melphalan-encapsulated liposomes were more efficient in reduction of lymph node metastasis 
weight than for the same dose of free melphalan (0.125 mg/kg).  An equivalent effect on the 
reduction of lymph node metastases was achieved comparing 0.125 mg/kg liposome-melphalan 
and 1 mg/kg free melphalan. The role of the liposomal size in lymphatic uptake was investigated 
in a separate study [63]. Both large and small melphalan-encapsulated liposomes were prepared 
by sonication, with sizes of upto 250 nm or 34.3 ± 7.8 nm, respectively.  When melphalan 
encapsulated liposomes were given by subcutaneous injection into the left thigh of rats, the 
melphalan level in the ipsilateral lymph nodes was increased such that 24 h post dosing, the 
melphalan levels reached a 10-fold higher concentration for small liposomes compared to large 
liposomes, where the larger liposomes remained primarily at the injection site.  The melphalan 
concentration in the plasma was relatively low for both small and large liposome groups. 
A major issue of conventional liposomal formulations is that liposomes are poorly 
retained in the draining lymph nodes following injection (<2% injected dose).  In order to 
enhance the retention of liposomes to lymph nodes, Phillips et al. developed an avidin activated 
biotin-coated liposome, resulting in prolonged lymphatic retention and extended lymph node 
localization, in an experimental rabbit model [64]. Biotin-coated liposomes were injected 
subcutaneously into both hind feet of rabbits, followed by an adjacent subcutaneous injection of 
avidin, causing the formation of liposomal aggregates in the lymphatic vessels.  Twenty-four 
hours post injection, the retention of the liposomes was increased by 7.1- and 6.7-fold in the 
popliteal and iliac nodes, respectively.   
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1.4.3.2  Dendrimers 
Kobayashi et al. reported successful detection of lymphatic drainage of breast cancer in 
normal mice and spontaneous (BALB-neuT mice) and xenografted (PT-18) breast tumor models 
after a direct mammary gland or peritumoral injection of the generation-6 polyamidoamine 
dendrimer Gd contrast agent [41]. In a following study, Gd-labeled dendrimer-based contrast 
agents (1 to 12 nm in diameter) were compared in terms of the efficiency of delivery of the 
agents to the sentinel lymph nodes [40]. The generation 6 polyamidoamine (PAMAM-G6) Gd-
dendrimer agent (ca. 9 nm) illustrated the axillary lymph nodes and lymphatic vessels more 
clearly in non-tumor-bearing mice than the other agents including PAMAM-G2, G4, G8 and 
generation 5 polypropylenimine dendrimer Gd agents. The peak concentration of the PAMAM-
G6 agent (> 400 ppm) was achieved at 24 – 36 min post injection with high signal-to-
background ratio (> 100).  Although no significant differences were found between 
micrometastatic or non-metastatic lymph nodes for the accumulation of Gd in the axillary lymph 
nodes, the PAMAM-G6 Gd dendrimer showed the potential for targeted delivery to the lymph 
nodes. 
Dendrimers are appealing for lymphatic imaging and drug delivery due to their low 
polydispersities, compact size (nm in size), multi-valent surface groups, and high water solubility 
[65-68].  However, issues with their clearance, toxicity, and biodegradability have limited their 
use as therapeutic or imaging agents.  Two commercially available dendrimers are 
polyamidoamine (PAMAM) and polypropylenimine diaminobutane (DAB), where PAMAM is 
the most commonly used dendrimer in part due to its increased solubility, owing to its polyamido 
backbone, and decreased immunogenicity [69].  Both PAMAM and DAB dendrimers are highly 
cationic with terminal amino groups, but these groups can be derivatized to give neutral or 
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negatively charged surface chemistries that are more optimal for lymphatic uptake and reduced 
toxicity [70,71].  In addition, PAMAMs are not biodegradable, thus the sizes for in vivo use are 
limited to less than 5 to 6 nm for renal clearance, corresponding to a G6 PAMAM dendrimer 
[39,72].  Particles less than 10 nm no longer have specific lymphatic uptake, as they can also be 
absorbed by the blood capillaries, which have pores up to 12 nm in size depending on their 
location [23,73,74].  Further, dendrimer based-imaging agents optimized for lymphatic uptake 
and renal clearance (i.e. small and negatively charged), easily migrate through the lymphatics 
with little to no nodal retention, thus limiting their use as a localized sustained release drug 
delivery platform.  Because of the toxicity issues, very little investigation into their use as a 
lymphatic drug delivery carrier has been conducted.  Although biodegradable dendrimers have 
been developed using polyether imine, phosphates, melamine, amino acids as their building 
blocks to list a few, they are unlikely to exhibit significant accumulation, however, they have 
been shown to induce hemolysis (polyether imine), echinocytosis (phosphate), in vivo liver 
necrosis (melamine), and toxic degradation products (amino acids) [69,75]. 
 
1.4.3.3  Quantum Dots (QDs) 
Quantum dots have only been recently investigated in the last decade for in vivo imaging, 
since their discovery in the late 1980s [76].  Quantum dots are semiconductor nanoparticles that 
exhibit extremely bright fluorescence, have tunable emission spectra, high quantum yields, 
"#$"%%"&'!()*'*+',-.%.'/0!and are typically 5 to 20 nm in size [77,78].  There has been a growing 
interest in their use for lymphatic imaging due to their enhanced penetration depth, improved 
photostability, and broad absorption bands coupled with narrow emission spectra.  However, 
there is considerable toxicity concerns surrounding the heavy metals (e.g. Cd, Te, and Se) used 
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in the construction of the QD cores.  Further, the surface of QDs must be functionalized due to 
their innate water insolubility and hydrophobicity for their use in vivo [79]. The size and charge 
of the QD dictate their clearance mechanism and residence time in vivo.  For effective renal 
clearance, nanoparticles (NP) must be small, especially when vehicle toxicity is of concern, to 
minimize tissue exposure; the size cut-off for renal clearance of QDs is <6 nm [80,81].  Larger 
and negatively to neutrally charged (PEG coated) QDs have shown significant liver and spleen 
retention, from 1 to 6 months [77,78].  Even though, QDs can be conjugated to therapeutic drugs 
for theranostic applications, with the correct size and emission in the NIR range; toxicity is the 
greatest concern, therefore biodegradable polymeric carriers utilizing NIR dyes for imaging are 
of great interest to many researchers, including our laboratory, for lymphatic imaging and drug 
delivery.  
 
1.4.3.4  Synthetic and Natural Polymer Platforms 
Surface properties, including surface charge and hydrophobicity, of nano-/microparticles 
are one of the chief determinants of lymphatic uptake and biodistribution in vivo.  Hawley et al. 
investigated the relationship between surface properties of nanoparticles and in vivo 
biodistribution [82]. Poly(lactide)-poly(ethylene glycol) (PLA:PEG) copolymers with PEG 
lengths of 750, 2,000 and 5,000 Da were used as a surface coating of PS and poly(DL-lactide-co-
glycolide 75:25) (PLGA) nanoparticles. The PLGA–PLA:PEG nanoparticles were prepared by 
an oil-in-water emulsion of PLGA and PLA:PEG. All of the nanoparticles were sub-100 nm in 
size and negatively charged on their surfaces, with the PEG portion forming steric barriers.  125I 
radiolabeled, uncoated PS or PLGA nanospheres were retained in the injection site ! 24 h after 
subcutaneous administration in rats.  The lymphatic uptake of the nanoparticles was strongly 
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dependent on the surface characteristics.  Polystyrene or PLGA nanospheres coated with 
PLA:PEG (molar ratio 1.5:0.75, PEG length 750 Da) had the most lymph node uptake, ca. 15 to 
20%, owing to a suitable hydrophilicity on the surface, which provided an adequate steric barrier 
to promote drainage from the injection site, while remaining hydrophobic enough to be 
recognized by the lymph node macrophages. Less than 3% of naked PLGA nanoparticles 
injected were retained in the lymph nodes, whereas the lymphatics retained 17 and 16% of the 
nanoparticles prepared by co-precipitation of PLGA and PLA:PEG (1.5:0.75) with 75 and 65% 
PLGA content, respectively. The uptake into the lymph nodes decreased with further increase (> 
65%) of PLA:PEG content, possibly owing to the surface being too hydrophilic. The 
incorporation of hydrophilic PEG onto PS and PLGA nanoparticles improved their lymphatic 
drainage, but the rate of lymph node uptake was closely related to the length of the PEG chain 
and eventually the hydrophilicity of the nanoparticles. 
Rao et al. studied the effect of size, charge, and hydrophobicity of polymeric 
nanoparticles on the lymphatic uptake after s.c. administration in rats [18].  The effect of size and 
hydrophobicity were studied in parallel studies using PLGA-PMA:PLA-PEG (75:25) (PP) 
[poly(D,L-lactic-co-glycolic) labeled with 1-pyrenemethylamine (PLGA-PMA): polylactic acid-
co-polyethylene glycol (PLA-PEG)] and polystyrene (PS) nanoparticles of ca. 50, 100, and 200 
nm in size.  With both the PP and PS nanoparticles, the cumulative nodal uptake decreased with 
increasing nanoparticle size.  The hydrophilic PP nanoparticles had significantly increased nodal 
accumulation (10 to 30-fold increase) compared to the PS nanoparticles of similar size (p<0.05) 
for all three sizes studied.  For studying the effect of the degree of negative charge on the 
lymphatic uptake, the ratio of poly(D,L-lactic-co-glycolic) acid with a terminal carboxylic acid 
group (PLGA-COOH) to 1-pyrenemethylamine labeled PLGA (PLGA-PMA, 1:1) polymers was 
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varied to give a series of different PLGA-PMA:PLGA-COOH nanoparticles with increasing 
degrees of negative charge.  As the amount of PLGA-COOH was increased from 20% to 80%, 
thus decreasing the zeta potential from -44.6 ± 11.3 to -57.1 ± 11.1 mV, the cumulative 
lymphatic uptake was increased by 10-fold.  The authors demonstrated that for polymeric 
nanoparticles, 50 nm hydrophilic particles had the greatest lymph node accumulation and the 
lymphatic uptake increases with increased negative charge.   
Natural polymers, for example, dextran and HA, have been studied for their potential use 
as carriers for lymphatic drug delivery for cancer.  Mitomycin C (MMC) was conjugated to 
dextran (average MW of 10, 70 and 500 K), and distribution of the mitomycin–dextran (MMC–
D) conjugate was compared to free MMC after injection into the left thigh muscle of rats [83]. 
The MMC–D conjugate slowly cleared from the injection site with a significant amount 
remaining in the muscle after 48 h (3.4, 13.2, and 21.8 %, for the 10, 70 and 500 kD dextran, 
respectively), whereas only 0.56% of the free MMC remained at the injection site after 30 min.  
The free MMC reached a peak regional lymph node concentration of 11.8 µg/g after 5 min, but 
no drug was detectable after 30 min. MMC-D (T-70K and T-500K) showed a higher and 
sustained accumulation in the regional lymph nodes even ! 48 h post dose.  In rats inoculated 
with L1210 leukemia cells in the left thigh, no significant tumor suppression was observed in the 
lymph node metastases with free MMC or MMC-D (T-10K) groups owing to low MMC uptake 
by the nodes.  In contrast, the T-70K and T-500K MMC-D (2.5 mg/kg dose) reduced the weight 
of the left iliac node, indicating the suppression of tumor growth and metastasis via lymphatic 
system.  In subsequent studies, when comparing the drainage of cationic, neutral, and anionic 
dextran-MMC conjugates, the authors found that negatively charged dextran conjugates were 
more readily taken up by the lymphatics compared to neutrally to positively charged dextran 
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conjugates [24,26].  In conclusion, anionic dextran-MMC conjugates may be useful for 
preventing lymphatic metastasis of cancer. 
Hyaluronic acid is a natural polysaccharide of D-glucuronic acid and D-N-
acetylglucosamine found in the interstitial space of tissues and in the synovial fluid of joints.  
Cisplatin was incorporated with HA by anionic polymer–metal complexation between the HA 
and cisplatin [84]. The nanoparticles were ca. 100 to 200 nm in size, with cisplatin loading from 
3.9 to 11.8% (wt/wt).  The cisplatin release kinetics demonstrated that the cisplatin–HA 
conjugate had an initial burst release in the first 12 h followed by a sustained release for 4 days.  
The cisplatin release rate was enhanced by the addition of hyaluronidases (HAses), the enzyme 
that degrades HA.  Cai et al. reported an in vivo study of cisplatin–HA nanoparticles (25% wt/wt 
cisplatin), where the cisplatin–HA conjugates showed similar anti-tumor activity and were well 
tolerated in rodents compared to intravenous cisplatin [85].  The AUC of cisplatin in the axial 
lymph nodes after subcutaneous injection of cisplatin-HA increased 74% compared to free 
cisplatin.  Therefore, the cisplatin–HA nanoparticles are suitable drug delivery vehicles for 
platinum chemotherapy in the lymphatics. 
 
1.5  Conclusions 
New non-invasive methods for the accurate determination of the SLN and the metastatic 
nodes are crucial for the improved survival and quality of life for those with lymphatically 
metastatic cancers.  Developing new platforms that can both image and treat the diseased nodes 
would serve as a stepping-stone for improved treatment outcomes and reduced toxicities in the 
lives of those affected by cancer.  Great strides have been made in the SLNB procedures for the 
staging of melanoma and breast cancer, providing patients with more treatment options, 
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minimizing drastic surgery, reducing relapse, and providing hope.  However, as with any 
medical procedure, further optimization and development are needed, which has led to the 
investigations into multiple new imaging agents and carriers for lymphatic imaging and drug 
delivery.  With the advantages of particle engineering and a better understanding of the 
lymphatic anatomy and the drug transporting mechanism by the lymphatic system, lymphatic 
delivery via polymeric nano-/micro-particles may improve the efficacy of current cytotoxic 
chemotherapeutics.  However, many of the newly developed agents and carriers have substantial 
toxicities associated with them, thus limiting their use to preclinical research rather than 
translational research into the clinic.  Promising results in the area of liposomes have been made, 
especially with the DoxilTM formulation, however, the limited nodal retention after s.c. 
administration still remains a hurdle to developing a localized sustained release formulation.  Our 
efforts have focused on the development of biodegradable carriers, including hyaluronan and star 
polymers, for the use in lymphatic imaging and drug delivery utilizing NIR dyes and 
chemotherapeutics, such as cisplatin, doxorubicin, and geldanamycin for the treatment of 
lymphatically metastatic cancers.   
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Chapter 2.  Development of Hyaluronan (HA)-Fluorescent Dye 
Conjugates and the Molecular Weight Optimization of HA for 
Intralymphatic Delivery Using in vivo Fluorescence Imaging    
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2.1  Introduction 
Cancer cells can metastasize by either the lymphatic or vascular routes, but many 
cancers, including melanoma and breast cancer, metastasize preferentially via the lymphatics [1-
3].  The sentinel lymph node (SLN) status is important for staging cancers and formulating the 
treatment plan.  Therefore developing a multifunctional platform that can both identify the 
sentinel lymph node and treat the lymphatic metastases, would be pivotal in treating 
lymphatically metastatic cancers such as melanoma and breast cancer. 
Drugs can enter the lymphatics from the vascular system or from the interstitial space 
after subcutaneous injection.  Size is the predominant biophysical property that affects lymphatic 
uptake, but charge, chemistry, and hydrophobicity also affect the kinetics of both passive and 
macrophagal uptake [4,5].  Lymphatic capillaries consist of a single layer of non-fenestrated 
endothelial cells that lack a continuous basal lamina [6].  There is a considerable amount of 
overlapping and gapping within the intercellular junctions, leading to the formation of clefts and 
pores along the capillary.  These gaps allow the preferential uptake of materials within a specific 
size range (ca. 10 to 100 nm) and are the basis of lymphatic recycling of extracellular proteins, 
fluids, and lipids, from the interstium to the systemic circulation [5,7,8].  Particles larger than 
100 nm are diffusion limited and tend to form a depot at the injection site, and particles less than 
10 nm are reabsorbed by the blood capillaries.  Further, it has been shown that particulates 
carrying a net negative charge have enhanced lymphatic uptake and retention in draining lymph 
nodes [5,9-11].  
For effective tissue penetration and enhanced signal to noise ratio for in vivo imaging, the 
utilized fluorophore must emit in the near infrared range (600-1000 nm) to minimize background 
fluorescence from hemoglobin, and the autofluorescence of elastin, collagen, chlorophyll (from 
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food), and various other biological chromophores [12,13].  The two chromophores commonly 
used for in vivo imaging are quantum dots (QDs) and NIR organic fluorophores.  In the last 
decade, QDs have been investigated extensively for in vivo imaging, due to their inherently 
bright fluorescence, narrow emission spectra, high quantum yields, and small size (5 to 20 nm) 
[14,15].  Further, their enhanced imaging depth, photostability, and broad absorption bands 
coupled with narrow emission spectra, are beneficial characteristics for in vivo imaging in the 
NIR range, which most conventional NIR dyes lack.  However, the principal concern with the 
use of QDs is the toxicity associated with the use of heavy metals (e.g. Cd, Te, and Se) used in 
the construction of the QD cores.  The size and charge of the QD dictate their clearance 
mechanism and residence time in vivo.  Because of the considerable toxicity concerns, the size of 
the QDs is limited to less than 6 nm to ensure renal clearance and minimize tissue exposure 
[12,16].  Larger and negatively to neutrally charged (i.e. PEG coated) QDs have shown 
significantly prolonged liver and spleen retention, from 1 to 6 months [14,15].  Quantum dots are 
appealing nanodevices for lymphatic imaging and drug delivery given their photostability, 
optimum size range, and rich surface groups for the conjugation of drugs and ligands.  However, 
their long bioresidence time and potential heavy metal toxicity preclude clinical development, 
therefore we developed a NIR organic fluorophore-polymer conjugate with low potential toxicity 
for in vivo imaging or drug delivery applications.  One polymer well suited for delivery and 
imaging applications to the lymphatic system is hyaluronan.  
Hyaluronan (HA) is a naturally occurring linear biopolymer consisting of repeating 
disaccharide units of !(1,4)-D glucuronic acid-!(1,3) N-acetyl-D-glucosamine, found in the 
extracellular matrix (ECM), synovial fluid, umbilical cord, and vitreous humor of the eye with a 
molecular weight ranging from 105 to 107 Da.  Hyaluronan has multiple biological roles 
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important to cancer including modulation of inflammation, angiogenesis, and cell proliferation, 
and the effects can be pro- or antagonistic depending on the molecular weight [17-20].  
Hyaluronan is mainly found in the ECM, and approximately half of the total HA is found 
in the dermis and epidermis (ca. 7 to 8 g in the average adult) [21].  The turnover of HA is 
relatively short, with a half life of ca. 12 hours [22].  The turnover of HA is not from its 
degradation in the ECM, but from one of two mechanisms:  1) local cell-mediated catabolism or 
2) drainage into the lymphatics where is it then catabolized by the lymph nodes, liver and spleen 
[23].  The concentration of HA in the lymph is 10 to 100 times higher than in the plasma, 
suggesting that the major route of HA entering the plasma is through its lymphatic uptake from 
the ECM [22].  In addition to HA meeting the requirements for lymphatic uptake, and its natural 
elimination route through the lymphatics, its primary receptors, CD44 and RHAMM (receptor 
for HA mediated motility), are overexpressed on most malignant cancer cells [19,20,24] 
including invasive breast cancer and melanoma [25].  Further, it has been shown that malignant 
cells with a high metastatic potential have enhanced HA binding and internalization [19,20], 
making HA an ideal candidate for a lymphatic carrier.  In addition, HA is FDA approved and has 
multiple functional groups for conjugation of imaging agents or chemotherapeutics. 
Our previous studies targeted lymphatic drug delivery of 35-kD HA-chemotherapeutic 
(cisplatin and doxorubicin) conjugates have shown its improved efficacy, decreased toxicity, and 
superior pharmacokinetics compared to their standard iv counterparts [26-31].  Herein, we 
describe the kinetics of lymphatic uptake of a series of different molecular weight (6.4 kD to 697 
kD, radius of gyration (Rg) ! 7 to 100 nm, respectively) hyaluronan-NIR dye (IR820) conjugates 
after subcutaneous injection.  Because lymphatic uptake is mainly dependent on the size of 
particles injected into the extracellular space, the molecular weights of hyaluronan that were 
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chosen to fall around the optimal size range for lymphatic uptake, 10 to 100 nm.  The molecular 
weights examined were 6.4, 35, 74, 132, 357, and 697 kD.  Their corresponding sizes (Table 2.1) 
were calculated according to the equations derived from Takahashi et al. data for radius of 
gyration (Rg) and hydrodynamic radius (Rh) for different molecular weights of HA in 0.2 M 
NaCl at 25°C [32].  The following equations were developed after fitting the data reported: 
              
 Rg = 2.35 [MW (kD)]0.57              Rh = 0.87 [MW (kD)]0.63 
  
 
 
 
HA MW (kD) Rg (nm) Rh (nm) 
6.4 6.77 2.80 
35 17.8 8.17 
74 27.3 13.1 
132 38.1 18.9 
357 67.0 35.3 
697 98.1 53.8 
 
Table 2.1.  Radius of gyration (Rg) and hydrodynamic radius (Rh) calculated from the fitted 
equations from Takahashi et al. reported data for each MW of HA used in the in vivo imaging 
[32]. 
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2.2  Experimental 
 
2.2.1 Synthesis of HA-Texas Red using N-(3-Dimethylaminopropyl)-N!-ethylcarbodiimide 
hydrochloride (EDAC) (Scheme 2.1) 
Sodium hyaluronate (100 mg, 35 kD, from bacterial fermentation, Lifecore Biomedical, 
Chaska, MN) was dissolved in 7 mL ddH2O, and the pH was adjusted to 4.75 with 0.1 M HCl.  
N-hydroxysuccinimide (NHS, 200 mg, Sigma) was added and allowed to stir, and the pH was 
maintained.  Texas Red! hydrazide (2 mg, Anaspec, San Jose, CA) was dissolved in 3 mL 
DMSO and was added to the HA solution.  EDAC (100 mg, Sigma) was added to the stirring 
solution, the pH was rechecked and maintained at pH 4.75.  The reaction mixture was allowed to 
react for 48 hours at ambient temperature (ca. 20 °C), protected from the light.  The resulting 
HA-Texas Red conjugate was purified by dialysis against ddH2O for 48 hr at ambient 
temperature followed by lyophilization under protection from the light. 
 
2.2.2 Synthesis of HA-Texas Red using 2-chloro-1-methylpyridinium iodide (CMPI) (Scheme 2.1) 
Sodium hyaluronate (100 mg, 35 kD, Lifecore Biomedical) was dissolved in 3 mL 
ddH2O, followed by the addition of 7 mL EtOH and was activated by the addition of CMPI (33 
mg, Sigma) and triethylamine (35 µL).  Texas Red! hydrazide (2 mg, in 0.4 mL DMSO, 
Anaspec, San Jose, CA) was added to the HA activated solution.  The reaction mixture was 
allowed to reflux for 48 hr, protected from the light.  The resulting HA-Texas Red conjugate was 
purified by dialysis against ddH2O for 48 hr at ambient temperature followed by lyophilization 
under protection from the light. 
!
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Scheme 2.1.  Texas Red conjugation reaction to HA using either EDAC and DMAP (pH 4.75, 
30:70 DMSO:ddH2O, ambient temperature, ca. 20 °C) or CMPI and TEA (70:30 EtOH:ddH2O, 
reflux). 
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2.2.3  Characterization of HA-Texas Red Conjugates 
The loading degree of Texas Red for both the EDAC and CMPI conjugation methods was 
determined by UV spectroscopy at 588 nm using a calibration curve (0.25 to 5 µg/mL) in 
ddH2O.  A series of Texas Red hydrazide concentrations were prepared from a 5 mg/mL stock 
solution of Texas Red hydrazide in DMSO.  
Conjugation of Texas Red to HA was verified by equivalent size exclusion 
chromatography (SEC) retention times using refractive index (Shimadzu RID-10A) and 
fluorescence detection (Shimadzu RF 535, !ex/!em = 590/610 nm).  All SECs were collected 
using a Shodex OHpak SB-806M HQ column thermostated at 35°C using ddH2O at 0.75 mL/min 
as the mobile phase.  
 
2.2.4  In Vivo Imaging with HA-Texas Red 
 A nude mouse bearing a 100- to 300-mm3 MDA-MB-468LN breast tumor was 
anesthetized using isoflurane, and was injected s.c. over the left mammary fatpad with HA-Texas 
Red (20 µL, 10 mg/mL in saline).  The injection area was massaged gently for 5 min and the 
mouse was fluorescently imaged after 5 and 18 h (CRI Maestro Flex; CRI Inc., Woburn, MA) 
using a 445-490-nm filtered halogen excitation light and a 515-nm longpass emission filter.  
Fluorescence was measured in 10-nm bandpass segments from 520 to 720 nm, using a cooled 
CCD camera with autoexposure.  Images were spectrally unmixed by using the automatic 
deconvolution tools (Maestro version 2.4) to limit skin and intestinal autofluorescence resulting 
from chlorophyll in the food. 
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2.2.5  Synthesis of 5-carboxypentyl-amino-IR-820 (Scheme 2.2) 
The 6-aminohexanoic acid (2 eq., Sigma) was dissolved in 20 mL dry DMF with 2 eq. of 
triethylamine, and the solution was stirred under argon for ca. 5 min.  After the addition of 500 
mg (0.47 mmol) of IR-820 (Sigma), the reaction mixture was refluxed at 85°C for 3 hrs in the 
dark.  The solvent was removed under reduced pressure, and the 5-carboxypentyl-amino-IR-820 
was purified by silica column chromatography using a gradient of 2:1 to 1:1 ethyl 
acetate:methanol.  The blue 5-carboxypentyl-amino-IR-820 solid was confirmed by 1H NMR 
(400 MHz, Bruker) in CDCl3 (Cambridge Isotope Laboratories, Andover, MA); 1H-NMR 
(CDCl3, 400 MHz): ! = 8.13 (d, J = 8.4 Hz, 2H), 7.98-7.91 (m, 4H), 7.63 (d, J = 13.2 Hz, 2H), 
7.56-7.52 (m, 4H), 7.35 (t, J = 8.0 Hz, 2H), 5.77 (d, J = 15.2 Hz, 2H), 4.06-4.00 (m, 4H), 3.05 (q, 
J = 12.4 Hz, 6.4 Hz, 1H), 2.57-2.51 (m 4H), 2.16 (t, J = 6.4 Hz, 2H), 2.07 (t, J = 7.2 Hz, 1H), 
1.88 (bs, 11H), 1.82-1.68 (m, 14 H), 1.62-1.53 (m, 3H), 1.48-1.35 (m, 4 H), 1.28-1.22 (m, 1H). 
 
2.2.6  Synthesis of HA-IR820 Conjugates (Scheme 2.2) 
Typically 5-carboxypentyl-amino-IR-820 was dissolved in ddH20 (<20 mL) with N-(3-
dimethylaminopropyl)-N"-ethylcarbodiimide hydrochloride (EDAC, 1.2 eq., dye basis, Sigma) 
and 4-(dimethylamino)pyridine (DMAP, 0.5 eq., dye basis, Sigma), the pH was adjusted to 4.0 to 
4.5, and the solution was stirred for approximately five minutes.  Sodium hyaluronate (100 mg, 
Lifecore Biomedical) was dissolved in 10 mL of ddH2O and added to the solution (see Table 2.2 
for molar equivalents of reagents used).  The mixture was stirred at ambient temperature (ca. 
20°C) in the dark.  The reaction was monitored by TLC, using 6:4:1 MeOH:EtOAc:DCM as the 
mobile phase; the total reaction time was typically 1 to 5 days and increased with HA molecular 
weight.  The HA-IR820 conjugate was dialyzed once against 95% EtOH and twice against 
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ddH2O.  The purple HA-IR820 conjugate was lyophilized and stored at -20°C until further use.  
The ratio of 1H NMR peaks the acetamide methyl of HA and the third methylene group on the 5-
carboxypentyl-amino linker moiety, in D2O were used to determine the dye content per HA 
polymer.  
 
 
 
 
 
 
 
HA MW 
(kD) 
Dye 
Equivalents 
EDAC 
Equivalents 
DMAP 
Equivalents 
6.4 1.5 1.8 0.75 
35  3 3.6 1.5 
74  10 12 5 
132  25 30 12.5 
357  50 60 25 
697  100 120 50 
 
 
 
Table 2.2.  Molar equivalents of each reagent used in the conjugation of 5-carboxypentyl-amino-
IR-820 (dye) to each MW of HA to form the HA-IR820 conjugates. 
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2.2.7  Size Exclusion Chromatography (SEC) of HA-IR820 
Conjugation of IR820 to HA was verified by equivalent SEC column retention times 
using evaporative light scattering (ELSD) and UV detection.  HA (same MWs used in 
conjugation reactions) and PEG standard samples (1 mg/mL total concentration, Scientific 
Polymer Products, Ontario, NY) were used for a calibration curve, and the retention times of 
HA-IR820 were compared to that of HA and PEG to determine the molecular weight changes 
post conjugation reactions.  All SECs were collected using a Shodex OHpak SB-806M HQ 
column thermostated at 35°C, with 0.8 mL/min mobile phase of 5-mM acetate buffer adjusted to 
pH 5.  Detection was with a UV (Shimadzu LC2010CHT) (!=520 nm) and an evaporative light 
scattering detector (Shimadzu ELSD-LT II, 70 °C and 3.6 bar purified air).  
 
2.2.8  Fluorescence of HA-IR820 conjugates 
The HA-IR820 samples were dissolved in ddH2O at a concentration of 0.1 mg/mL IR820.  
The maximum excitation and emission wavelengths were determined using a fluorescent 
spectrophotometer (Shimadzu RF-5301 PC, Columbia MD; Panorama Fluorescence Software).  
The total fluorescence emission spectrum (!ex= 700 nm, !em=800-900 nm) was determined for 
the HA-IR820 samples, which was used for the normalization of the in vivo imaging data.  
 
2.2.9  Zeta Potential of HA 
HA samples (4.7, 6.4, 35, 74, 132, 357, and 697 kD) were dissolved at a concentration of 
100 µg/mL in pH 7.25 1-mM phosphate buffer with the addition of 1 mM of KCl.  After dilution, 
the pH was rechecked.  Zeta potentials were measured on a ZetaPALS (Brookhaven Instruments 
Corporation, Holtsville, NY) at 20°C. 
!
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2.2.10  In Vivo Imaging of HA-IR820 Conjugates 
All mice were fed a low chlorophyll diet at least one week prior to imaging to decrease 
food induced organ and skin autofluorescence (Harlan 2918 irradiated diet).  The mouse’s hair in 
the area of interest for imaging was removed 24 hours prior to imaging with clippers followed by 
depilatory cream.  Female Balb/c mice (20-25 g, Charles River) (3 per group) were anesthetized 
under isoflurane, placed on a heating pad to help regulate body temperature, and were injected 
subcutaneously (s.c.) with 10 µL of a 1-mg/mL 5-carboxypentyl-amino-IR-820 or HA-IR820 
(dye basis) in the center of the right hind footpad or on the inner-side of the right front forearm.  
The mice were imaged on both the dorsal and right sides (for footpad injections) or ventral and 
right sides (for front forearm injections), both with and without the injection site being covered, 
using whole body fluorescence imaging (Cambridge Research and Instrumentation Maestro 
multi-spectrum imager, Woburn, MA) using an excitation filter of 710-760 nm and broadpass 
emission filter of 800-950 nm.  The animals were imaged for 7 days in the footpad studies and 
14 days in the forearm studies.  Images were acquired using the autoexposure function in the 
imaging software.   
 
2.2.11  In Vivo Imaging Data Analysis of HA-IR820 Conjugates 
Image analysis was performed using Maestro software (ver. 2.10).  Regions of interest 
were placed over the popliteal and iliac lymph nodes or axillary lymph node package.  The total 
signal (scaled counts/s) intensity values (arbitrary units, AU) were recorded for each region of 
interest (ROI), for all positions (dorsal, ventral, and right sides), and were plotted versus time in 
GraphPad Prism (ver. 4).  The total emission fluorescence was determined by integrating the 
resultant emission spectrum (!ex= 700 nm, !em=800-900 nm) from each HA-IR820 sample (0.1 
!
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mg/mL IR820).  The ROIs were normalized to their corresponding total emission fluorescence.  
The normalized ROI vs. time graphs were then integrated to give the cumulative fluorescence vs. 
time graphs.  In addition, the area under the curve (AUC) was determined from the normalized 
ROI vs. time graphs. 
 
Scaled counts/s = counts/full scale ! 1/exp(s) ! 1/bin2 ! 1/gain 
 
2.3  Results  
 
2.3.1  HA-Texas Red Characterization  
The synthesis of Texas Red with HA using EDAC as a coupling agent was adapted from 
Gajewiak et al. [33]. The use of CMPI, previously used as a crosslinking agent in the preparation 
of covalently cross-linked HA films, was adapted as an alternative coupling reagent in the 
conjugation of Texas Red with HA [34,35] which we have previously reported [29]. 
The loading degree of Texas Red on HA for both the EDAC and CMPI conjugation 
reactions was determined by UV spectroscopy at 588 nm using a calibration curve (0.25-5 
µg/mL) in ddH2O.  The concentrations used for the standard curve of Texas Red were 0.25, 
0.375, 0.5, 0.625, 1.25, 2.5, and 5.0 "g/mL (R2=0.994) in ddH2O.  The absorbance of the HA-
Texas Red was measured at 588 nm was measured, and the resulting optical density 
measurements were due to the absorbance of Texas Red and not HA, as HA does not exhibit UV 
absorbance at 588 nm.  The loading degree of Texas Red was calculated to be 2% and 4% for the 
EDAC and CMPI activated coupling reactions, respectively.  The extinction coefficient at 588 
nm of Texas Red on HA-Texas Red in ddH2O was determined to be 81813 M-1cm-1, whereas it 
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was reported from the manufacturer to be 100,500 M-1cm-1 in MeOH at 582 nm.  The CMPI 
activation method for the conjugation of Texas Red to HA was used for further studies due to the 
higher loading degree obtained with this method.   
Conjugation of Texas Red to HA was verified by equivalent retention times using size 
exclusion chromatography coupled with refractive index and fluorescence detection (!ex/!em = 
590/610 nm).  Equivalent elution times for the fluorescence (from Texas Red) and refractive 
index (from HA-Texas Red) signals indicated that the Texas Red was bound to HA and was pure 
with no free Texas Red present in the sample.  
 
2.3.2  In Vivo Imaging with HA-Texas Red 
HA-Texas Red drained into the left lymphatic basins after a subcutaneous injection into 
the left mammary fatpad, with no observed bilateral drainage into the right basin.  After 5 h, 
localization of HA-Texas Red in the nodes surrounding the tumor can be clearly observed 
(Figure 2.1 B).  Most of the carrier has localized in the basin of the tumor at 18 h with a lesser 
amount remaining in the adjacent axillary node basins (Figure 2.1 C). 
!
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Figure 2.1.  A nude mouse bearing a MDA-MB-468 breast lymphatic tumor (expressing green 
fluorescent protein [GFP], panel A) was subcutaneously injected with HA-Texas Red in the left 
mammary fat pad.  After 5 hrs and 18 hrs (B and C, respectively), significant HA localization in 
the draining nodes, and it was co-localized with the tumor (GFP-channel in green, Texas Red 
channel in red, blue arrow denotes the injection site). 
!
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2.3.3  HA-IR820 Characterization 
The synthesis of the HA-IR820 conjugate was adapted from Masotti et al. procedure for 
forming IR820 dye complexes with polyethylenimine [36].  The number of dyes per polymer 
(Table 2.3) were determined by the integration ratio from the 1H NMR of the methyl on the 
acetamide of HA to the third methylene group on the linker between IR820 and HA (Scheme 
2.2).  
Conjugation of IR820 to HA was verified by equivalent elution times using size 
exclusion chromatography coupled with ELSD and UV detection (data not shown).  Linear 
responses between molecular weight and elution time were observed for both PEG standards and 
HA samples (R2=0.993 and 0.999, respectively).  Both PEG and HA are linear polymers, but 
they exhibit drastically different characteristics in solution for the same given molecular weight.  
The MW of the conjugates were similar to that of the original HA used, with the exception of the 
highest MW of 697 kD, which exhibited a significantly lower MW than that of the original HA 
(Figure 2.2). 
  
2.3.4  Spectral Properties of HA-IR820 
The maximum excitation and emission wavelengths of HA-IR820 (all MWs) were 
determined to be 675 nm and 725 to 735 nm in H2O, respectively, having a moderate Stokes shift 
of 50 to 60 nm.  A blue shift in the UV absorbance was observed after each IR820 reaction (data 
not shown).  The concentrations used for the determination of the maximum wavelengths and 
total emission spectra over the specified wavelengths (same as used in the imaging experiments), 
was a 1:10 dilution of that used for the imaging experiments.  Larger concentrations caused self-
quenching of the dyes.  
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HA MW (kD) IR820 wt % # dyes/HA polymer 
6.4 2.12% 0.16 
35 4.69% 1.93 
74 3.21% 2.75 
132 4.95% 7.72 
357 4.44% 18.6 
697 3.97% 32.3 
 
Table 2.3.  The IR820 loading degree, determined by 1H NMR in D2O, onto the different 
molecular weights of HA that were used for the in vivo imaging experiments.   
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Retention time vs. molecular weight for PEG standards, HA samples, and HA-IR820 
conjugates from SEC, using a Shodex OHpak SB-806M HQ column, 5 mM acetate buffer (acetic 
acid/ammonium acetate) at pH 5 (0.8 mL/min flow rate) coupled with UV detection (!=520 nm) 
and evaporative light scattering detection (ELSD, 70 °C).  
!
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2.3.5  Zeta Potential of HA 
The zeta potentials of the HA samples were determined at pH >> pKa, to ensure that all 
of the carboxylic acid functional groups were fully ionized to minimize the effects of pH changes 
on measurements due to partial protonation of the carboxylic acids.  Further, the pH studied 
would be indicative of the ionization state in vivo.  The zeta potential was independent of the 
molecular weight of HA (R2=0.75) (Table 2.5). 
 
 
HA MW (kD) Zeta Potential (mV) 
4.7 -24.20 ± 2.44 
6.4 -25.33 ± 4.19 
35 -22.54 ± 2.57 
74 -31.18 ± 2.26 
132 -54.82 ± 2.49 
357 -51.72 ± 3.06 
697 -50.06 ± 3.63 
 
 
Table 2.5.  Zeta potentials of various different MW HAs in 1-mM phosphate buffer pH 7.25 with 
1 mM KCl at HA concentration of 100 µg/mL and 25°C. 
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2.3.6  Optimization of In Vivo Lymphatic Imaging  
The intense fluorescence signal from the injection site saturated the camera, so we 
covered the injection area with a piece of black tape allowing visualization of the draining 
lymphatic vessels and lymph nodes.  The use of the autoexpose function resulted in different 
exposure times for each image.  We corrected for this in the image analysis by using the scaled 
counts/s, which is normalized for the exposure time.  
Mice in the footpad injection group were imaged from both their right and dorsal sides to 
detect drainage into the popliteal and iliac nodes.  Mice in the forearm group were imaged from 
the right and ventral sides to capture the axillary node drainage.  The same trends were observed 
for both imaging positions; but the right side was analyzed as it produced greater signal 
intensities and a higher signal to noise ratio compared to the dorsal or ventral positions.  We 
found that the ventral position led to a decreased signal to noise ratio due to the increased 
fluorescence contributions of the organs in the abdomen, along with the inability to visualize the 
iliac node due to its increased depth in this position.  With both injection sites, both the lymph 
nodes and draining lymphatic vessels were clearly visualized against the background tissues 
using fluorescence imaging (Figures 2.3 A and B). 
The position of the injection site within the footpad is also of importance.  We found that 
injections into the center of the hind footpad will drain solely into the popliteal node; however 
injections closer to outer edge of the footpad will drain partially into the inguinal node.  This is 
contrary to reports by Ruddell et al. [37] stating that the inguinal node is the major draining 
lymph node from the hind leg.  The non-central injections are not representative of the human 
lymph drainage since the human foot and leg drain to the popliteal node or the superficial 
inguinal nodes in the groin area, which correspond to the popliteal and iliac nodes on a mouse 
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[38].  The human lymph nodes corresponding to the mouse inguinal nodes are not the draining 
lymph nodes of the lower limbs in humans.  Over the course of 50 injections into the rear hind 
footpad, the inguinal lymph node was visualized in less than 3% of mice.  In addition, bilateral 
drainage was not observed for any of the subcutaneous injections.  Due to limitations of in vivo 
fluorescence imaging, only shallow nodes were identified; we do not discount further drainage 
past the axillary lymph node package or iliac nodes. 
!
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Figure 2.3.  Representative images of whole body fluorescence imaging of mice imaged on their 
right sides after a s.c. injection of HA-IR820 into the A) right hind footpad or B) right front 
forearm.  The A) popliteal (top lymph node), iliac (bottom lymph node), and B) axillary lymph 
nodes can be clearly visualized through the skin along with the draining lymphatics (lines 
connecting the lymph nodes).  The injection sites are covered in the images in order to see the 
definition of the draining lymphatics. 
A 
B 
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2.3.7  In Vivo Imaging Control Experiments 
An injection of free 5-carboxypentyl-amino-IR820 (free dye) was compared to HA-
IR820 in both the right hind footpad and the right front forearm injections.  The axillary lymph 
node was readily visualized through the skin less than five minutes after injection of the free dye.  
However with the HA-IR820 conjugates, the enhancement of the axillary node was only possible 
with fluorescence imaging.  Drainage to the popliteal and iliac nodes was only visualized with 
fluorescence imaging for both the free dye and HA-IR820 conjugates.  The free dye cleared 
rapidly from the nodes compared to the HA-IR820 conjugates.  The free dye was observed in 
both the lymph and blood capillaries via in vivo imaging (data not shown), whereas the HA-
IR820 conjugates were visualized only within the lymphatic capillaries.  More than 75% of the 
free dye cleared from the lymph nodes within 20 hrs post injection, and it was completely 
cleared within 48 hrs (Figures 2.4 A-C).  
Mice in the free dye footpad injection group exhibited significantly longer time to reach 
maximal fluorescence (tmax) compared to the HA-IR820 conjugates after the footpad injections, 
but for the forearm injections, the free dye and HA-IR820 groups had a similar tmax (Table 2.6).  
Because the in vivo fluorescence spectra of the free dye (!em=823 nm) and HA-IR820 (!em= 835 
and 870 nm) are different, their individual contributions are easily identified after spectral 
unmixing.  The nodal fluorescence signal can be attributed to the sole contribution of the intact 
HA-IR820 conjugate and not the free dye, after spectral unmixing.  The free dye and the intact 
HA-IR820 were detected in the livers of mice after the injection of the HA-IR820 conjugates.  
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Figure 2.4.  Drainage kinetics of the free dye (5-carboxypentyl-amino-IR820) into the A) 
popliteal (red), B) iliac (blue), and C) axillary (green) lymph nodes after a s.c. injection into the 
right hind footpad (corresponding to the popliteal and iliac nodes) or the right front forearm 
(corresponding to the axillary nodal package). 
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2.3.8  Molecular Weight Dependence on Lymphatic Uptake 
The molecular weight dependence of lymphatic uptake was determined using six 
different HA-IR820 conjugates within the size range reported to have efficient lymph uptake, 
generally 10 to 100 nm [5,8].  Mice were injected subcutaneously in the center of the hind 
footpad or in the front forearm with the HA-IR820 conjugates and were imaged at predetermined 
time points for up to one week (footpad injections) or two weeks (forearm injections).  The 
drainage kinetics of the HA-IR820 conjugates exhibited a similar trend for both injection sites 
and all three lymph nodes (Figures 2.5 A, 2.6 A, and 2.6 C).  A clear trend in the MW 
dependence of lymphatic uptake of HA-IR820 conjugates is easily identified when looking at the 
total AUC of each MW conjugate (Figures 2.5 B, 2.5 C, 2.6 B, and 2.6 D).  Both 6.4-kD and 74-
kD HA-IR820 have greatly enhanced uptake (large AUC) compared to the other conjugates 
(Figure 2.5 C, 2.5 D, and 2.5 E); however, excluding the 6.4-kDa conjugate, there is a normal 
distribution curve over the HA molecular weight range (Figure 2.5 C), with a maximum at 74 
kD.  As the HA MW increased, significant retention in all three lymph nodes was observed 
compared to the lower molecular weight HA-IR820 conjugates, as indicated by the long t50% 
values (time required for the fluorescence signal to reduce by 50%) (Table 2.6).  Furthermore, 
the HA-IR820 conjugates were retained longer in the axillary lymph node package than the 
popliteal node for all molecular weights (Table 2.6).  
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HA MW (kD) AUC (AU) 
6.4 19679 ± 2530 
35 12155 ± 786 
74 24190 ± 296 
132 7897 ± 1101 
357 5514 ±1669 
697 4381 ± 545 
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Figure 2.6.  "#$%&'()*! +,')-'./! (0! (&/! %0%1)(/'1! 234! 56! '-+! )1)'*! 274! 86! 1#$%&! -0+/9! 0:!
+)::/,/-(!;<!2=>?!@8A,/+!9BC',/9D!EF!@8A0,'-./!(,)'-.1/9D!G?!@8A.,//-!)-H/,(/+!(,)'-.1/9D!
IEJ! @8A1).&(! K1C/! +)'$0-+9D! EFG! @8AK1C/! *),*1/9D! =LG! @8A%C,%1/! 9(',96! M3ANOPJQ!
*0-RC.'(/9!':(/,!9>*>!)-R/*()0->!!N-*,/'9/+!1#$%&'()*!C%('@/!0:!(&/!G?@8!M3ANOPJQ!*0-RC.'(/!
)-(0!(&/!%0%1)(/'1!'-+!)1)'*!1#$%&!-0+/9!)9!/H)+/-(!)-!(&/!36!()$/!H9>!:1C0,/9*/-(!9).-'1!:0,!
(&/! %0%1)(/'1! -0+/4! *C$C1'()H/! :1C0,/9*/-*/! 9).-'19! )-! (&/! 56! ()$/! H9>! (0('1! :1C0,/9*/-*/!
9).-'1!:0,!(&/!%0%1)(/'1!-0+/4!76!()$/!H9>!:1C0,/9*/-(!9).-'1!:0,!(&/!)1)'*!-0+/4!'-+!*C$C1'()H/!
:1C0,/9*/-*/! 9).-'19! )-! (&/!86! ()$/!H9>! (0('1! :1C0,/9*/-*/! 9).-'1! :0,! (&/! )1)'*!-0+/!.,'%&9>!!
S&/! ;<! +)9(,)KC()0-! (,/-+9! 9&0T-! ',/! ,/%,/9/-('()H/! 0:! (&/! (,/-+9! 9//-! ':(/,! )$'.)-.!
$)*/!0-! (&/),! ,).&(! 9)+/9!%09(!M3ANOPJQ!'+$)-)9(,'()0->! !U6!S'KC1',!3V7!H'1C/9! :0,! /'*&!
;<!M3ANOPJQ!*0-RC.'(/!:0,!+,')-'./!)-(0!(&/!%0%1)(/'1!'-+!)1)'*!1#$%&!-0+/9!':(/,!'-!9>*>!
)-R/*()0-!)-(0!(&/!:0,/',$>!!!!
HA MW (kD) Popliteal AUC (AU) Iliac AUC (AU) 
6.4 9734 ± 1821  3860 ± 466 
35 3968 ± 1512  1019 ± 425  
74 11464 ± 1916 4173 ± 1071 
132 3589 ± 507  1505 ± 207  
357 4887 ± 385 1901 ± 282 
697 2867 ± 469  1088 ± 375  
E 
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2.4  Discussion 
 
2.4.1  In Vivo Imaging with HA-Texas Red 
Conjugation of Texas Red to HA easily executed with using both EDAC and CMPI as 
activating agents.  The use of CMPI yielded higher loading degrees than activation using EDAC, 
with 4% vs. 2% Texas Red loading on HA.  In the initial imaging study investigating the 
lymphatic drainage of the HA-Texas red conjugate in tumor bearing mouse, the addition of a 
large hydrophobic fluorescent dye did not impede the lymphatic drainage of the s.c. injected HA 
conjugate into the tumor lymphatic basin.  However, the signal to noise ratio of the HA-Texas 
Red conjugate in vivo could be improved by the use of a NIR dye, where the autofluorescence of 
the animal’s skin and organs is minimized (preferably wavelengths >800 nm).  In order to 
achieve deeper tissue penetration and increased signal to noise ratios of the fluorescent dye-HA 
conjugates, we chose to develop a HA-NIR dye conjugate utilizing an inexpensive NIR laser 
dye, IR820 for further optimization of the use of HA as a lymphatic carrier. 
 
2.4.2  Characterization of HA  
 
2.4.2.1  HA Polydispersities 
In order to prevent significant overlap in the size of the HA polymers for the 
determination of the optimal MW for lymphatic uptake, we selectively chose HA samples with 
corresponding MWs falling within 10-100 nm range size by doubling the size with each increase 
in MW, thus allowing for the study of a wide variety of sizes.  Once concern with using 
biopolymers, especially with HA, is their inherent polydisperse nature.  The MW and 
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polydispersities of the HAs purchased from Lifecore Biomedical were determined by multi-angle 
laser light scattering (MALLS) for the low MW HA polymers (! 357 kD), whereas intrinsic 
viscosity was used for MW determination of high MW HA polymers (" 697 kD) preventing their 
polydispersity index (PDI) determination.  The manufacturer reported polydispersities are listed 
in Table 2.4.  The PDI of the lower MW HAs (6.4 kD – 74 kD) are relatively narrow 
distributions for biopolymers, where the PDIs for the larger MW HAs (132 kD – 697 kD) are 
moderately dispersed.  
 
 
 
MW (kD) PDI (Mw/Mn) 
6.4 1.075 ± 0.018 
35 1.295 ± 0.004 
74 1.293 ± 0.007 
132 1.598 ± 0.012 
357 1.663 ± 0.008 
697 ------ 
 
 
Table 2.4.  Reported Polydispersity Indexes (PDI) from the HA manufacturer (Lifecore 
Biomedical).  MW and PDIs were determined using MALLS for low MW HA, where the MW 
for high MW HA was determined by intrinsic viscosity, resulting in no PDI value. 
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2.4.2.2  Zeta Potential of HA 
The zeta potentials of the HA samples were determined at pH >> pKa, to ensure that all 
of the carboxylic acid functional groups were fully ionized to minimize effects of pH changes on 
the measurements due to partial protonation of the carboxylic acids.  Partial protonation would 
lead to minor changes in the pH, and a reduction in the double layer thickness leading to zeta 
potentials of lower magnitude than for fully ionized polymers.  Further, the pH studied would be 
indicative of the ionization state in vivo, thus a leading to biologically relevant zeta potentials for 
HA.  There is no clear trend between the MW of HA and the zeta potential (Table 2.5).  It would 
be expected that the zeta potential would remain constant over the entire MW range, or the 
magnitude of the zeta potential would become larger as the MW was increased.  The expectation 
of a constant zeta potential is due to the fact that the number of carboxylic acids per disaccharide 
remains constant as the MW is increased, leading to the assumption of a constant zeta potential 
for all HA MWs.  Further, for a linear decrease in the zeta potential with increasing HA MW 
would be a result of a proportional increase of the number of carboxylic acids with increasing 
polymer length.  However, neither trend is evident in the HA samples.  One possible explanation 
of the variation in the zeta potential is that for HA, it may indicate the stability of the polymer 
rather than the extent of negative charge on the polymer chain or a measure of anionic nature, as 
the number of carboxylic acid groups is proportional to the increase in HA MW.  
 In general a zeta potential of ± 30 mV is the cutoff for indicating the stability of a 
particle.  If the -30 < zeta potential <30, then it is thought that the particles are regarded as 
unstable or have the propensity to aggregate.  Whereas if the zeta potential is above 30 or below 
-30, then the particles in solution are considered to be a stable suspension and are unlikely to 
form aggregates.  As the MW of HA is increased in low ionic strength solutions pH 3-9, HA 
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forms an extensively stable entangled network that is stabilized by hydrogen bonds and other 
non-covalent interactions even at low concentrations <1 !g/mL.  Further, the longer the HA 
chain, the entangled network becomes more consistent and extensive.  It has been reported that 
HA polymers of less than 7 disaccharides do not self-associate, 7-20 disaccharides (~2800-8000 
Da) in length form monomer or dimers, and fragments of greater than 35 disaccharides (>14 
kDa) can form intermolecular “hairpins”; and polymers of at least 60 disaccharides (~24 kDa) 
form stiffened segments [39].   These self-associations with HA polymer fragments are 
dependent on concentration, pH, ionic strength, and counterions.  Dilute solutions of HA can 
aggregate in NaCl and CaCl2; however, it does not do so in KCl. 
As this study was conducted at a relatively high concentration (100 µg/mL), low ionic 
strength (1 mM), and in the presence of K+ ions, it is likely that aggregates are not being formed 
at any MW.  It is likely that the dramatic jump in the zeta potential is due to the formation of the 
stable stiffened sections along the HA polymer along with the formation of a stable 
interconnected long range network, which is reflected by the jump in the magnitude of the zeta 
potential as the MW is increased, suggesting a stable HA network in solution. 
 
2.4.3  Characterization of HA-IR820 
The conjugation efficiency of IR820 to HA is approximately 30%.  This low efficiency 
could be in part due to the dialysis purification of HA-IR820 against water.  The initial dye 
loading degree could be higher than the ca. 5% determined by NMR, however, a significant 
amount of dye could be lost due to hydrolysis of the ester bond between carboxyl group on the 
IR820 linker and the alcohol group on HA during the dialysis purification against water.  Two 
possible ways to circumvent this possible loss in efficiency is by purification with a centrifugal 
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filter device, or utilizing an amide bond between an amino terminated linker on IR820 with the 
carboxylic acid on HA.    
Linear polymers, PEG and HA, of the same given molecular weight, can exhibit 
dramatically different solution characteristics.  One example is HA has a larger excluded volume 
than that of PEG, as displayed by the shorter SEC retention time of HA.  This is likely due to the 
conformation of the polymers in solution, where HA resides in an stiffened random coil with 
extensive intermolecular hydrogen bonding whose size is dependant on the solution water 
content, pH, ionic strength and composition [32,39].  Where PEG forms a more compact coiled-
coil conformation that presents moderate swelling with the unique packing of water molecules 
within the coiled-coil [40].  The MW of the conjugates were similar or slightly lower to that of 
the original HA used, with the exception of the highest MW of 697-kD, which exhibited a 
significantly lower MW than that of the original HA (Figure 2.2).  This is possibly due to the 
nature of the conjugation reaction between HA and IR820 as EDAC is commonly used as a HA 
crosslinking agent [35,41], in which it is possible for intramolecular cross linking between the 
carboxylic acid and alcohol groups on HA, thus leading to a lower apparent MW.  The 
intramolecular crosslinking is likely more evident with the 697-kD conjugate due to the 
increased equivalents of EDAC and extended reaction time used in the conjugation reaction.  
With the 35-kD to 357-kD conjugates, there is some decrease in the apparent MW, as seen in the 
SEC longer retention times, compared to the original HA, but the change is minimal compared to 
that of the highest MW conjugate.   
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2.4.4  In Vivo Fluorescence Imaging Optimization and Data Analysis  
Selective targeting of the sentinel lymph node is possible by s.c. injections into different 
anatomical regions in rodents [42].  The drainage pattern for a s.c. injection into the hind footpad 
results in drainage to the popliteal lymph node through the efferent popliteal trunk to iliac node.  
Likewise, the drainage pattern for a s.c. injection into the front forearm results in drainage to the 
axillary lymph node package.  Because melanoma and breast cancer metastasize primarily via 
the lymphatics [2,43], identification of the sentinel lymph node is crucial staging and treatment 
of the disease.  Drainage to the popliteal and axillary lymph nodes in rodents would serve as 
model for the SLN involved in melanoma and breast cancer.  For localized limb melanoma in 
humans, the axillary nodal package is the SLN for the arms, while the popliteal or inguinal 
lymph nodes of the groin (popliteal and iliac are the corresponding nodes in rodents) are the 
sentinel lymph nodes for the legs [38]. Furthermore, the axillary lymph node package is the SLN 
in breast cancer [44,45].  Modeling the SLN drainage kinetics to the popliteal or axillary nodes 
instrumental in the development of lymphatically targeted carriers for imaging and drug delivery.   
For the imaging studies, mice were injected with HA-IR820 on a dye basis, due to the 
different loading degrees of IR820 on HA.  Failure to do so would have lead to artificial 
differences in the uptake due to differing concentrations of the fluorophore.  Although the dye 
concentration was held constant, slight variations in the fluorescence intensities were observed.  
In order to normalize the imaging data for the slight variations, the total integrated fluorescence 
emission was determined using the in vivo imaging excitation and emission parameters (!ex= 700 
nm, !em=800-900 nm) for each conjugate (0.1 mg/mL).  The emission wavelengths of 800-900 
nm were used due to the limitations of the spectrofluorometer, where the in vivo imager recorded 
the emission from 800 to 950 nm.  After the fluorescence signal intensities were determined from 
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the ROI placed over the lymph nodes, the intensities were normalized to the corresponding 
integrated fluorescence emission ratios.  The MW distribution patterns for the lymphatic uptake 
remained unchanged after normalization.  
 
2.4.5  In Vivo Imaging Control Experiments 
After s.c. injection of the free dye, drainage via the lymphatic and vascular routes were 
observed using in vivo imaging.  In contrast, the HA-IR820 conjugates exhibited only lymphatic 
drainage.  This indicates that the free dye can diffuse into blood capillaries whereas HA is 
excluded from hematological uptake within the tissues.  More than 75% of the free dye cleared 
from the lymph nodes within 20 hrs post injection, and it was completely cleared within 48 hrs.  
Similarly, in a study evaluating the lymphatic drainage of free indocyanine green (ICG) and ICG 
encapsulated liposomes (LP-ICG), both the ICG and LP-ICG cleared within 48 hr post injection 
[46]. Lymphatic imaging dyes such as isosulfan blue drains rapidly from the injection site, with 
34%, 69%, and 100% absorption at 30 min, 1 hr, and 24 hr post s.c. injection [47].  IR820 has 
some lipid solubility and may accumulate in lipid membranes.  It also may form conjugates with 
intracellular proteins that retain it. 
After injection of the HA-IR820 conjugates, free dye was detected in the liver and not the 
lymph nodes.  This suggests that the IR820 is not released until the conjugate progresses through 
the lymphatics and into the systemic circulation, where it is cleared and degraded by the liver 
[24].  However, it cannot be disregarded that the IR820 could release before emptying into the 
circulation but after the draining to the first two lymph nodes, due to the depth limitations of 
fluorescence imaging (ca. 1 cm) further lymph drainage to the echelon nodes cannot be detected 
with live animals.  The intact HA-IR820 was also detected in the liver 4 to 8 h after 
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administration; however, the fluorescence signal intensity was weak compared to that of the free 
dye.  
 
2.4.6  Molecular Weight Dependence on Lymphatic Uptake 
Although both 6.4-kD and 74-kD HA-IR820 had similar lymphatic uptake in all three 
lymph nodes studied, 74-kD HA-IR820 was chosen as the optimal MW.  Low molecular weight 
HA (ca. 1-kDa to 10-kDa) stimulates angiogenesis [48] and inflammation [18,49], so there may 
be a different underlying mechanism for uptake of low molecular weight HA leading to the 
unexpectedly large AUC of 6.4-kD HA-IR820.  Further investigation into the increased uptake 
of low molecular weight HA compared to larger HA is underway.  It is worth noting, that no 
signs of toxicity were observed in any of the experimental groups (free dye and all HA-IR820 
conjugates) for the entire length of the study (one week for the footpad group, and two weeks for 
the forearm group).  The reported optimal liposomal size for lymphatic uptake after 
subcutaneous injection is 40 nm [50], which correlates well with our observation that 74-kD HA-
IR820 is optimal for lymphatic uptake (30-50 nm in diameter, based on calculated Rg and Rh 
values, see Table 2.1). 
A similar effect of molecular weight on lymphatic uptake has been observed with 
proteins; as the MW of s.c. injected proteins increases, the percent recovered dose also increases 
and approaches a plateau at 84-kD.  There was a linear correlation with percent recovered to 
protein molecular weight up to 30-kD (83.9 % ± 3.3 %), which eventually approached 100% 
with an 84-kD protein  (96.9 % ± 6.6 %) [51,52].  However, molecular weight was not the only 
factor governing the lymphatic uptake in the protein studies, as the charge of the different 
proteins also varied but was not considered in their analysis.  With the various proteins reported 
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in the studies, as increase the protein MW increases, the overall size doesn’t differ dramatically, 
as they are all relatively small (< 10 -15 nm); however, with HA, as MW increases, the size also 
increases.  The minimal changes in size of the proteins are due to the compact nature of globular 
proteins, whereas the large hydrated volume of HA in solution and its random coiled structure 
are ascribed to its large hydrodynamic volume.  Ogston and Stainer best describe HA as it 
“behaves hydrodyamically like a large solvated sphere containing a thousand times more water 
than organic material [39].”  Reddy et al. demonstrated that 71-kD FITC-labeled dextran has a 
faster solute velocity within the interstitium compared to a 3-kD, 40-kD, and 2-MD dextran-
FITCs or 69-kD bovine serum albumin [53].  This agrees with our observation that the 74-kD 
HA has the greatest lymphatic uptake within the study’s timeframe. 
 
2.5  Conclusions 
We optimized the molecular weight of HA for use as a multimodal carrier for lymphatic 
imaging and drug delivery, using a NIR-dye-HA conjugate with in vivo fluorescence imaging.  
Hyaluronan with a molecular weight of 74-kD was determined to be optimal for lymphatic 
imaging, due to its maximal lymphatic uptake and enhanced lymph node retention.  This 
corresponds to a calculated size of ca. 30 to 50 nm, which is consistent with the reported optimal 
size of liposomes for lymphatic uptake [50].  Previous studies which optimized the particulate 
size for enhanced lymphatic uptake have focused either on several small dendrimers between 5 
and 20 nm in size, which are near the point of capillary uptake [54,55], or two to three different 
liposomes or nanoparticles with differing compositions over an extremely wide size range (100-
150 nm spread) [5,50].  In addition, the differently sized particles often have very different 
overall charges or hydrophobicities, such as different proteins.  These new variables further 
!
!
67!
complicate the investigation of the effect of size on lymphatic uptake.  We utilized a single 
polymer, HA, so the resulting differences in the uptake kinetics were independent of charge or 
hydrophobicity.  Since HA is a linear polymer, the molecular weight was directly proportional to 
the number of surface carboxylic acid groups, whereas with dendrimers, the number of surface 
groups increases exponentially with molecular weight and the exposure of the more hydrophobic 
core can change with size.   
Hyaluronan is more favorable for clinical imaging than non-biodegradable imaging 
agents, such as PAMAM dendrimers and QDs, and no toxicities were observed over several 
weeks in these studies.  Agents such as QDs must be limited to 5 nm or less in size for renal 
clearance, but still are susceptible to long bioretention and heavy metal leakage.  In addition, 
most dendrimers currently under investigation contain multiple amino groups that have to be 
further functionalized with PEG or anionic or neutral ligands to reduce their cationic nature and 
minimize their toxicity [56].  
Hyaluronan holds great promise as a natural biopolymer for drug delivery and lymphatic 
imaging.  It is non-immunogenic, non-toxic, and it naturally degrades within the lymphatics, 
unlike most other drug delivery platforms.  We have shown that the retention of HA can be 
tailored from periods of hours to days within the nodal tissues, making it suitable for both 
sustained drug delivery and long-term imaging of the lymphoid tissues.   
One issue that has arisen in the development HA dye and chemotherapeutic conjugates, is 
that HA is extremely viscous thus limiting the MW < 74-kD (optimal MW) and dilute solutions, 
leading to large injection volumes in order to achieve therapeutic doses.  Further, the loading 
degree is also limited due to the possible alterations in its biocompatibility and solubility.  In 
order to overcome these challenges, we developed a new biodegradable star polymer with 
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variable anionic charge as a new lymphatic delivery vehicle.  The effect of the degree of negative 
charge on the lymphatic uptake utilizing the same techniques presented in this chapter with the 
use of the IR820 NIR dye and whole body fluorescence imaging is discussed in Chapter 3.  The 
size optimization of the conjugate lays the foundation for further investigation into the effect of 
negative charge on the lymphatic uptake of star polymers (Chapter 3) and the differences in the 
drainage kinetics of HA in a murine melanoma tumor model (Chapter 4). 
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Chapter 3.  Development and Optimization of Polyanionic Star 
Polymer-Fluorescent Dye Conjugates for Intralymphatic Delivery 
Using in vivo Fluorescence Imaging  
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3.1  Introduction 
In addition to the effects of size on lymphatic uptake that we investigated in the previous 
chapter, the charge, hydrophobicity, injection site, and dose also play an important role [1-3].  A 
number of different delivery vehicles have been employed for lymphatic imaging and drug 
delivery, including:  liposomes, dendrimers, quantum dots, synthetic polymers, and natural 
polymers.  In Chapter 2, I discussed our previous studies using a natural biopolymer, hyaluronan 
(HA), for targeted lymphatic drug delivery [4-8] and its dependence on size for optimal 
lymphatic uptake and nodal retention.  Using a series of HA-near infrared (NIR) fluorescent dye 
conjugates developed for in vivo fluorescence imaging, we determined that the optimal 
particulate size for lymphatic uptake was 30-50 nm. 
Reports have demonstrated that negatively charged particles have increased lymphatic 
uptake compared to neutral to positively charged particles [9-11], in part due to the electrostatic 
repulsions between the negatively charged particles and the extracellular matrix [1], which is 
primarily negatively charged [1-3].  Also, negatively charged particles are retained longer by 
lymph nodes [1,10,12].  However, little research has been conducted into the extent of negative 
charge required for enhanced lymphatic uptake.  To date, only one report on the effects of 
varying the degree of negative charge of particles on the lymphatic uptake, in which Rao and 
coworkers varied the ratio of carboxylic acid terminated poly(D,L-lactic-co-glycolic) with non-
terminated PLGA to give nanoparticles with various degrees of anionic charge.  The lymphatic 
uptake of the three of different negatively charged nanoparticles was investigated in rats after a 
subcutaneous (s.c.) injection into the hind footpad [1].  An increase in the negative charge of the 
nanoparticles resulted increased lymphatic uptake. 
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In this study, we sought to determine the optimal degree of anionic character needed for 
lymphatic uptake of a drug delivery system.  However, additional surface modification to our 
previous lymphatic delivery platform HA was not a viable option as it is already highly charged.  
These high degrees of modification are synthetically difficult, may alter the solubility profile, or 
could change its biological behavior in vivo, such as loss of receptor recognition or initiation of 
immune responses, essentially defeating the purpose of using a biopolymer as the carrier.  
Liposomes and dendrimers are the most commonly used platforms for lymphatic delivery, both 
of which can be modified to have polyanionic surface charges.  Dendrimers are appealing due to 
their low polydispersities, compact size (nm in size), multi-valent surface groups, and high water 
solubility.  Dendrimers are more attractive, due to their compact structure which resembles 
globular structure of endogenous proteins, rather than linear polymers that form random coils in 
solution [13].  Further, dendrimers exhibit low solution viscosities [14].  However, issues with 
their clearance, toxicity, and biodegradability have limited the use of dendrimers as delivery 
vehicles.  Polyamidoamine (PAMAM) and diaminobutane (DAB) dendrimers are the most 
commonly used dendrimers, in part due to their commercial availability, compact size, and the 
polyamido core assists in increasing the water solubility and reducing the immunogenicity [13].  
Both PAMAM and DAB dendrimers are highly cationic; however, fictionalization of the 
terminal amino groups with neutral or negatively charged ligands, is desirable for optimizing the 
lymphatic uptake [15,16].  However, PAMAMs are not biodegradable, thus limiting the size for 
lymphatic drug delivery and imaging to particles less than 5 to 6 nm for renal clearance [17,18].  
Particles of this size are not selective for lymphatic uptake, and can also be absorbed by the 
blood capillaries.  Further, dendrimer based imaging agents optimized for lymphatic uptake and 
renal clearance, migrate readily through the lymphatics with little to no nodal retention, thus 
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limiting their use as a localized sustained release drug delivery platform.  In addition, high 
conjugation of hydrophobic chemotherapeutics and fluorescent dyes limits the dendrimer 
solubility.  Although biodegradable dendrimers have been developed using amino acids as their 
building blocks, they are unlikely to exhibit significant accumulation, and the degradation 
products have shown toxicity [13].  There is a great need to develop biodegradable drug delivery 
system for lymphatic delivery that have both the optimal size and charge for enhanced lymphatic 
uptake. 
For these reasons, we developed a new water soluble, degradable star polymer as a 
lymphatic delivery platform with various degrees of anionic charge.  Star polymers are three-
dimensional with linear polymeric arms emanating from a branched central core [19,20].  Like 
dendrimers, star polymers are branched polymers that have a compact structure, are globular in 
shape, and have large surface areas, which make them optimal platforms for lymphatic delivery.  
Further, hyperbranched polymers and multi-arm star polymers exhibit low intrinsic viscosities 
and increased solubilities compared to their linear counterparts [21,22].  Star polymers can be 
synthesized using a living radical polymerization techniques, including reversible addition-
fragmentation chain transfer (RAFT) and macromolecular design via the interchange of 
xanthates (MADIX) with a broad range of reaction conditions and functional groups [23].   With 
the use of RAFT polymerization, it is possible to construct star polymers while accurately 
controlling the molecular weight [23,24], resulting in low polydispersities.   
A series of 4-armed star-polymers with varying degrees of negative charge were 
developed for the investigation of the extent of anionic character required for optimal lymphatic 
uptake.  A near infrared dye, IR820, was conjugated to the polymers to utilize the capabilities of 
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whole body fluorescent imaging to detect the effects of negative charge on the lymphatic uptake 
of star polymers.  
 
 
3.2  Experimental 
 
3.2.1  Star Polymer Synthesis 
A series of 4-arm star polymers with various degrees of anionic charge, were previously 
synthesized by Dr. Duan in our laboratory using the MADIX/RAFT polymerization method 
(macromolecular design by interchange of xanthates/reversible addition-fragmentation chain 
transfer).  For the detailed synthetic procedure of the star polymer synthesis and the 1H NMR 
assignments, see Appendix 1.  Briefly, the synthetic procedure for the MADIX agent was the 
same as previously reported by Stenzel et al. [25].  The MADIX agent was formed by the 
addition of a xanthate group to pentaerythritol to form the 4-armed core for the star polymer 
(Scheme 3.1).  The RAFT agent and the MADIX/RAFT polymerization were synthesized 
according to Ting et al [26]. Briefly, a 6-O-methacryloyl-D-galactose was used as the repeating 
unit in the polymerization reaction initiated by AIBN to give the sugar-star polymer (Scheme 
3.2).  After deprotection, the sugar-star polymer was conjugated with various amounts of 
succinic anhydride to vary the degree of anionic charge on the star polymer.  Briefly, 20, 40, 60, 
and 90 wt% succinic anhydride was reacted with the sugar-star polymer in DMF/pyridine to 
yield the sugar-acid star polymers with 20, 40, 60, and 90 wt% acid (Scheme 3.3).  All of the 
synthesized compounds were verified by 1H-NMR. 
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The molecular weights and polydispersity index (PDI) of the protected (star poly-
(1,2:3,4-Di-O-isopropylidene-6-O-methacryloyl-!-D-galactopyranose)) and deprotected (star 
poly-(6-O-methacryloyl-D-galactose)) sugar-star polymers were determined by size exclusion 
chromatography (SEC) (Shimadzu 2010CHT) using a TSK gel multipore Hx-M column coupled 
with a refractive index detector (Shimadzu RID-10A), and using 0.8 mL/min of DMF containing 
10-mM LiCl as the mobile phase.  Calibration curves were generated with polystyrene standards 
(1,180 to 339,500 g/mol) or polyethylene glycol (PEG) standards (3070 to 66,100 g/mol) for the 
protected and deprotected sugar-star polymers, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.1.  Synthesis of a MADIX agent. 
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Scheme 3.2.  Synthesis of the 4-arm sugar star polymers by MADIX/RAFT polymerization. 
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Scheme 3.3.  Modification of the star poly-(6-O-methacryloyl-D-galactose) with succinic 
anhydride to give the 20, 40, 60, and 90%  wt/wt star-polymer. 
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3.2.2  Star-IR820 Synthesis 
To the series of various wt% acid star polymers synthesized in our laboratory, IR-820 
was added to yield a series of star-IR820 conjugates with various degrees of anionic charge for in 
vivo imaging.  First, to a solution of IR-820 (100 mg, 0.094 mmol) in 20 mL dry DMF, 1,3-
diaminopropane (40 µL, 0.47 mmol) was added dropwise.  The solution was gradually heated to 
60 °C, and was allowed to react for four hours protected from light.  The solvent was evaporated 
under reduced pressure followed purification by column chromatography (1:1 EtOAC:MeOH).  
The fractions were combined and the solvent was removed under reduced pressure, yielding a 
dark blue solid (65 mg, 78%) (Scheme 3.4).  The 3-aminopropyl-amino-IR820 derivative was 
then conjugated to the sugar-acid star polymer in dry DMF with EDAC activation and 
HOBt!H2O as the catalyst (Scheme 3.5).  Briefly, to a cooled solution (0 °C) of the sugar-acid-
star polymer (60% acid) (75 mg) in 20 mL dry DMF, then EDAC (28.1 mg, 0.147 mmol) and 
HOBt!H2O (22.5 mg, 0.147 mmol) were added.  After five minutes, the 3-aminopropyl-amino-
IR820 derivative (65 mg, 0.073 mmol) in DMF (5 mL) was added dropwise.  The reaction was 
allowed to proceed at ambient temperature overnight, protected from light.  The resulting sugar-
acid-star-polymer-IR820 (star-IR820) was purified by dialysis against EtOH:H2O (1:1) followed 
by 100% EtOH.  The resulting series of acid-star-IR820 conjugates were bluish-purple in color, 
and the loading degree of IR820 on the star polymers was determined by 1H NMR in MeOD.  
The 3-aminopropyl-amino-IR820 derivative conjugation reactions with the 20, 40, and 90% 
wt/wt acid-star polymers along with the 1H NMR assignments can be found in Appendix 1. 
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Scheme 3.4.  Synthesis of the 3-aminopropyl-amino-IR820 derivative. 
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Scheme 3.5.  Conjugation of 3-aminopropyl-amino-IR820 to a sugar-acid-star polymer to give 
the star-IR820 conjugate. 
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3.2.3  Rheological Properties 
The viscosities of the different molecular weight HA samples used for lymphatic imaging 
in Chapter 2, along with the different acid star polymers were determined in PBS at pH 7.4.  
Sugar star polymer and sugar acid star polymer samples were dissolved in PBS (at ca.100 
mg/mL conc.) and dialyzed against PBS (pH 7.4) for 48 hours at ambient temperature using a 
3.5-kD MWCO dialysis tubing (regenerated cellulose, Fisherbrand) to adjust the pH.  The HA 
samples were dissolved in PBS pH 7.4 and were used without any further adjustment in pH.  The 
polymers (star and HA) were then diluted to 1, 5, and 10 mg/mL with PBS (pH 7.4).  The 
rheological properties were measured in triplicate using an Advanced Rheometer 2000 (TA 
Instruments, New Castle, DE), at 25°C using a 40 mm 2° aluminum cone geometry and a 49 !m 
gap distance.  The shear rate was increased using a steady state flow step, from 10 to 100 s-1 with 
10 points per decade using a log scale and a sample period of 10 s. The steady state parameters 
were set to 5% deviation for three consecutive points within a maximum time of 1 minute per 
shear rate. 
 
3.2.4  Zeta Potential of the Star Polymers 
Sugar-star and sugar-acid-star polymer samples were dissolved in ddH2O to a 
concentration of ca. 1 mg/mL, the pH was then adjusted to 7.2 ± 0.1 with sodium hydroxide, and 
the final concentration was noted.  The samples were then diluted to 1, 10, and 100 !g/mL with 
pH 7.25 1-mM phosphate buffer with the addition of 1mM of KCl.  After dilution, the pH was 
rechecked.  Zeta potentials were measured on a ZetaPALS (Brookhaven Instruments Corporation, 
Holtsville, NY) at 20°C and the sample measurements were repeated six times.  
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3.2.5  In Vitro Toxicity of the Star Polymers 
B16F10 (lymphatically metastatic murine melanoma, ATCC), MDA-MB-231 (human 
breast cancer), MDA-1986 (lymphatically metastatic human head and neck cancer), and HUVEC 
(normal human endothelial) cell lines, were maintained in Dulbecco's modified Eagle’s medium 
(DMEM) supplemented with 1% L-Glutamine and 10% bovine growth serum in 5% CO2 
atmosphere.  The HER2 expressing murine breast cancer cell line, 4T1.2 Neu, was a gift from Dr. 
Zhaoyang You, from the University of Pittsburg, and was maintained in DMEM supplemented 
with 1% L-Glutamine, 10 % bovine growth serum, and 500 µg/mL of G418 (geneticin) in 5% 
CO2 atmosphere.  The lymphatically metastatic human melanoma cell line, A2058, was 
purchased from ATCC, and was maintained in low sodium bicarbonate DMEM supplemented 
with 1% L-Glutamine, and 10% bovine growth serum in 5% CO2 atmosphere.  
The sugar-acid star polymer samples (20, 40, 60, and 90 wt% acid) were dialyzed against 
PBS (as described in rheometry section) for 48 hours to adjust the pH to 7.4.  The solutions were 
concentrated to ca. 100 mg/mL using a Speedvac concentrator (Labconoco) and then diluted in 
sterile 1! PBS (Fisher BioReagents, pH 7.4) to eight concentrations between 10-4 to 10-9 M.  
Prior to cell growth inhibition studies, cells were trypsinized and seeded at 3000 cells/well 96-
well tissue culture treated plates. After 24 hours, the 20%, 40%, 60%, and 90% acid-sugar star 
polymers in PBS were added to the HUVEC, A2058, and 4T1.2 Neu cells (n=8, 10 µL/well, 8 
concentrations).  Only the 60% acid-sugar star polymer sample was added to the B16F10, MDA-
MB-231, and MDA-1986 cells 24 hours after seeding (n=8, 10 µL/well, 8 concentrations).  A 
solution of 10% trichloracetic acid was used as a negative control, and media was used as a 
positive control (n=8, 10 µL/well).  At 72 hours post addition, 10 µL of resazurin blue in PBS 
was added (5 µM final concentration) to each well and the well fluorescence was measured  after 
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3 hours (!ex/!em = 560/590 nm) (SpectraMax Gemini, Molecular Devices).  IC50s were 
determined using the nonlinear regression curve fit for a one-site competition (GraphPad Prism 
10). 
 
3.2.6  In Vivo Imaging of Star-IR820 
In vivo imaging with the star-IR820 conjugates was performed as previously discussed 
for the HA-IR820 conjugates in the hind footpad.  As in chapter 2, all mice were fed a low 
chlorophyll diet (Harlan 2918 irradiated diet) for at least one week prior to imaging to decrease 
food induced organ and skin autofluorescence.  The mouse’s hair in the area of interest for 
imaging was removed 24 hours prior to imaging with clippers followed by depilatory cream.  
Female Balb/c mice (20-25 g, Charles River) (3 per group) were anesthetized under isoflurane, 
placed on a heating pad to help regulate body temperature, and were injected subcutaneously 
(s.c.) with 10 µL of a 0.1 mg/mL (IR820 dye conc.) of star-IR820 conjugates (20%, 40%, 60%, 
and 90% acid-star-IR820) in the center of the right hind footpad.  The mice were imaged from 
both the dorsal and right sides, both with and without the injection site being covered, using 
whole body fluorescence imaging (Cambridge Research and Instrumentation Maestro multi-
spectrum imager, Woburn, MA) using an excitation filter of 710-760 nm and broadpass emission 
filter of 800-950 nm.  The animals were imaged, under isoflurane anesthesia, for a maximum of 
7 days.   
Due to the intense fluorescence signal from the injection site saturating the camera, the 
injection area was covered with a piece of black tape allowing the visualization of the draining 
lymphatic vessels and lymph nodes.  Images were acquired using the autoexposure function in 
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the imaging software.  The use of the autoexpose function resulted in different exposure times 
for each image, which were corrected for using the scaled counts/s in the image analysis. 
 
3.2.7  In Vivo Imaging Data Analysis 
Image analysis was performed using Maestro software (ver. 2.10).  Regions of interest 
(ROI) were placed over the popliteal and iliac lymph nodes.  The total signal (scaled counts/s, 
see equation below as described by the Maestro software) intensity values (arbitrary units, AU) 
were recorded for each ROI, for both positions (prone and right), and were graphed versus time 
in GraphPad Prism (ver. 4).  The total fluorescence intensity vs. time graphs were integrated to 
give the cumulative fluorescence vs. time graphs.  In addition, the area under the curve (AUC) 
was determined from the total fluorescence intensity vs. time graphs.  Comparisons between 
multiple groups were made with one-way ANOVA analysis with a Turkey Multiple 
Comparisons post-test.   
 
Scaled counts/s = counts/full scale ! 1/exp(s) ! 1/bin2 ! 1/gain 
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3.3  Results 
 
3.3.1  Characterization of the Star Polymer and Star-IR820 Conjugates 
The sugar-star polymers synthesis was verified by mass spectroscopy and NMR (data not 
shown).  From the SEC calibration curves with polystyrene (1,180 to 339,500 g/mol) and PEG 
(3070 to 66,100 g/mol) standards, the molecular weights and PDI were calculated to be 75,000 
and 1.132, for the protected sugar-star polymer and 45,000 and 1.15 for the deprotected sugar-
star polymer, respectively.  Following the conjugation of IR820 to the acid-star polymers, the 
acid-star-IR820 conjugates were bluish-purple in color.  The IR820 loading degree was 
determined by 1H NMR in MeOD, by the ratio of the aromatic ring protons of IR820 with the 
proton on the repeating unit of the star-polymer.  The calculated MWs and the IR820 loading 
degrees are presented in Table 3.1. 
 
 
 
% Acid 
Theoretical 
Polymer   
MW (Da) 
Mn, SEC* 
(Da) wt% IR820 
# dyes/HA 
polymer 
20 54, 000 45,890 7.8% 5.3 
40 63, 000 54,390 6.8% 5.3 
60 72,000 60,110 5.2% 4.6 
90 85,500 75,100 8.6% 9.3 
 
 
Table 3.1.  IR820 loading degree on the various wt% acid-sugar star polymers. 
*Mn  obtained from PEG standards, DMF (10mM LiCl) as the mobile phase at a flow rate of 1 
ml/min. 
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3.3.2  Rheological Properties 
The trends between the two polymer systems (sugar star polymers and HA) with respect 
to increasing the concentration and MW on the apparent viscosity were determined by rheology.  
The viscosities of the star polymer and HA samples in Figures 3.1 A and B represent the 
apparent viscosities of the polymers at a shear rate of 100 s-1. The data obtained for the other 
shear rates exhibited the same trends as presented in Figures 3.1 A and B for a shear rate of 100 
s-1; however, the apparent viscosities observed for the lower shear rates were observed to be 
slightly lower than for that at the shear rate reported du to the shear thinning of the polymers.   
As the concentration increases in Figure 3.1 A, for each individual sugar or sugar-acid star 
polymer, the apparent viscosity also increases.  However, as the MW is increased (sugar < 20% 
< 40% < 60% < 90%) at a given concentration, the apparent viscosity remains relatively constant. 
In contrast, as the concentration of HA is increased, the viscosity also increases; the same trend 
is also observed with MW (Figure 3.1 B).  
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Figure 3.1.  A) Viscosity of the sugar-star polymers in pH 7.4 PBS at a shear rate of 100 s-1.      
B) Viscosity of HA and star polymers at 1, 5, and 10 mg/mL in PBS pH 7.4 at a shear rate of 100 
s-1.  (n=3)!! 
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3.3.3  Zeta Potential of the Star Polymers 
A linear response between the wt% acid and zeta potential was observed (R2 = 0.9831).  
The zeta potentials in Figure 3.2 were for the 100 !g/mL concentration.  The zeta potentials of 
the star polymer samples were determined at pH >> pKa, to ensure that all of the carboxylic acid 
functional groups were fully ionized to minimize effects of pH changes on the measurements due 
to partial protonation of the carboxylic acids.  Partial protonation would lead to minor changes in 
the pH, and a reduction in the double layer thickness leading to zeta potentials of lower 
magnitude than for fully ionized polymers.  Further, the pH studied would be indicative of the 
ionization state in vivo, thus a leading to biologically relevant zeta potentials for the star 
polymers.  The zeta potential readings for the other concentrations  (1 and 10 !g/mL) resulted in 
erratic readings, suggesting that the concentration was too dilute in order to achieve an adequate 
signal to noise ratio obtain quantitative data.  Further, in a previous zeta potential study, the pH 
was not controlled and the samples were 5" more concentrated, which also lead to erratic zeta 
potential readings with no real correlation (data not shown).  
 
!
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Figure 3.2.  Zeta potentials of the different wt% acid sugar star polymers at 20 °C, 100 !g/mL, 
and a 1-mM phosphate buffer (pH 7.25) with 1-mM KCl.   
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3.3.4  In Vitro Toxicity of the Star Polymers 
 
All four of the sugar-acid star polymers had similar anti-proliferative activity in all of the 
cell lines examined, with the exception of the 60% acid sugar star polymer in the MDA-1986 
cells, which exhibited a 10-fold increase in toxicity compared to the other cell lines (Table 3.2).  
 
 
 
 
 
 Cell Line 
wt % 
Acid HUVEC A2058 4T1.2 Neu B16F10 MDA1986 MDA-MB-231 
20 ~50 µM (2.7 mg/mL) 
~50 µM     
(2.7 mg/mL) 
~50 µM   
(2.7 mg/mL) ------ ------ ------ 
40 ~55 µM   (3.5 mg/mL) 
~40 µM   
(2.5 mg/mL) 
~50 µM   
(3.2 mg/mL) ------ ------ ------ 
60 ~100 µM (7.2 mg/mL) 
~60 µM   
(4.3 mg/mL) 
~100 µM 
(7.2 mg/mL) 
>100 µM 
(7.2 mg/mL) 
10 µM     
(0.72 mg/mL) 
!100 µM     
(7.2 mg/mL) 
90 ~55 µM   (4.7 mg/mL) 
~50 µM   
(4.3 mg/mL) 
~55 µM 
(4.7 mg/mL) ------ ------ ------ 
 
 
Table 3.2.  IC50 values of the sugar-acid star polymers in various cell lines. 
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3.3.5  In Vivo Imaging of Star-IR820 
In this study, the four sugar-acid-star-IR820 conjugates are approximately the same 
molecular weight but have various degrees of anionic charges and a wide zeta potential 
distribution.  The differences in the lymphatic uptake of the star polymers after s.c. 
administration are governed by the effect of charge rather than size.  Drainage from the injection 
site occurs at similar rates for all four of the sugar-acid-star-IR820 conjugates, as indicated by 
the same tmax (time to reach maximal fluorescence signal) of 45 min (Table 3.3). As described in 
Chapter 2, with a series of six different MW HA-IR820 conjugates with the same charge, the tmax 
increased with the polymer MW. 
The drainage kinetics to the popliteal and iliac nodes of the acid-star-IR820 conjugates 
post s.c. administration are presented in Figures 3.3 A and 3.4 B, respectively.  The kinetic 
profile for the lymphatic drainage of the 20% acid-star-IR820 conjugate to both the popliteal and 
iliac nodes indicates that the 20% acid-star-IR820 conjugate has statistically lower lymphatic 
uptake and increased retention in the popliteal and iliac lymph nodes over the length of the study 
compared to the 40, 60 and 90% acid-star-IR820 conjugates (popliteal node, p<0.05, <0.0001, 
and <0.001, for the 40, 60 and 90% acid, respectively; iliac node, p<0.0001 for all three 
conjugates).  The 20% acid conjugate is highly retained at the injection site and the popliteal 
node, as indicated by the lower maximum fluorescence signal and longer t50% (time required for 
the fluorescence signal to reduce by 50%) (Table 3.3 and Figure 3.3A).    
Over the first 24 and 6 hr, the kinetic profile for the lymphatic drainage to the popliteal 
node of the 40 and 90% acid-star-IR820 conjugates were significantly different than that of the 
60% acid-star conjugate (p<0.05), as indicated by its significantly shorter t50% (Figure 3.3A and 
Table 3.3).  Whereas, the 40 and 90% acid-star-IR820 conjugates did not exhibit any significant 
 95!
differences in their lymphatic uptake to the popliteal node, which both have similar t50% values 
(Figure 3.3A and Table 3.3).  The kinetic profiles for the lymphatic uptake to the iliac node 
revealed slightly different trends than that for the popliteal node.  The 90% acid-star-IR820 
conjugate profile was statistically different than the 40 and 60% acid-star-IR820 conjugates over 
the first 24 and 50 hrs, respectively (p<0.05), in that the 90% acid-star-IR820 conjugate 
exhibited the shortest tmax and a longer t50% than for the 40 and 60% conjugates which had 
similar t50% and tmax values Figure 3.4A and Table 3.3).  
The 40-90% acid-star-IR820 conjugates exhibit remarkably different nodal retentions in 
the popliteal and iliac lymph nodes.  The 60% acid-star-IR820 cleared rapidly from the popliteal 
node compared to the other conjugates (indicated by the short t50% )(Table 3.3), but was retained 
in the iliac node for almost a day.  In contrast, the 40% and 90% acid-star-IR820 conjugates have 
similar popliteal t50% values of ca. 7 hrs, but the 90% acid-star-IR820 was retained two times 
longer in the iliac node in comparison with 40% and 60% acid-star-IR820 conjugates (Table 3.3).  
Further, the 20% acid-star-IR820 conjugate was highly retained in both the popliteal and iliac 
nodes compared to its more anionic counterparts as demonstrated by its long t50% values.  
However, the distribution of the AUC for the different degrees of anionic charge were similar for 
both the popliteal and iliac nodes (Figures 3.3 C and 3.4C).  The 40-90% acid-star-IR820 
conjugates exhibited a 2.5- to 3.5-fold increase in the lymphatic uptake compared to the 20% 
acid-star-IR820 conjugate for both the popliteal and iliac nodes.  For both the popliteal and iliac 
nodes, the cumulative drainage and AUCs of the 40, 60, and 90% acid-star-IR820 conjugates are 
similar, with no statistical differences between the three conjugates (Figures 3.3 B, 3.3 C, 3.4 B, 
and 3.4C). 
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Table 3.3.  tmax and t50% values for the popliteal and iliac lymph nodes after s.c. administration of 
the 20%, 40%, 60%, and 90%-acid-star-IR820 conjugates in the right hind footpad of mice. 
 Popliteal Iliac 
wt% Acid tmax (min) t50% (hr) tmax (hr) t50% (hr) 
20 45-50 19.5 1 113.6 
40 45-50 6.9 2 18.6 
60 45-50 1.9 1 19 
90 45-50 7.7 0.5 40 
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Figure 3.3.  Star-IR820 drainage to the popliteal lymph node. A) Drainage kinetics to the 
popliteal lymph node after s.c. administration into the right hind footpad.  B) Cumulative 
drainage of the star-IR820 conjugates to the popliteal node.  C)  AUCs in the popliteal node of 
the various wt% acid star-IR820 conjugates.  (AU ! Arbitrary Units) (* p = 0.0194)  
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Figure 3.4.  Star-IR820 drainage to the iliac lymph node. A) Drainage kinetics to the iliac lymph 
node after s.c. administration into the right hind footpad.  B) Cumulative drainage of the star-
IR820 conjugates to the iliac node.  C) AUCs in the iliac node of the various wt% acid star-
IR820 conjugates. 
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3.4  Discussion  
The use of star polymers for the carrier optimization for lymphatic imaging and drug 
delivery rather than a linear polymers was due to the inherent low viscosities, increased 
solubility, decreased solution entanglement, and enhanced thermodynamic properties of star 
polymers [20,21,27].  The apparent viscosities of the star polymer were virtually independent of 
increases in the concentration and MW; while there were observed differences in the apparent 
viscosities, when compared to water and HA, these differences are negligible.  Further, the 
viscosity of water at 20°C is 0.001 Pa!s, and the apparent viscosities of the star polymers is ca. 
0.001 to 0.0012 Pa!s, which is statistically insignificant compared to viscosity of water.  
Conversely, HA is a viscoelastic, non-Newtonian behaving polymer that exhibits shear thinning 
in the presence of shear stress.  Further, the viscosity of HA is concentration, pH, and ionic 
strength dependent [28].  Even at low shear rates and concentrations, HA exhibits shear thinning 
behavior.  Figure 3.1 B clearly demonstrates the MW and concentration dependence of HA on 
the apparent viscosity, which are not factors with the star polymer samples.    
In addition to size, the charge plays a critical role in the lymphatic uptake, retention, and 
disposition of intralymphatic carriers [1,9-11].  The extracellular matrix, consisting of 
polyanionic glycosaminoglycans (GAGs), carries a net negative charge at physiological pH due 
to the ionization of the carboxylic acids of the GAGs [3,29].  Negatively charged particles are 
readily drained from the interstitium after subcutaneous administration due to the electrostatic 
repulsions between the negatively charged particles and the extracellular space [1].  Conversely 
positively charged particles drain more slowly from the injection site due to the attractive forces 
between the particles and the negatively charged matrix.  Zeta Potential can be used to measure 
the ionic nature of nanoparticles; where a zeta potential greater than 30 mV is indicative of a 
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strongly cationic particle, between +10 and -10 mV is considered to be a neutral particle, and less 
than -30 mV is indicative of a strongly anionic particle [30].   
The correlation between the zeta potential and the percent substitution of succinic 
anhydride on the star polymer, allows for potential comparisons of the lymphatic uptake of the 
star polymer with other polymeric systems.  As observed for the star-polymers, an increase in the 
anionic character resulted in an increase in lymphatic uptake until the zeta potential (!) 
approached -40 mV (! = -44.72 ± 4.45 mV for the 40% acid-star polymer, Figure 3.2); once the 
zeta potential falls below ca. -40 mV, no significant increases in the total lymphatic uptake is 
expected for the star polymers.  A similar trend with an increase in the anionic character 
resulting in an increase in the lymphatic uptake was observed by Rao and coworkers [1].  In 
which the authors developed a series of PLGA-PMA:PLGA-COOH nanoparticles with an 
increasing ratio of PLGA-COOH to PLGA-PMA to increase the anionic character, resulting in a 
decrease in zeta potential (from -44.6 ± 11.3 mV to -57.1 ± 11.1 mV).  As the zeta potential 
decreased, an increase in the lymphatic uptake was observed.  A 4.7-fold increase in the 
nanoparticle concentration in the popliteal node and a 10.1-fold increase in the cumulative nodal 
uptake (combination of the popliteal, internal inguinal, iliac, and renal lymph nodes) was 
observed for the -57.1 mV (20:80 PLGA-PMA:PLGA-COOH) nanoparticles.  
Optimization of intralymphatic drug delivery vehicles for rapid lymphatic uptake and 
enhanced nodal retention requires modifying the particle’s charge in addition to its size, which 
can determine the ultimate fate of subcutaneously injected particles.  Cationic particles drain the 
slowest from the injection site after a s.c. injection, are poorly retained by the lymph nodes, have 
increased toxicity, liver accumulation, and have a high propensity to be engulfed by 
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macrophages [9,10,13,31,32].  Whereas negatively charged particles exhibit enhanced lymphatic 
uptake, increased nodal retention, and decreased toxicity.  
Toxicity both in vitro and in vivo are of great concern in the development of synthetic 
polymers for enhanced lymph node retention for localized sustained delivery.  Cationic 
dendrimers exert their toxicity by interacting with the negatively charged lipid bilayer, resulting 
in destabilization of the cellular membrane [13,32].  The star polymers do not exhibit significant 
toxicity in vitro when compared to similar poly-ionic polymers currently used for drug and gene 
delivery (IC50 ca. 5 mg/mL).  For example, Malik et al. demonstrated that G3 and G4 PAMAM, 
G3 and G4 DAB, and G1-G3 DAE dendrimers exhibited similar toxicity to that of 56-kD poly-
L-lysine (ca. 50 µg/mL) in B16F10 cells after a 72 hr incubation [33].  Further, Roberts et al. 
demonstrated that PAMAM toxicity is concentration and generation dependent in V79 Chinese 
hamster lung fibroblast cells, where as the PAMAM generation was increased, the toxicity also 
increased (G3, G5 and G7; 100 nM, 10 µM, and 1 mM).  For a G7 PAMAM (MW 116,493 Da), 
incubation with only 100 nM (ca. 11 µg/mL) PAMAM, for 24 hr, resulted in 90% cell death in 
the V79 cells [34].  Additionally, polyethylenimine (PEI) which is commonly used in gene 
transfection, also exhibits a relatively high IC50 value (19 µg/mL for a 25 kD branched PEI) in 
HR5-CL11 (human cervical cancer) cells after a 48 hr incubation [35].  In comparison, the sugar-
acid star polymers are 100-fold less toxic than most cationic dendrimers and PEI used for drug 
and gene delivery.  Peng et al. demonstrated that chlorin-core star block m-PEG-bPCL 
copolymer micelles exhibited no observable toxicity against MCF-7 breast cancer cells after 24 
hr incubation at the highest concentration of 500 µM [36], which is similar to our star polymers 
(IC50  ca. 50 to 100 µM).  
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 To assess the effect of increasing negative charge on the lymphatic drainage and nodal 
retention of the series of anionic star polymers, we employed whole body fluorescence imaging.  
Mice were imaged from both their right and dorsal sides to detect drainage into the popliteal and 
iliac nodes.  The same trends were observed for both imaging positions; but the right side was 
analyzed as it produced greater signal intensities and a higher signal to noise ratio compared to 
the dorsal or ventral positions.  The ventral position resulted in a decrease in the signal to noise 
ratio, due to the increased fluorescence contributions of the organs in the abdomen.  In addition, 
the iliac node was not visualized due to its increased depth in this position.  Both the lymph 
nodes and draining lymphatic vessels were clearly visualized against the background tissues 
using fluorescence imaging (Figure 2.3 A found in Chapter 2).  Due to limitations of in vivo 
fluorescence imaging, only shallow nodes were identified; we do not discount further drainage 
past the iliac node of these star-IR820 conjugates.   
Reports on the effects of charge on the lymphatic uptake have demonstrated that 
negatively charged particles have increased lymphatic uptake compared to neutral to positively 
charged particles [9-11], along with increased nodal retention [1,12].  Therefore, the effect of 
varying the negative charge on the cumulative lymphatic uptake and nodal retention of a series 
of star polymers was investigated.  Increasing the anionic charge from 20% to 40% wt-acid star 
polymer resulted in approximately a 3-fold increase in the lymphatic uptake for both the 
popliteal and iliac lymph nodes.  Similar trends were observed for the 40-90 % acid star 
polymers for the cumulative fluorescence signals and AUCs over the course of the one-week 
study (Figures 3.3 B, 3.3 C, 3.4 B, and 3.4 C), suggesting that there is a threshold for the 
lymphatic uptake with regards to the degree of anionic charge required.  The threshold for the 
sugar-acid star polymer system this is 40 wt% acid substitution (! " -40 mV); additional 
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increases in the anionic character did not lead to an increase in the lymphatic uptake, as seen 
with the similar AUCs for the 60 and 90% acid-star-IR820.   
In a similar study, Rao and coworkers investigated the effect of increasing anionic charge 
on the lymphatic uptake of PLGA nanoparticles [1]. Rao et al. observed a 10-fold increase in the 
cumulative lymphatic drainage as the amount of carboxylic acid terminated PLGA (PLGA-
COOH) was increased from 20% to 80%, thus decreasing the zeta potential from -44.6 ± 11.3 to 
-57.1 ± 11.1 mV.  In contrast to Rao’s observations of increasing the negative charge of the 
nanoparticles resulting in a continuous increase in the lymphatic uptake, for the star polymers 
described herein, increased lymphatic uptake was observed with increasing the negative charge 
until a zeta potential of -40 mV (40% acid-star polymer); whereas further increases in the 
negative charge did not effect the lymphatic uptake.  Even though the 40-90% acid-star polymers 
exhibited similar cumulative lymphatic uptake, the 60% acid-star polymer conjugate was 
selected as the optimal star polymer platform for further lymphatic imaging and drug delivery 
development, in part due to the rapid drainage observed from the popliteal lymph node coupled 
with the long retention in the iliac node.  The sugar moiety in the repeating unit of the star 
polymer was included for its increased solubility, but also for enhanced lymphatic uptake and 
nodal retention as previously demonstrated by the addition of saccharides to liposomes [37]. 
Additionally, no signs of toxicity or adverse effects were observed for the duration of the study 
with the concentrations of star polymers injected (ca. 0.4 to 0.7 mg/kg star-IR820 conjugate). 
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3.5  Conclusions 
 A new star-polymer with various degrees of anionic charge for lymphatic imaging and 
drug delivery was developed.  The star-polymer platform displays similar characteristics to 
dendrimers, but entails more straightforward synthesis and cost effectiveness.  In addition, this 
platform exhibited significantly reduced toxicities compared to conventional dendrimers such as 
PAMAM.  Star polymers are advantageous, with the addition of the sugar moieties and the 
polyanionic nature, they exhibit similar characteristics to endogenous polysaccharide, such as 
HA, but are significantly less viscous.  The sugar-star polymers exhibited viscosities similar to 
that of water and were independent of increases in both the molecular weight and concentration, 
unlike molecular weight and concentration dependence on the HA viscosity.  Further, the star 
polymer platform provides a compact, low polydispersity carrier with numerous functional 
groups for conjugation. 
 The effect of negative charge on the lymphatic uptake was successfully determined using 
in vivo fluorescence imaging.  The 40%-90% acid-star polymers did not exhibit significant 
differences in the cumulative drainage to both the popliteal and iliac lymph nodes; however, the 
retention in the popliteal node for the 60% acid was significantly shorter than for the other wt% 
acid-star polymers.  The 60% acid-star polymer was selected as the optimal degree of succinic 
acid modification, due to the rapid drainage from the popliteal lymph node and enhanced 
retention in the iliac node.   
The star polymers were highly retained within the iliac node compared to the popliteal 
node, suggesting that the star polymer platform may be beneficial for treatment of the deep 
lymphatics where metastases in the echelon nodes are present.  The star polymers have the 
potential to be used for the treatment of locally advanced lymphatically metastatic cancers with 
 105!
the involvement of two or more lymph nodes, due to the enhanced retention in the iliac lymph 
nodes for all of the conjugates.  Further, the rapid drainage of the 40-90% acid-star polymer 
could aid in minimizing the local release of chemotherapeutics at the injection site due to their 
rapid drainage from the injection site and enhanced lymphatic uptake relative to the 20% acid 
star polymer.  Additionally, the acid-star polymers would be ideal carriers for a drug conjugate 
with a rapid release half-life, such as the star-GA conjugate discussed in Chapter 4, in order to 
minimize the potential toxicities related to a slow draining carrier with a fast releasing drug.  The 
local release of chemotherapeutics at the injection site can lead to undesirable local toxicities, 
such as inflammation and tissue necrosis, or toxicities associated with the systemic uptake of the 
free drug.  After selection of the 60% acid-star polymer as the optimal new delivery platform, we 
developed a chemotherapeutic-, such as a geldanamycin analogue, star polymer conjugate for 
intralymphatic drug delivery to the lymphatics of metastatic cancers such as melanoma and 
breast cancer, which is discussed in Chapter 4. 
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Chapter 4.  Development of a Star Polymer-Geldanamycin (GA) 
Conjugate and the Intralymphatic Delivery of Star-GA for the 
Treatment of Three Orthotopic Tumor Models 
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 4.1  Introduction 
Many cancers metastasize via the lymphatic system, including melanoma, breast, colon, lung, 
and ovarian cancers [1,2].  Accurate determination of the lymph nodes involved in the early 
lymphatic spread of the primary tumor and adequate treatment is paramount for survival of the 
patient.  The first non-hematologic metastatic site is usually the regional lymph node basin in 
both melanoma and breast cancer [3,4].  For melanoma and breast cancer, the 5-year survival 
rates drop dramatically when the primary tumor has metastasized; the 5-year survival for 
melanoma and breast cancer, respectively, are >90% and 98% for localized disease with no 
lymphatic involvement, 40 to 60% and 84% if 1 to 3 local nodes are involved, and 15 to 20% 
and 23% when distant nodes and sites are involved [5,6].  Further, lymphatic vessel growth 
within the tumor has been shown to have a positive correlation with the metastatic spread of 
melanoma, breast, and head and neck cancers [7], as metastasizing cancer cells will follow 
cytokine gradients into the draining lymphatics [1].  Lymph node biopsies have been used since 
the 1950s, in the diagnosis of breast cancer, and sentinel lymph node biopsies, reviewed in 
chapter 1, have been used for the clinical staging of melanoma and breast cancer since the early 
1990s [8].  Lymph nodes that test positive for micrometastases by pathology are identified and 
removed, potentially saving the patient from a complete lymphadenectomy of unaffected nodes 
or a radical mastectomy.   
The current therapies for regional lymph node involvement in melanoma are wide local 
excision of the primary tumor and removal of the regional lymph nodes [9,10]; frequently 
surgery is followed by chemotherapy.  It has been reported that 40-50% of primary melanomas 
are present on the limbs.  Furthermore, melanoma is considered to be relatively resistant to 
chemotherapeutics along with radiation [9], with response rates of only 20% with systemic 
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treatment of the extremities [11].  Therefore to improve the response rates to chemotherapeutics, 
isolated limb perfusion (ILP) was introduced, which allows 15-20 times the maximum tolerated 
dose (MTD) of the chemotherapeutic, melphalan, to be delivered locally [11,12], resulting in a 
10-fold increase in the limb drug concentrations and minimized toxicities [11-13].  In addition to 
its toxicity, melphalan is poorly water solubility and extremely unstable in solution (plasma half 
life is ca. 1 hr) [14,15].  Patients treated with melphalan at local doses far above the MTD, using 
ILP, achieve complete response rates of 55% and partial responses of 26% [16], although the 
perfusate can leak into the systemic circulation in up to 12% of patients which causes systemic 
toxicities [17]. However, with melanoma metastases past the extremities, the most common and 
effective treatment is dacarbazine, which offers response rates of only 10-13%, and complete 
response rates less than 5% [18].  Although, after 30 years of the use of dacarbazine alone, it has 
not been shown to significantly improve survival time in a large trial.  A recent randomized 
Phase III trial of the immunotherapeutic ipilimumab plus dacarbazine has demonstrated the first 
improvement in patient survival and a possible improvement over dacarbazine, with an overall 
survival of 11.2 months vs. 9.1 months, respectively [19].  
Since the introduction of sentinel lymph node biopsy (SLNB) for breast cancer staging, 
treatments have become more specialized leading to a decrease in the number of radical 
mastectomies with complete axillary lymph node dissections [20,21] and an increase in the 
detection of micrometastases [22,23].  However, in a 700 patient study, it was reported that there 
is a high risk for relapse due to the presence of undetected nanometastases (<0.2 mm in 
diameter) upon initial staging [24].  In order to prevent these relapses, lymph node dissection is 
often followed by radiation, chemotherapy, or immunotherapy (for HER2 positive breast cancer).  
But these “preventative” measures also come at the high cost of side effects, including 
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cardiotoxicity, associated with radiation [25], or chemotherapy using doxorubicin [26], and 
trastuzumab treatment alone and in combination with doxorubicin [27].  Additionally, about 25% 
of all breast cancers are HER2 positive, which represents an aggressive type of breast cancer that 
leads to poor prognosis and an increased potential for relapse [28-30].  Despite the improved 
outcome with the treatment of HER2 positive breast cancers with trastuzumab, a HER2 targeted 
humanized murine monoclonal antibody; almost all of the patients will experience relapse and 
metastatic progression due to the acquired resistance to treatment [31,32].  Although the 
prognosis is promising for those diagnosed with early breast cancer, treatment options are limited 
for those with undetected micro or nanometastases, locally advanced, or trastuzumab-resistant 
breast cancer.  There is a critical need for the development of localized treatments for patients 
with micro-, nano- and in-transit lymphatic metastases for both localized and metastatic 
melanoma and breast cancer that are less radical than surgical dissection, radiation, or systemic 
chemotherapy, which carry their own associated risks and side effects. 
Localized chemotherapy, such as ILP used for the treatment of limb melanomas, avoids 
systemic toxicities associated with intravenous therapy by restricting the toxic chemotherapy 
agents to the diseased tissue and minimizing the exposure to the normal unaffected tissues.  
However, current localized therapies, such as ILP and isolated hepatic perfusion, utilize isolation 
of the blood flow to the affected organ or tissue while perfusing high doses of chemotherapeutics 
above the MTD through the local arteries and veins.  However, these techniques for localized 
delivery are not viable options for melanoma metastases beyond the limbs, melanomas of the 
head and neck or trunk, or breast cancer.  Further, systemic chemotherapy offers limited 
penetration into lymphatics to treat lymphatic metastases [33].  Targeting polymeric-anticancer 
drug conjugates to the lymphatics will have improved efficacy and reduced toxicity compared to 
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conventional systemic therapy, while treating lymph node metastases associated with 
lymphatically metastatic cancers, such as melanoma and breast cancer.  Targeting particulates for 
lymphatic delivery is governed by the size and charge of the nanoparticles, with 10 to 100 nm 
anionic nanoparticles having the ideal characteristics for lymphatic uptake.  We previously 
determined the optimal size and charge for the lymphatic delivery of nanoparticles to be 30-50 
nm (Chapter 2) and polyanionic, with a zeta potential less than -40 mV (Chapter 3).  With the 
previous experiences in our laboratory of the localized delivery of a hyaluronan-doxorubicin 
conjugate for the treatment of breast cancer [34], and the challenges arising from the highly 
viscous hyaluronan polymer and limited drug loading due to solubility issues, we sought to 
develop a multifunctional drug conjugate with low viscosity and improved carrier solubility 
utilizing star polymers.  Star polymers have compact structure (like dendrimers), narrow 
polydispersities, large surface areas, low toxicity (Chapter 3), and low intrinsic viscosity [35-37].   
Geldanamycin (GA), an ansamycin benzoquinone antibiotic, is HSP90 inhibitors that 
exhibits both antimicrobial activity and anticancer activity [38]. The anti-cancer activity of GA 
was first determined in the 1970s against L1210 murine leukemia and KB cells [39]; despite its 
encouraging in vitro and in vivo activity in early preclinical studies, its development was limited 
due to its significant hepatotoxicity in vivo [40].  Nevertheless, two of its C-17 analogues, 17-
AAG and 17-DMAG, have been pursued in the clinic due to their enhanced activity, decreased 
liver toxicity, and increased water solubility (17-DMAG) [41].  Further, 17-AAG was found to 
have efficacy in both HER2 positive (SKBr3) and negative (MCF7) breast cancer cell lines, and 
deplete the HER2 oncoprotein in the SKBr3 cell line [42].  Due to its increased water solubility 
and equivalent activity, the development of 17-DMAG over 17-AAG has grown in interest.  
With the combined reports of HSP90 overexpression in melanoma [43], its function in the 
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metastasis of melanoma [44], and activity against HER2 positive breast cancer [42], we 
developed a lymphatically targeted geldanamycin derivative-star polymer conjugate for the 
localized delivery to both locally advanced melanoma and breast cancers. 
 
4.2  Experimental 
 
4.2.1  Synthesis and Characterization of the Star-Geldanamycin Conjugate 
 The GA analogue, star polymer (described in Chapter 3 and Appendix 1), and star-GA 
conjugate were synthesized in our laboratory by Dr. Duan.  Briefly, to a solution of 
geldanamycin (100 mg, 0.178 mmol, LC Laboratories) in dry chloroform (20 mL), ethanolamine 
(30 eq, Sigma) was added dropwise.  The reaction was protected from light and was allowed to 
proceed at ambient temperature (ca. 20 °C) under argon protection for 4 h until the TLC showed 
complete consumption of the starting materials.  The reaction mixture was then washed with 1-M 
HCl (100 mL) and dried over Na2SO4.  The solvent was removed under reduced pressure, and 
the compound was used without further purification.  1H-NMR in CDCl3 was used to confirm the 
structure, and the NMR spectrum was consistent with the reported data and showed the 
compound was determined to be pure.  The desired 17-((2-hydroxyethyl)amino)-17-
demethoxygeldanamycin analogue (17-HEAG) was obtained as a purple solid (101 mg, 96%) 
(Scheme 4.1).  1H-NMR (CDCl3, 400 MHz): ! = 9.16 (s, 1H), 7.29 (s, 1H), 6.96 (d, J = 11.4 Hz, 
1H), 6.61 (t, J = 11.7 Hz, 1H), 5.92 (d, J = 9.9 Hz, 1H), 5.87 (d, J = 10.6 Hz, 1H), 5.21(s, 1H), 
4.79 (bs, 1H), 4.33 (d, J = 9.8 Hz, 1H), 3.93 (t, J = 5.2 Hz, 2H), 3.81-3.76 (m, 1H), 3.72-3.66 (m, 
1H), 3.60 (d, J = 8.5 Hz, 1H), 3.49-3.45 (m, 1H), 3.38 (s, 3H), 3.29 (s, 3h), 2.81-2.74 (m, 1H), 
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2.70 (d, J = 13.6 Hz, 1H), 2.42 (dd, J = 10.5 Hz, 2.8 Hz), 2.06 (s, 3H), 1.83-1.85 (m, 5H), 1.78-
1.54 (m, 3H), 1.02 (d, J = 7.0 Hz, 3H),   1.02 (d, J = 6.9 Hz, 3H).  
Sugar-acid-star polymer (60% acid) (72 mg) was dissolved in dry DMF (20 mL) and was 
cooled to 0 °C. EDAC (65.2 mg, 0.34 mmol, Sigma) and HOBt!H2O (52.3 mg, 0.34 mmol, 
Sigma) were added to the polymer solution.  After five minutes, the 17-HEAG analogue (100 
mg, 0.17 mmol) was added in one portion.  The reaction was protected from light and allowed to 
proceed at room temperature (ca. 20 °C) overnight.  The resulting solution was dialyzed (MWCO 
10 kD, SpecraPor 7, Spectrum Laboratories) against EtOH: H2O (1:1) for 12 hours with solvent 
exchanges every 3 hours followed by dialysis against 100% EtOH for 6 hours with solvent 
exchanges every 3 hours.  The solvent was removed under reduced pressure yielding the pure 
star-GA conjugate (Scheme 4.1).  
The conjugation degree of 17-HEAG to the star polymer was determined by 1H-NMR (Bruker, 
400MHz) in MeOD (Cambridge Isotope Laboratories) and UV spectroscopy (SPECTRA MAX 
PLUS, Molecular Devices) at 330 nm using a standard calibration curve (1-30 "g/mL) in MeOH.  
The conjugation degree was determined by comparing the ratio of the proton on the C19 position 
on the benzoquinone ring with the proton of the repeating unit of the star polymer from the 1H-
NMR spectra. 
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Scheme 4.1.  Pictorial reaction scheme of the geldanamycin reaction with ethanolamine to give 
the 17-HEAG analogue, followed by the reaction of 17-HEAG with the 60% acid-star polymer 
resulting in the Star-GA conjugate. 
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4.2.2  In Vitro Cytotoxicity 
B16F10 (lymphatically metastatic murine melanoma, ATCC), MDA-MB-231 (human 
breast cancer), and HUVEC (normal human endothelial) cell lines, were maintained in 
Dulbecco's modified Eagle’s medium (DMEM) supplemented with 1% L-Glutamine and 10% 
bovine growth serum in 5% CO2 atmosphere.  The HER2-expressing murine breast cancer cell 
line, 4T1.2 Neu, was a gift from Dr. You, from the University of Pittsburg, and was maintained 
in DMEM supplemented with 1% L-Glutamine, 10 % bovine growth serum, and 500 µg/mL of 
G418 (geneticin) in 5% CO2 atmosphere.  The lymphatically metastatic human melanoma cell 
line, A2058, was purchased from ATCC, and was maintained in low sodium bicarbonate 
containing DMEM supplemented with 1% L-Glutamine, 10% bovine growth serum in 5% CO2 
atmosphere.  
Prior to cell growth inhibition studies, cells were trypsinized and seeded at 3000 
cells/well into 96-well tissue culture plates.  After 24 hours, geldanamycin, 17-DMAG, 17-AAG, 
17-HEAG, Star-GA (GA basis), or melphalan hydrochloride dilutions in 1# PBS (Fisher 
BioReagents, pH 7.4) with up to 3% DMSO (final well concentration, for the highest drug 
concentration) were added to the B16F10, A2058, HUVEC, 4T1.2 Neu, or MDA-MB-231 cells 
(n=8 or 12, 10 µL/well, 8 or 6 concentrations 10-10 to 10-3 M, respectively).  Solutions of 10% 
trichloracetic acid was used as a negative control, media was used as a positive control, and 3% 
DMSO was used as an additional control (n=8 or 12, 10 µL/well).  At 72 h post addition, 10 µL 
of resazurin blue in PBS was added (5 µM final concentration) to each well.  After 3 hours, well 
fluorescence was measured ("ex/"em = 560/590 nm) (SpectraMax Gemini, Molecular Devices).  
IC50s were determined using the nonlinear regression curve fit of a one-site competition 
(GraphPad Prism 10). 
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4.2.3  In Vitro Release 
Star-GA was dissolved in PBS at a GA concentration of 0.075 mg/mL (0.5 mg/mL total 
conc.) and was sealed in a dialysis bag (3500 MWCO, n=3, Pierce).  The dialysis bags were 
placed in a temperature controlled bath set to 37 °C containing PBS under sink conditions; the 
bath was protected from light for the experiment duration.  At predetermined time intervals, 150 
µL aliquots were taken from the bags for 50 hr and were placed at -20 °C until analysis.  The 
release samples were analyzed using a UV absorbance detector with a 17-HEAG standard curve 
(0.8 to 80 µg/mL, 11 concentrations).  The release samples were diluted to 200 µL with PBS (3:4 
dilution), the 17-HEAG standard curve dilutions (n=2), PBS (n=2), and the release samples 
(n=3) were added to a 96-well plate, and the UV absorbance of the plate was measured at 330 
nm on a UV plate reader (SPECTRA MAX PLUS, Molecular Devices). 
 
4.2.4  B16F10 Murine Melanoma Tumor Model 
 
4.2.4.1  B16F10 Tumor Model Optimization 
B16F10 cells were maintained in DMEM supplemented with 10% bovine growth serum 
and 1% L-Glutamine in 5% CO2 atmosphere.  Cells were trypsinized (0.25% w/v trypsin), and 
five different cell dilutions were made in 1#PBS (5#105, 5#106, 5#107, 1.1#108, and 2#108 
cells/mL).  Fifty microliters of each B16F10 suspension in PBS were injected (2.5#104, 2.5#105, 
2.5#106, 5.5#106, and 1#107 cells/animal) s.c. into the right hind thigh of female Balb/c mice 
(20-25 g, Charles River) under isoflurane anesthesia.  The tumors were measured and recorded, 
the volumes were calculated using the equation: Tumor Volume (mm3) = 0.52#(width)2#length. 
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4.2.4.2  In Vivo Imaging with 74-kD HA-IR820 Conjugate in B16F10 Tumor Bearing Mice 
Fifty microliters of a 1.1 # 108 cells/mL suspension of B16F10 cells were injected (5.5 # 
106 cells) s.c. into the right hind thigh of female Balb/c mice (20-25 g, Charles River, n=5) under 
isoflurane anesthesia (Day 1).  All mice were fed a low chlorophyll diet at least one week prior 
to imaging to decrease food-induced organ and skin autofluorescence (Harlan 2918 irradiated 
diet).  The mouse’s hair in the area of interest for imaging was removed 24 h prior to imaging 
(Day 3) with clippers followed by depilatory cream.  On Day 4, mice with similar tumor 
volumes, shape, and location, were chosen for the imaging study.  Three mice were anesthetized 
under isoflurane, placed on a heating pad to help regulate body temperature, and were injected 
subcutaneously (s.c.) with 10 µL of a 1.0 mg/mL solution (IR820 dye basis) of 74-kD HA-IR820 
(described in Chapter 2) in the center of the right hind footpad.  The mice were imaged on both 
the dorsal and right sides, both with and without the injection site being covered at 
predetermined time intervals, using whole body fluorescent imaging (Cambridge Research and 
Instrumentation Maestro multi-spectrum imager, Woburn, MA) using an excitation filter of 710-
760 nm and broadpass emission filter of 800-950 nm.  The animals were imaged for a maximum 
of seven days.  Images were acquired using the autoexposure function in the imaging software.   
  Image analysis was performed using Maestro software (ver. 2.10).  Regions of interest 
were placed over the popliteal and iliac lymph nodes.  The total signal (scaled counts/s) intensity 
values (arbitrary units, AU) were recorded for each region of interest (ROI), for both positions 
(dorsal and right sides), and were plotted versus time in GraphPad Prism (ver. 4).  The total 
fluorescence intensity vs. time graphs were integrated to give the cumulative fluorescence vs. 
time graphs.  In addition, the area under the curve (AUC) was determined from the total 
fluorescence intensity vs. time graphs. 
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Scaled counts/s = counts/full scale # 1/exp(s) # 1/bin2 # 1/gain 
 
 
 
4.2.4.3 Anticancer Efficacy in B16F10 Tumor Bearing Mice 
Fifty microliters of a 1.1 # 108 cells/mL suspension of B16F10 cells were injected (5.5 # 
106 cells) s.c. into the right hind thigh of female Balb/c mice (20-25 g, Charles River) under 
isoflurane anesthesia.    
In the first study, when the B16F10 tumors reached 200-300 mm3 in size (ca. Days 7-9, 
n=5), the mice were injected once with melphalan (5 mg/kg) intravenously via the tail veil under 
isoflurane anesthesia.  The formulation used to treat mice bearing B16F10 tumors was modified 
slightly from the product insert for ALKERAN$ (melphalan hydrochloride) for injections into 
humans.  Melphalan (Bosche Scientific) was dissolved in concentrated hydrochloric acid (35-
38%) to give a 15 mg/mL solution.  The melphalan solution was then aliquoted into vials to give 
0.75 mg melphalan/vial, and was dried using a speedvac concentrator (Labconoco) for 1.5 hr at 
35°C followed by 1 hr at ambient temperature.  The vials containing dry melphalan 
hydrochloride were sealed and placed at -20°C until further use.  The reconstituted solution was 
prepared by first pre-sterilizing propylene glycol, 95% ethanol, and 0.02 g/mL sodium citrate 
solution, using a sterile syringe fitted with a 0.22 µm sterile filter (Millex GP PES membrane 
sterile filter, Millipore) into a sterile falcon tube.  Then the reconstituted solution was prepared 
by combining 6 mL sterile propylene glycol, 0.52 mL sterile ethanol (95%), and 3.48 mL sodium 
citrate solution, and the solution was mixed well and filtered a second time with at 0.22 µm 
sterile filter.  Immediately prior to injection, the 150 µL of the sterile reconstituted solution was 
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rapidly added to the melphalan hydrochloride, the vial was immediately shaken vigorously until 
dissolved, followed by the rapid addition of 150 µL of sterile saline yielding a 2.5 mg/mL 
melphalan solution.  The melphalan was dosed within 10 to 15 min after reconstitution to 
minimize degradation.  
In the second study, when tumors reached 200-350 mm3 (Days 6-9), mice were randomly 
divided into four groups and injected with 17-DMAG (i.v., n=4), Star-GA (s.c., n=7), 60% acid-
star polymer (s.c., n=6), or no treatment (n=4).  The 17-DMAG was dissolved in sterile DMSO 
and administered i.v. via the tail vein at a dose of 15 mg/kg (MTD).  Star-GA was dissolved in a 
1:1 mixture of DMSO:PBS, and the pH was adjusted to ca. 5.7 with NaOH, giving a Star-GA 
solution in 30% sterile DMSO and 70% sterile PBS, the Star-GA solution was administered at an 
equivalent dose to the 15 mg/kg 17-DMAG (13.64 mg/kg 17-HEAG, 15 wt% loading, i.e. 90.93 
mg/kg total conjugate) with one peritumoral injection.  Finally, the 60% acid-star polymer was 
dissolved in sterile PBS and the pH was adjusted to 5.4 with 2-M sterile NaOH, the 60% acid-
star polymer was then administered at an equivalent polymer dose to the Star-GA (i.e. 77.29 
mg/kg star polymer) with one peritumoral injection.   
 
4.2.5  4T1.2 Neu Murine Breast Cancer Tumor Model 
The 4T1.2 Neu, was maintained in DMEM supplemented with 1% L-Glutamine, 10 % 
bovine growth serum, and 500 µg/mL of G418 (geneticin) in 5% CO2 atmosphere.  During cell 
preparation of the 4T1.2 Neu cells for implantation, G418 free media was used.  Dr. Cai 
previously optimized the in vivo tumor growth of the 4T1.2 Neu cell line in Balb/c mice.  Prior 
to tumor implantation, the hair surrounding the right upper portion of the mouse’s chest was 
removed with depilatory cream.  Female Balb/c mice (20-25 g, Charles River) were injected in 
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the first mammary fat pad on the right side with 50 µL of a 2#107 cell/mL suspension in 1# PBS 
(1#106 4T1.2 Neu cells/animal) under isoflurane anesthesia (Day 1).   
 
4.2.5.1 Anticancer Efficacy Pilot Study in 4T1.2 Neu Tumor Bearing Mice  
 Seven 4T1.2 Neu tumor-bearing mice were randomly divided into three treatment groups, 
once the tumors reached ca. 200 mm3 (Day 9-10), including 17-DMAG (n=2), Star-GA (n=3), 
and no treatment (n=2).  The 17-DMAG was dissolved in sterile DMSO and administered via the 
tail vein at a dose of 10 mg/kg (MTD is 15 mg/kg).  Star-GA was dissolved in a 1:1 mixture of 
DMSO:PBS, and the pH was adjusted to 6.8 with NaOH, giving a Star-GA solution in 30% 
sterile DMSO and 70% sterile PBS, the Star-GA solution was administered at an equivalent dose 
to the 10 mg/kg 17-DMAG (9.56 mg/kg 17-HEAG, 15 wt% loading, i.e. 63.74 mg/kg total 
conjugate) divided into two peritumoral injections on either side of the mammary tumor.   
 
4.2.5.2 Increased Maximum Tolerable Dose (MTD) of Star-GA 
 Four healthy female Balb/c mice (20-25 g, Charles River) were randomly divided into 
two groups and were dosed with two s.c. injections on either side of the first nipple on the right 
side with either 30 or 50 mg/kg Star-GA (17-HEAG basis, 31 wt% loading) in 30% DMSO and 
70% PBS.  Mice were monitored for at least one week for signs of toxicity, including losses in 
body weight, rough coat, fecal/urine soiling of the coat, diarrhea or dehydration, abnormal 
breathing patterns, or self-isolation.  
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4.2.5.3 Anticancer Efficacy in 4T1.2 Neu Tumor Bearing Mice  
Seven week old (18-22 g) female Balb/c mice purchased from Jackson Laboratory (Bar 
Harbor, Maine) were used in this study.  On Day 7, when tumors reached 100-250 mm3, mice 
were randomly divided into four treatment groups, consisting of no treatment (n=7), 60% acid-
star polymer (n=5), 17-DMAG (n=7), and Star-GA (n=8).  The 17-DMAG was dosed at 10 
mg/kg i.v. as a 1:1 sterile DMSO:PBS solution.  Star-GA was dosed at 45 mg/kg (17-HEAG 
basis, 15% loading, 300 mg/kg Star-GA conjugate), in sterile 35% DMSO and 65% PBS, which 
was divided into two peritumoral injections on either side of the mammary tumor.  Finally, the 
60% acid-star polymer was dosed at an equivalent star polymer concentration used for the 45 
mg/kg Star-GA (255 mg/kg 60% acid-star polymer), which was divided into two peritumoral 
injections onto either side of the mammary tumor.  Tumor volumes were monitored and reported 
every two days. 
 
4.2.5.4 Metastatic Analysis of Axillary Lymph Nodes by Nodal Volume and Real Time 
Polymerase Chain Reaction (rtPCR)  
The metastatic state of the 4T1.2 Neu tumor model post treatment was assessed by 
axillary lymph node volume and the nodal HER 2 expression.  The visible axillary lymph nodes 
on the right side were harvested from mice in each treatment group (17-DMAG, 60% acid-star 
polymer, Star-GA, and no treatment, dosing for each treatment group described in Section 
4.2.5.3) once the mice reached a humane endpoint, i.e., tumor volume > 2000 mm3, body score 
index of 1, or signs of necrosis or toxicity.  The mice were euthanized and the nodes were flash 
frozen and stored at -80°C until real-time PCR (rtPCR) analysis. The lymph nodes were 
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measured with digital calipers and the axillary lymph node volumes were calculated using the 
same equation used to calculate tumor volume, i.e. volume = 0.52 # (width)2 # (length).  
The rtPCR analysis was conducted by our collaborator, Dr. Li, at the University of 
Kansas Medical Center.  Briefly, the total RNAs from the frozen lymph node samples were 
extracted using TriZol reagent (Invitrogen).  The first-strand cDNA was synthesized using the 
Omniscript-RT Kit (QIAGEN, Valencia, CA).  Primers for the Erbb2 (HER2 RT2 qpCR primer 
assay, proprietary primer sequence, QIAGEN) and 18S housekeeping gene (forward: 5’-
GGGAGGTAGCGAAAAATAACAA-3’ reverse: 5’-CCCTCCAATGGATCCTCGTT -3’) (IDT 
Inc, Coralville, IA) were used.  The real-time PCR, in a reaction volume of 25 "L, was 
performed using the SYBR Green Supermix kit with the Bio-Rad iQ5 system (Hercules, CA).  
Denaturation at 95 °C for 15 s and annealing/extension (temperature varied due to different 
primer sequence and composition) for 1 min was performed for 40 cycles.  
 
4.2.6  A2058 Human Melanoma Tumor Model 
The lymphatically metastatic human melanoma cell line, A2058, was purchased from 
ATCC, and was maintained in low sodium bicarbonate containing DMEM supplemented with 
1% L-Glutamine, 10% bovine growth serum in 5% CO2 atmosphere.  Female nude mice (20-25g, 
Charles River) were implanted s.c. in the right hind thigh with 50 µL of 4#107 cells/mL (n=2, 
2#106 cells/animal), 1#108 cells/mL (n=1, 5#106 cells/animal), 1.5#108 cells/mL (n=1, 7.5#106 
cells/animal), or 2#108 cells/mL (n=1, 1#107 cells/animal) of A2058 cells in sterile PBS under 
isoflurane anesthesia in this pilot study.  Tumors were monitored at least twice weekly using 
digital calipers in a laminar flow hood.   
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Of the three mice with palpable tumors, once the tumors reached 200-300 mm3, the mice 
were divided into three treatment groups:  no treatment (2#106 cell/animal mouse), i.v. 10 mg/kg 
17-DMAG (1:1 DMSO:PBS, 2#106 cell/animal mouse), and peritumorally 20 mg/kg Star-GA 
(17-HEAG basis, 30:70 DMSO:PBS, 1#107 cell/animal mouse).  
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4.3  Results 
 
4.3.1  Synthesis and Characterization of the Star-Geldanamycin Conjugate 
The degree of conjugation of 17-HEAG to the star polymer was determined to be 15 wt% 
by 1H-NMR (Bruker, 400MHz) in MeOD and 14.8 wt% by UV spectroscopy (SPECTRA MAX 
PLUS, Molecular Devices) at 330 nm using a standard calibration curve (1-30 "g/mL).  The 
conjugation degree was determined by comparing the ratio of the proton on the C19 position of 
the benzoquinone ring with repeating unit proton of the star polymer from the 1H-NMR spectra.  
A series of 17-HEAG concentrations were prepared from a stock solution of 17-HEAG in 
MeOH.  The concentrations used for the standard curve of 17-HEAG were 1, 2, 5, 8, 10, 20, and 
30 "g/mL (R2=0.997) in MeOH.  The absorbance of the star-GA was measured at 330 nm, and 
the resulting absorbance measurements were due to 17-HEAG and not the star polymer (Figure 
4.1), as the star polymer does not exhibit UV absorbance at 330 nm.  The loading degree of 17-
HEAG was calculated to be 14.8 % (wt/wt); and the same star-GA batch was used for all 
experiments unless otherwise noted. 
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Figure 4.1.  UV absorbance spectra of 17-HEAG, 60% acid-star-polymer, and star-GA conjugate 
in methanol.  (Note:  sample concentrations were not held constant, thus the relative intensities 
cannot be compared).  
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 4.3.2  In Vitro Cytotoxicity 
The calculated IC50 values for geldanamycin, 17-DMAG, 17-AAG, 17-HEAG, star-GA, 
60% acid-star polymer, and melphalan, in the B16F10, A2058, HUVEC, 4T1.2 Neu, and MDA-
MB-231 cell lines are presented in Table 4.1.  Melphalan was compared to the geldanamycin 
analogues in melanoma cell lines, as it is used clinically with ILP treatment for melanoma.  
Geldanamycin and its derivatives exhibited similar cytotoxicity in the B16F10 and 4T1.2 Neu 
murine cell lines.  The HUVEC and MDA-MB-231 cell lines were investigated to compare the 
cytotoxicities observed in the B16F10, A2058, and 4T1.2 Neu cell lines to human cell lines for 
normal cells and human breast cancer, respectively.  In the B16F10 cell line, the 17-HEAG 
analogue exhibited similar cytotoxic effects as the parent drug GA.  Similarly, in the A2058 
human melanoma cell line the star-GA conjugate exhibited less in vitro toxicity than GA, 17-
DMAG, and 17-AAG; however, it was two orders of magnitude more toxic than melphalan.  All 
of the GA analogues and the star-GA exhibited similar toxicities in the 4T1.2 Neu HER2 
expressing murine breast cancer cell line.  
 
 IC50 values (µM) 
 B16F10 A2058 HUVEC 4T1.2 Neu MDA-MB-231 
Geldanamycin 0.035 0.044 0.440 0.260 0.960 
17-DMAG 0.250 0.044 29 0.296 0.200 
17-AAG 0.450 0.053 64 0.315 ------ 
17-HEAG 0.038 49 0.550 0.422 ------ 
Star-GA 4.2 0.700 1.4 0.335 0.580 
60% acid-star >100 ~60 ~100 ~100 %100 
Melphalan 103 30 209 ------ ------ 
 
 
Table 4.1.  Corresponding IC50 values (µM) for geldanamycin, 17-DMAG, 17-AAG, 17-HEAG, 
star-GA, 60% acid-star polymer, and melphalan in B16F10, A2058, HUVEC, 4T1.2 Neu, and 
MDA-MB-231 cell lines (n=8-12).  The data for the 60% acid-star polymer is reprinted from 
Table 3.2 from Chapter 3 for data completion.   
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4.3.3.  In Vitro Release 
The star-GA conjugate was synthesized utilizing an ester linkage, the release of 17-
HEAG from the star polymer platform is achieved by the hydrolysis of the ester bond.  The 
release samples were analyzed on a UV plate reader with the 17-HEAG standard curve.  A series 
of 17-HEAG concentrations in PBS were prepared from a stock solution of 17-HEAG.  The 
concentrations used for the establishment of the 17-HEAG standard curve were 0.8, 1, 2, 4, 6, 8, 
10, 20, 40, 60, and 80 "g/mL (R2=0.999).  The 17-HEAG concentrations for the release samples 
at each time point were calculated from the standard curve and were normalized to account for 
the change in concentration due to sampling and osmosis, and were reported as the fraction of 
bound GA remaining in the dialysis bag.  The fraction of GA bound to the star polymer as a 
function of time is illustrated in Figure 4.2; the data was then fitted to a one-phase exponential 
decay function (GraphPad Prism 10) with a release half-life of 4.12 ± 0.35 hr (R2=0.99). 
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Figure 4.2.  Release kinetics of 17-HEAG from the star-GA conjugate in PBS at 37°C (n=3). 
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4.3.4  B16F10 Murine Melanoma Tumor Model 
 
4.3.4.1  B16F10 Murine Melanoma Tumor Model Optimization 
The tumor growth curves for the different concentrations of B16F10 cells that were 
injected into Balb/c mice are illustrated in Figure 4.3.  None of the mice injected with 2.5#104 
cells/animal (n=4) developed tumors after 48 days (data not shown).  Two of the four mice that 
were implanted with 2.5#105 cells/animal developed tumors within two weeks, however the 
tumor size did not change significantly within three weeks; while the other two mice in the group 
did not develop tumors within three weeks.  The lack of tumor growth over the three week 
monitoring timeframe, suggests that the “observed tumor” was merely a cell depot that was 
visualized by the discoloration due to the over-expression of melanin in the B16F10 cells and 
was not the development of a palpable tumor.  All of the mice implanted with 2.5#106 
cells/animal (n=5) developed tumors by day 11 post implantation, however, the tumor growth 
was very slow and inconsistent among the five mice.  By day 30, one mouse had a tumor of 25 
mm3, another with a 3800 mm3 tumor, while the remaining three mice developed tumors ca. 
1000 mm3.  Similarly, all mice injected with 1#107 cells/animal (n=3) developed tumors that 
appeared to grow steadily; however, their tumor growth was inconsistent.  In contrast, all of the 
mice injected with 5.5#106 cells/animal (n=8) developed tumors within three days post-
implantation, which grew at a constant and consistent rate.  The 5.5#106 cells/animal 
concentration was selected as the optimal cell concentration for future studies. 
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Figure 4.3.  Tumor growth curves for mice implanted with (2.5#105, 2.5#106, 5.5#106, and 1#107 
cells/animal) s.c. in the right hind thigh of Balb/c mice. 
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4.3.4.2  Effect of B16F10 Tumors on the In Vivo Lymphatic Drainage of 74-kD HA-IR820 using 
In Vivo Fluorescence Imaging 
Mice in the footpad injection group were imaged from both their right and dorsal sides to 
detect drainage into the popliteal and iliac nodes.  The same trends were observed for both 
imaging positions; but the right side was analyzed as it produced greater signal intensities and a 
higher signal to noise ratio compared to the dorsal or ventral positions.  The ventral position led 
to a decreased signal to noise ratio due to the increased fluorescence contributions of the organs 
in the abdomen, along with the inability to visualize the iliac node due to its increased depth in 
this position.  The intense fluorescence signal from the injection site led to saturation of the 
camera, to circumvent such signal saturations, the injection site was covered allowing 
visualization of the draining lymphatic vessels and lymph nodes.  Both the lymph nodes and 
draining lymphatic vessels were clearly visualized against the background tissues using 
fluorescent imaging (Figure 2.3A found in Chapter 2) with the injection site covered.  The use of 
the autoexpose function resulted in different exposure times for each image, which were 
corrected for in the image analysis where the scaled counts/s normalizes for the exposure time. 
Due to the limitations of in vivo fluorescence imaging (ca. 1 cm), only shallow nodes were 
identified; the authors do not discount further drainage of the 74-kD HA-IR820 conjugate past 
the iliac node. 
The lymphatic drainage data for the 74-kD HA-IR820 in normal, non-tumor bearing mice 
is reproduced from Chapter 2, and is presented here for comparison with the lymphatic drainage 
after s.c. administration of the 74-kD HA-IR820 in mice bearing a B16F10 murine melanoma 
tumor.   
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We examined the effect of a B16F10 melanoma tumor on the lymphatic drainage of both 
the popliteal (Figures 4.4 A and C) and iliac nodes (Figures 4.4 B and D) using the optimized 74-
kD HA-IR820 conjugate.  A significant difference was observed in the kinetic profiles for the 
lymphatic drainage to the popliteal node between the tumor bearing and normal mice (p=0.0320, 
student t-test)(Figure 5A); however, there were no significant differences in the AUC for the 
popliteal nodes between the two groups (Table 4.2).  The drainage from the popliteal node in 
tumor-bearing mice was almost three times slower than in the normal mice (t50% of 20 and 6.9 
hrs, respectively), whereas the drainage to the iliac node remained unchanged (t50% of 23 hrs and 
21 hrs, respectively) (Figures 4.4A and B, Table 4.2).  Furthermore the tmax in the popliteal and 
iliac nodes was unchanged for tumor-bearing mice compared to normal mice (Table 4.2).  
 
 
 
 
 
 
 
 
 
 
Table 4.2.  tmax, t50%, and AUCs for the popliteal and iliac nodes after s.c. administration of 74-
kD HA-IR820 into the footpad of normal and B16F10 tumor bearing mice. 
  
 
 
 
 
 
Lymph Node Animal tmax (hr) t50% (hr) AUC (AU) 
B16F10 Tumor 2 20 7597±1039 Popliteal  
Normal 1.5-2 6.9 11464±3318 
B16F10 Tumor 2 23 3086±171 Iliac 
Normal 1.5-2 21 3627±1644 
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Figure 4.4.  Lymphatic drainage kinetics of the 74-kD HA-IR820 into the A) popliteal and B) 
iliac lymph nodes in normal (blue triangles) and B16F10 tumors bearing mice (red squares).  
Cumulative drainage of the 74-kD HA-IR820 conjugate vs. time to the C) popliteal and D) iliac 
lymph nodes in normal (blue line) and B16F10 tumor bearing mice (red line).  
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4.3.4.3  In Vivo Treatment Efficacy with Melphalan in the B16F10 Murine Melanoma Tumor 
Model 
Mice bearing B16F10 tumors with no treatment exhibited extremely rapid tumor growth, 
which reached 2000 mm3 within 19 days post implantation (Figure 4.5).  On the contrary, mice 
treated with i.v. melphalan exhibited a complete response to treatment (p=0.0068, two-tailed 
unpaired t-test), with signs of tumor regression within two days post-treatment (Figure 4.5).  
Melphalan treated mice did not exhibit a relapse in tumor growth over the time course of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.  B16F10 tumor growth with and without melphalan treatment (5 mg/kg, i.v.), (n=4, 
no treatment, n=3 melphalan treatment). (p=0.0068) 
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4.3.4.4 In Vivo Treatment Efficacy with 17-DMAG and Star-GA in the B16F10 Murine 
Melanoma Tumor Model  
Mice bearing B16F10 tumors did not exhibit any statistically significant responses in the 
inhibition of tumor growth with all treatment groups, 17-DMAG, star-GA, or 60% acid-star 
polymer, in comparison to no treatment (Figure 4.6 A).  Although 17-DMAG and star-GA 
treatments demonstrated a 400-fold and 24-fold, respectively, increase in toxicity compared to 
melphalan in the B16F10 cell line in vitro (Table 4.1), the in vivo B16F10 tumors did not 
respond to either GA-based treatment, while treatment with melphalan exhibited a statistically 
significant efficacious response in B16F10 tumors (p=0.0068, Figure 4.5).  Further, the star-GA 
treatments led to a decrease in the mouse’s body weight, compared to an increase in body weight 
seen with mice with both the 60% acid-star polymer and non-treated groups (Figure 4.6 B).  
However, the loss in body weight after treatment with star-GA was not observed until day 23, 
which corresponds to only one animal with a decrease in its body weight, and was not 
statistically significant.  The remainder of the mice in the star-GA treatment group did not 
exhibit more than ±5% change in body weight, whereas the one mouse had a 14% decrease in 
body weight post-treatment (Figure 4.6 B).  No physical signs of toxicities were seen with either 
the star-GA or 60% acid-star treatments; however, all mice treated with i.v.17-DMAG displayed 
signs of severe tail necrosis, possibly due to extravasation of either DMSO or 17-DMAG into the 
subcutaneous space of the tail.  Although 17-DMAG has increased water solubility compared to 
the parent drug, GA, the concentrations required for a 15 mg/kg dose and an injection volume of 
ca. 50 µL i.v. exceeded the water solubility of 17-DMAG, thus the need for DMSO for the 
injection of 17-DMAG. 
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Figure 4.6.  A) B16F10 tumor growth in response to no treatment (red, n=4), 60% acid-star 
polymer (s.c. equivalent star polymer dose to star-GA, purple, n=6), 17-DMAG (i.v. 15 mg/kg, 
blue, n=4), star-GA (s.c. 15 mg/kg DMAG equivalent, green, n=7), or melphalan treatment (i.v. 
5 mg/kg, black, n=3).  B) Percent change in body weight in response to no treatment (red, n=5), 
60% acid-star polymer (s.c., purple, n=7), 17-DMAG (i.v., blue, n=7), or star-GA (s.c., green, 
n=8).   
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4.3.5  4T1.2 Neu Murine Breast Cancer Tumor Model  
 
4.3.5.1  In Vivo Treatment Efficacy with 17-DMAG and Star-GA in the 4T1.2 Neu Murine Breast 
Cancer Tumor Model - Pilot Study 
At the end of the pilot study, when the tumors reached ca. 2000 mm3, no statistical 
significances were observed between the three treatment groups (no treatment, i.v. 17-DMAG, 
and s.c. star-GA, Figure 4.7).  However, on day 17, there was a statistically significant difference 
in the tumor sizes in the three treatment groups; both the 17-DMAG and star-GA treatment 
groups exhibited significant delay in tumor growth in comparison to the non-treated group 
(p<0.005, one-way ANOVA with a Tukey’s Multiple Comparison post test) (Figure 4.7).  
Further analysis with a larger number of animals per treatment group was required to further 
characterize the treatment of 17-DMAG and star-GA in 4T1.2 Neu tumor bearing mice.  The 
study was repeated with larger treatment groups, with the addition of the free 60% acid-star 
polymer.  Additionally, no visual signs of toxicity from the star-GA conjugate at either 10 or 15 
mg/kg (17-DMAG equivalent) doses were observed.   
 140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7.  4T1.2 Neu tumor growth in a pilot study after treatment with 17-DMAG (i.v., 10 
mg/kg, n=2), star-GA (s.c., 10 mg/kg 17-DMAG equivalent, n=3), and no treatment (n=2). 
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4.3.5.2  Increased Maximum Tolerable Dose (MTD) of Star-GA 
In both the 4T1.2 pilot study and the B16F10 efficacy studies, star-GA was dosed at an 
equivalent GA dose as the observed 17-DMAG MTD (10 and 15 mg/kg, respectively).  We 
investigated the potential for increasing the MTD of the star-GA with respect to 17-DMAG.  For 
doses of 30 and 50 mg/kg star-GA (17-HEAG basis), no visual signs of toxicity were observed 
with either treatment group within one week post treatment.  Further, after three weeks post 
dosing, no visual signs of toxicity were observed.  Dose escalation studies above 50 mg/kg were 
not investigated, however, it is possible that the MTD of the star-GA conjugate is higher than 50 
mg/kg, on a 17-HEAG basis.  Subsequent studies using the 50 mg/kg star-GA (17-HEAG basis) 
dose was evaluated for the treatment of 4T1.2 tumor model along with an increase in the number 
animals per treatment group.   
 
4.3.5.3  In Vivo Treatment Efficacy with 17-DMAG and Star-GA in the 4T1.2 Neu Murine Breast 
Cancer Tumor Model 
In the pilot study with 4T1.2 Neu tumor model, 17-DMAG was dosed at 10 mg/kg i.v. in 
100% DMSO, however in this study it was administered as a 1:1 sterile DMSO:PBS solution to 
minimize possible toxicities due to the administration of intravenous DMSO.  A dose of 45 
mg/kg was used in contrast to the 50 mg/kg used in the MTD study, due to solubility issues and 
limited quantities of the star-GA conjugate.  
Although the MTD of the star-GA conjugate was increased from 15 mg/kg 17-DMAG to 
at least 45 mg/kg 17-HEAG by utilizing the star-GA conjugate, no statistically significant 
increases in efficacy were observed by a delay in tumor growth (Figure 4.8 A).  Further increases 
in the survival (Figure 4.8 B) of mice were also not observed with the star-GA conjugate 
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compared to both non-treated and i.v. 17-DMAG treatment groups.  In fact, no statistical 
significances were seen with regards to the tumor response for all three of the treatment (star 
polymer alone, 17-DMAG, or star-GA) compared to the non-treated mice (Figure 4.8 A).  In 
addition, neither 17-DMAG nor star-GA treatments exhibited an increase in survival (Figure 4.8 
B).  Further, all but two mice, one treated with the 60% acid-star polymer and the other treated 
with the star-GA conjugate, exhibited an increase in body weight throughout the duration of the 
study (Figure 4.8 E).  The two aforementioned mice exhibited a decrease in body weight coupled 
with a significant decrease in body score (body score of 1 or lower).  A body score of 1 is 
representative of a mouse that appears to be “emaciated, with a prominent skeletal structure with 
little flesh covering, and distinctly segmented vertebrae [45].”  The cause of the low body score 
in these two mice was not investigated further. 
 
4.3.5.4  Metastatic Analysis of Axillary Lymph Nodes by Nodal Volume and Real Time 
Polymerase Chain Reaction (rtPCR)  
In order to assess the metastatic state of the 4T1.2 Neu tumor model, after treatment with 
17-DMAG, 60% acid-star polymer, star-GA, or no treatment, the visible axillary lymph nodes on 
the right sides of the mice were harvested, measured, and analyzed by rtPCR.  During the lymph 
node harvesting, gross visualization of the organs was made to identify any obvious signs of 
metastases, growths, or toxicities associated with any of the treatments.  
All of the mice with 4T1.2 Neu tumors exhibited significantly enlarged spleens of at least 
twice the size of a normal mouse’s spleen.  The mouse treated with star-GA (referred to in the 
previous section, 4.3.5.3) with the low body score also appeared to have lung metastases and 
possible cardiac disease.  One mouse that did not receive treatment also exhibited signs of 
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cardiac disease.  Finally, one mouse treated with the 17-DMAG appeared to have liver 
metastases.  Before the lymph node samples were analyzed for HER2 expression by rtPCR to 
assess their metastatic state, the lymph nodes were measured with digital calipers and the axillary 
lymph node volumes were calculated using the same equation used to calculate tumor volume = 
0.52 # (width)2 # (length).  Although there are noticeable differences in the axillary lymph node 
volumes in Figure 4.8 C, these differences are not statistical significant.   
Typically when analyzing rtPCR data the amplification value of the target gene, HER2, 
would be normalized against the 18S housekeeping gene, however, the HER2 expression was 
very low in all of the axillary lymph node tissue samples for all treatment groups indicated by the 
average cycle threshold value of ca. 35 (Figure 4.8 D); indicating that the axillary lymph nodes 
did not have HER2 expressing metastases.  One animal in the star-GA treatment group did 
present a cycle threshold of ca. 29 for the HER2 expression; however, there were no statistically 
significant differences between the different treatment groups.   
 144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  A) 4T1.2 Neu tumor growth in mice treated with 17-DMAG (i.v., 10 mg/kg, n=7) 
(green inverted triangles), star-GA (s.c., 45 mg/kg 17-DMAG equivalent, n=8) (blue diamonds), 
60% acid-star polymer (s.c., equivalent star polymer dose to 45 mg/kg Star-GA, n=7) (purple 
triangles), and no treatment (n=7) (red squares).  B) 4T1.2 Neu survival curve after treatment 
with 17-DMAG (green inverted triangles), star-GA (blue diamonds), 60% acid-star polymer 
(purple triangles), and no treatment (red squares).  C) Right axillary lymph node volumes from 
mice treated with 17-DMAG (green), star-GA (blue), 60% acid-star polymer (purple), and no 
treatment (red) after primary tumors reached 2000 mm3.  Axillary lymph node volume = 
0.52#(width)2#(length).  D) Metastatic assessment of HER2 expression in axillary lymph nodes 
from mice treated with 17-DMAG (green), star-GA (blue), 60% acid-star polymer (purple), and 
no treatment (red) by rtPCR, representative cycle threshold values for HER2 expression in each 
treatment group.  E) Percent change in body weight in mice bearing 4T1.2 Neu tumors after 
treatment with 17-DMAG (green inverted triangles), star-GA (blue diamonds), 60% acid-star 
polymer (purple triangles), and no treatment (red squares). 
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4.3.6  A2058 Human Melanoma Tumor Model Optimization and Efficacy with 17-DMAG and 
Star-GA – Pilot Study 
The two mice implanted with 2#106 A2058 cells both developed primary melanoma 
tumors within two weeks, and both tumors continued to progress throughout the length of the 
study.  The mouse implanted with 5#106 cells developed a primary tumor in the inguinal lymph 
node by day 14, however, once the tumor reached ca. 100 mm3 on day 19, the mouse’s body 
condition decreased and the mouse was euthanized.  The mouse implanted with 7.5#106 cells 
developed a tumor within one week, and it continued to grow to ca. 100 mm3 by the end of the 
second week; however, the tumor then disappeared and the mouse did not develop another 
palpable tumor within one month post implantation.  Finally, the mouse implanted with 1#107 
cells developed a visible tumor by day 5, which continued to grow throughout the length of the 
study.  Of the five mice implanted with A2058 human melanoma cells, four developed palpable 
tumors, however, only three mice survived through the end of the study (2 mice implanted with 
2#106 cells and 1 mouse implanted with 1#107 cells). 
Of the three aforementioned mice with palpable tumors, the mice were divided into three 
treatment groups once the tumors volumes reached 200-300 mm3.  The treatment groups were as 
follows:  no treatment (2#106 cell/animal mouse), i.v. 10 mg/kg 17-DMAG (1:1 DMSO:PBS, 
2#106 cell/animal mouse), and s.c. 20 mg/kg star-GA (17-HEAG basis, 30:70 DMSO:PBS, 
1#107 cell/animal mouse). As with the other two in vivo models, neither 17-DMAG nor star-GA 
exhibited efficacy in the A2058 tumor model (Figure 4.9).  It is worth noting that the mouse 
treated with star-GA did show a slight decrease in tumor volume for a few days post treatment, 
however, the tumor continued to grow rapidly after the slight tumor recession (Days 16-20).  
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Figure 4.9.  A2058 tumor growth in a pilot study after treatment with 17-DMAG (i.v., 10 mg/kg, 
n=1), star-GA (s.c., 20 mg/kg 17-HEAG equivalent, n=1), and no treatment (n=1). Mice treated 
with 17-DMAG and no treatment were implanted with 2#106 cell/animal; the mouse treated with 
star-GA was implanted with 1#107 cell/animal. 
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4.4  Discussion 
 
4.4.1  In Vitro Characterization 
The procedure for the synthesis of the 17-((2-hydroxyethyl)amino)-17-
demethoxygeldanamycin analogue (17-HEAG) was modified from Tian et al. [41]. The loading 
degree of 15% wt/wt of 17-HEAG on the star polymer limited the water solubility of the 
conjugate to a minimum requirement of 30% DMSO for solubilization at the concentrations 
needed for treatment.  Higher loading degrees of 27 and 31 % were also synthesized, however 
these conjugates were not continued with due to the lack of water solubility even in high DMSO 
concentrations.    
The overexpression of HSP90 in malignant melanoma [43,46] combined with the 
inhibition of HSP90 resulting in the degradation of its client protein HER2 [46], we investigated 
the in vitro cytotoxicity of the geldanamycin derivatives (GA, 17-AAG, 17-DMAG, 17-HEAG, 
and star-GA) in both murine and human melanoma and breast cancer cell lines.  Previous reports 
have demonstrated surprising in vitro cytotoxicity of geldanamycin analogues against human 
melanoma cell lines, given that most melanomas are considered to be chemoresistant [47]. Zhang 
et al. reported that a 11-methoxy-17-formyl-17-demethoxy-18-O-21-O-dihydrogeldanamycin 
analogue exhibited significant anticancer activity (IC50 ca. 496 nM) in the SK-MEL-2 human 
melanoma cell line [48].  Comparable results were observed with 17-AAG in two human 
melanoma cell lines with IC50 values of 21±5 nM and 13±2 nM in a BRAF mutant of 
SKMEL28 and the BRAF wild type CHL-1 cell lines [49].  Similar nanomolar range IC50 values 
were observed in both of our B16F10 murine and A2058 human melanoma cell lines.  Even 
though the star-GA conjugate had substantially less toxicity in the B16F10 cells than the 17-
 148 
HEAG analogue, the star-GA conjugate was 24-fold more toxic than melphalan, the clinical 
chemotherapeutic used in ILP of melanoma.  Similarly, the star-GA conjugate exhibited less 
toxicity than GA, 17-DMAG, and 17-AAG in the A2058 human melanoma cell line, but 
exhibited two orders of magnitude more toxicity than melphalan.   
Tian et al. reported that in the SKBr3 cell line, a human HER2 over-expressing breast 
cancer, 17-AAG, 17-DMAG, and 17-HEAG all exhibited similar cytotoxicities, with IC50 values 
of 33±10, 24±8, and 50 nM, respectively [41].  Further, they all exhibited similar binding 
coefficients with human HSP90, with reported Kd values of 1.3, 0.5, and 0.8 µM, respectively 
[41]. Similarly, in our 4T1.2 Neu HER2 over-expressing breast cancer cell line, all of the GA 
derivatives exhibited similar toxicities with IC50 values slightly higher than Tian et al. reported, 
but still in the nanomolar range (Table 4.1).  The low in vitro IC50 values of 17-HEAG combined 
with the similar in vitro HSP90 binding in comparison to GA (Kd= 0.24 µM) [50], along with the 
increased toxicity compared to melphalan in both the B16F10 and A2058 cell lines, we decided 
to proceed with in vivo efficacy studies of the star-GA conjugate in the B16F10, 4T1.2 Neu, and 
A2058 tumor models despite the short release half-life of 4 hr.  
 
4.4.2 B16F10 Murine Melanoma Tumor Model 
In the tumor optimization study, five difference cell concentrations were orthotopically 
implanted into the hind thigh of Balb/c mice.  The lack of consistent tumor development below 
the 2.5#106 cells/animal concentration suggests that there is a minimum amount of B16F10 cells 
needed for to develop a palpable tumor in Balb/c mice.  The 5.5#106 cells/animal concentration 
was chosen as the optimal cell concentration for the B16F10 tumor studies due to its 
reproducible tumor growth and development.  Similar B16F10 tumor growth was observed by 
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Dirkx et al., where after implanting 106 cells subcutaneously into the flank of C57Bl/6 mice, the 
mice developed tumors of 1.5 cm within two to three weeks [51].  The primary tumor location of 
the hind flank is in contrast to most published reports of cell implantation into the hind footpad 
of mice to develop lymphatic metastases, where 2#105 cells are subcutaneously injected into the 
hind footpad and tumors develop to be 2 to 6 mm in diameter within three weeks [7,52,53].  
However, the hind thigh was chosen for both humane reasons and as a representative model for 
localized melanoma.  Whereas, implantation into the hind footpad not only limits the mobility of 
the mouse but also is less likely to be a representative model of the natural progression of 
melanoma metastases.  The footpad model would be representative of a locally advanced 
lymphatic metastatic model and was developed to intentionally form metastases within the 
lymph nodes by nature of the subcutaneous cell injection, which allows the B16F10 cells to 
directly drain into the rich lymphatic network in the mouse footpads leading to popliteal 
metastases. 
Recent reports with QDs, low MW Gd-DTPA, and indocyanine green liposomes have 
shown increased lymph flow to the SLN in the presence of B16F10 melanoma tumors [7,53,54].  
However, these studies only looked at the short term effects on the lymphatic drainage 
(maximum of two hours), reporting up to a 23-fold increase in lymph flow to the popliteal node 
in tumor bearing mice two minutes post injection, which later decreased to a two-fold increase 
30 min post injection [7].  Given that our HA conjugates are well-suited as sustained release drug 
carriers with a lymphatic absorption tmax of 1.5-2 hrs (74 kD, Figure 4.4 A and Table 4.2) and are 
retained within the lymph nodes for up to five days, the “downstream” effect of a B16F10 tumor 
on the lymph flow could not be fully characterized within the first two hours as with the previous 
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reports.  Further, the early studies only mentioned an increase in popliteal lymph flow, with no 
reference to the successive nodes (i.e. iliac). 
We examined the effect of a B16F10 melanoma tumor on the lymphatic drainage of both 
the popliteal (Figures 4.4 A and C) and iliac (Figures 4.4 B and D) nodes using the optimized 74-
kD HA-IR820 conjugate. A significant difference was observed in the kinetic profiles for the 
lymphatic drainage to the popliteal node between the tumor bearing and normal mice (p=0.0320, 
student t-test); however, there were no significant differences in the AUC for the popliteal nodes 
between the two groups (Table 4.2).  The drainage from the popliteal node in tumor-bearing 
mice was almost three times slower than in the normal mice, whereas the drainage to the iliac 
node remained unchanged (Table 4.2).  Furthermore the tmax in the popliteal and iliac nodes was 
unchanged for tumor-bearing mice compared to normal mice (Table 6).  Contrary to the 
previously published results for liposomes, QDs, and Gd-DTPA, our results indicate similar 
uptake into the popliteal node regardless of tumor presence; although, the conjugate drains 
slower from the popliteal node in the presence of a tumor. 
One possible reason for the differences in observed lymphatic drainage kinetics 
compared to the literature is due to the location of the primary tumor site (footpad vs. thigh).  
Our tumor model on the hind thigh of mice is representative of a localized limb melanoma, 
whereas the s.c. implantation of B16F10 cells into the footpad is more representative of a 
lymphatically advanced melanoma model with metastases within the lymph nodes. Further, this 
difference in tumor location may lead to induction of lymphangiogenesis at different sites 
leading to different drainage kinetics.  As the footpad model has been reported to induce long 
range lymphangiogenesis within the popliteal lymph node, visualized by the increased lymphatic 
sinuses without lymphatic or blood vessel growth within the footpad tumor [7].  Another 
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possible reason for the difference is that our conjugates are composed from a naturally occurring 
polymer, rather than  “foreign materials” leading to a different retention mechanisms, such as 
strong interactions between HA and CD44 receptors on the surface of epithelial, mesenchymal, 
and lymphoid cells [55].  While the long retention of these conjugates within the sentinel lymph 
nodes of tumor-bearing animals may not be favorable to imaging, where rapid clearance is 
desired, it may benefit drug delivery applications.  The lymphatic uptake of the HA-IR820 
conjugate is not impeded by the presence of a large primary tumor and the conjugate is highly 
retained in the sentinel lymph node, which may facilitate sustained release of anti-cancer drugs 
from HA conjugates. 
 While our objective in this study was to develop an intralymphatic chemotherapy for the 
treatment of localized melanoma, the present star-GA conjugate does not exhibit increased 
efficacy over traditional i.v. melphalan.  This is consistent with the literature, in that there are no 
published reports indicating that melanoma exhibits efficacious responses to 17-AAG as a single 
agent [56].  Although melphalan is unstable and exhibits significant systemic toxicities upon 
leakage from the ILP perfusate, our studies indicate that it still remains the most effective 
treatment of melanoma, exhibiting complete rapid (within 2 days post treatment) responses to 
treatment compared to non-treated animals (p=0.0068).  Further, melphalan treated mice did not 
exhibit a relapse in tumor growth.  Based on our in vitro toxicity results, we hypothesized that 
the geldanamycin treatments would exhibit improved efficacy over melphalan treatment; 
however, the in vivo results do not confirm these initial results.  Although preliminary data 
discussed in Chapter 5 suggest that multiple dosing with geldanamycin derivatives may exhibit 
improved efficacy compared to the non-treated groups in B16F10 tumor bearing mice.  
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4.4.3  4T1.2 Neu Murine Breast Cancer Tumor Model  
The pilot study with the treatment of murine breast cancer with 17-DMAG and star-GA 
demonstrated potentially positive efficacy results with the statistically significant differences in 
the delayed tumor growth on day 17 with the 17-DMAG and star-GA treatment groups compared 
to the non-treated group (p<0.005).  It was hypothesized that if more animals were used in a 
follow-up study, that these differences would become more pronounced; however, with the 
addition of more animals in the study, the significance between these early differences in tumor 
growth proved to be insignificant.  Further, no statistically significant differences were observed 
with any of the treatment groups.  However, the use of a multiple dosing schedule is 
hypothesized to produce more distinct differences between the treatment groups as suggested in 
the pilot study.  Multiple dosing over a period of weeks is commonly used in the clinic rather 
than a single dose as investigated in these studies.  Preliminary data, discussed in Chapter 5, 
investigates the use of multiple dosing with geldanamycin derivatives to improve efficacy 
compared to the non-treated groups in 4T1.2 Neu tumor bearing mice. 
However, in these studies, the maximum deliverable dose of the star-GA was increased 
by 5-fold compared to that of i.v. 17-DMAG, with no visual signs of toxicity.  Further 
pathological examination is needed to determine the overall treatment related toxicities 
associated with the administration of the star polymer and star-GA compared to the liver 
toxicities often associated with geldanamycin administration [38,41].  Further 
immunohistopathology of the state of the enlarged spleens in this tumor model is worth 
investigating.  In a similar 4T1 HER2 tumor model, both the spleen and livers were enlarged due 
to extramedullary hematopoiesis; further, the lungs (6/6), spleen (3/6) and liver (5/6) all 
exhibited metastases [57]  
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In addition to developing an intralymphatically delivered chemotherapeutic is the 
potential for reduction in the lymphatic metastatic potential.  Although we did not observe any in 
vivo efficacy against the primary tumor growth of the 4T1.2 Neu tumor model, it is possible that 
the star-GA lymphatically targeted chemotherapeutic could prevent and/or treat lymphatic 
metastases.  The 4T1.2 Neu tumor model is reported to be characteristic of spontaneous 
metastatic breast cancer with the formation of bone marrow metastasis within one week post 
implantation into the mammary fatpad [58].  Where the 4T1.2 tumor model metastasize by both 
the lymphatic and hematological routes, with metastases in the draining lymph nodes, lungs, and 
liver [59].  In order to investigate the metastatic state of the mice after treatment, the contralateral 
axillary lymph nodes were harvested, measured, and analyzed for the HER2 expression.  No 
statistically significant differences were observed in the lymph node volume with all of the 
treatment groups; however, all of the axillary lymph nodes in the tumor bearing mice appeared to 
be enlarged compared to that of non-tumor-bearing mice.  The HER2 expression was determined 
in the axillary lymph node samples; however, the HER2 expression was very low in all mice, 
suggesting that this tumor model was not metastatic at the end of this study.   
It is possible that due to the limited size of the mice and the shear massiveness in the size 
of the tumors relative to the overall body size, that the primary tumor developed around or 
encompassed the metastatic lymph nodes, thus enabling their individual distinction for 
harvesting.  Additional possibilities for the lack of HER2 expression in the axillary lymph nodes 
is that the tumor model did not reach a metastatic state by the end of the study (tumor volume = 
2000 mm3), the metastatic cells “lost” their ability to express HER2 (as this was a transfected 
gene), or the tumor model was not as metastatic as it was originally presented in the reported 
tumor model [58]. 
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4.4.4 A2058 Human Melanoma Tumor Model 
John et al. reported that two weeks post implantation of 5#106 A2058 cells into nude 
mice yielded a tumor 1-cm in diameter [60].  In contrast, the mouse injected with twice the 
A2058 cell concentration (1#107 cells) reported by John et al. developed a tumor 1 cm in 
diameter by day 16, whereas the implantation with 2#106 cells yielded a 1 cm tumor within 20 
days.  From the pilot study with the A2058 tumor model, we determined that for future studies, 
mice would be implanted with 1#107 cells/animal, in that tumors are visible in less than one 
week post implantation, but develop at a similar rate as the 2#106 cells/animal injection.  The 
early visual conformation of successful tumor implantation in athymic mice is advantageous 
because the success rate of tumor implantation is often lower than that of “normal” mice, and the 
tumor growth progression is much slower in athymic mice compared to normal mice.  The 
visualization of the inguinal lymph node tumor is promising in the development of a natural 
progressing lymphatically metastatic model for human melanoma.   
Ideally, one would like to implant all mice in a study with the same concentration of 
cells, however this was a pilot study to determine if the A2058 tumor model responded to GA 
treatment.  In order to minimize the amount of nude mice used, we decided to continue with the 
study using mice with different concentrations of implanted A2058 tumor cells.  If positive 
results were observed, then future studies would be designed to utilize more animals per 
treatment group, and mice would be implanted with 1#107 cells/animal.  However, as with the 
other two in vivo models, neither 17-DMAG nor star-GA exhibited efficacy in the A2058 tumor 
model (Figure 4.9).  It is worth noting that the mouse treated with star-GA did show a slight 
decrease in tumor volume for a few days post treatment, however, the tumor continued to grow 
rapidly after the slight tumor recession (Days 16-20).  It is possible that the mouse treated with 
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star-GA did have a slight response to the treatment, however, this response was not significant 
compared to the non-treated mouse to progress with this conjugate in the A2058 tumor model.  
Mutiple dosing of 17-DMAG and/or the star-GA conjugate or improving the star-GA conjugate 
to be a sustained release formulation, could increase the efficacy of the geldanamycin treatment 
in this tumor model or the 4T1.2 Neu tumor model.  
 
4.5  Conclusions 
 We developed a star-GA conjugate that exhibited increased solubility over the parent 
drug geldanamycin and had the potential to be delivered as a localized intralymphatic drug 
delivery system for the treatment of melanoma and breast cancers.  Even though the release half-
life of 17-HEAG from the star polymer was less than ideal, ca. 4 hrs in vitro, the potential for 
localization of the chemotherapeutic to the lymphatics still offered promising results as the star 
polymer drains rapidly (tmax= 45-50 min, Table 3.3) to the sentinel lymph node and successive 
nodes (popliteal t50%= 1.9 hr, and iliac tmax= 1 hr, Table 3.3) after s.c. administration, allowing 
for localized release of the 17-HEAG within the affected tumor draining lymphatic basin.  On the 
other hand, we were able to significantly increase the deliverable dose of the geldanamycin 
analogue, 17-HEAG, from 10 mg/kg i.v. 17-DMAG to at least 50 mg/kg 17-HEAG without any 
visual signs of toxicity associated with the star polymer or 17-HEAG. 
Despite the promising in vitro results with 17-DMAG, 17-HEAG, and star-GA treatment 
in the B16F10, A2058, and 4T1.2 Neu cell lines, none of the in vivo tumor models responded to 
treatment with the geldanamycin analogues either by i.v. or s.c. intralymphatic administration.  
Although it was expected that the geldanamycin analogues would offer some efficacy towards 
the melanoma and breast cancer in vivo tumor models, given that the literature has shown 
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evidence of the efficacious responses to HSP90 inhibitors in HER2 positive in vitro and in vivo 
models [42], along with the reports that melanomas overexpress HSP90 and role in the 
progression of melanoma metastases [43,44], we unfortunately did not observe any response to 
treatment with a single dose of the geldanamycin analogues.  It is possible that inhibition of the 
HSP90 pathway does not play a major role in the anti-proliferative pathways of these particular 
tumor models in that both melanoma and HER2 positive breast cancers are known to be resilient 
and develop chemoresistance [30,47].  It is possible that treatment of these tumor models would 
be feasible with geldanamycin analogues, if the release profile of the geldanamycin analogue 
was modified to exhibit more of a sustained release character; thus allowing for an increased 
exposure of the tumor to the chemotherapeutic.  In addition, the use of a multiple dosing 
schedule could increase the chance of the geldanamycin analogue to reach the primary tumor and 
metastases.  In a preliminary study with two mice, we found that treatment of mice bearing 
B16F10 tumors with three weekly doses of 17-DMAG i.v. exhibited a positive response to 
treatment, with a temporary halt in the tumor progression of one mouse, and tumor regression in 
the other mouse.  Future studies to optimize the dosage and dosing schedule will be discussed in 
Chapter 5. 
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Chapter 5.  Summary and Future Work 
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5.1  Summary 
With the development of the HA-Texas Red conjugate we were able to visualize the HA 
conjugates drain from the injection site around the tumor, confirming our hypothesis that 
peritumoral injections of HA could potentially deliver chemotherapeutics to tumors via the 
lymphatics.  However, the use of Texas Red was not optimal for deep tissue penetration and 
large signal to noise ratios, so we decided to pursue a different fluorescent dye in the NIR range, 
IR820.  A series of six different molecular weight HA-IR820 conjugates were synthesized with 
similar dye loading degrees (ca. 5 % wt/wt).  The size of HA was optimized for lymphatic 
delivery utilizing whole body fluorescent imaging using the series of HA-IR820 conjugates.  
From the kinetic and cumulative fluorescent data obtained after the image fluorescence analysis, 
it was determined that 74-kD HA (30-50 nm) was the optimal MW for lymphatic delivery of HA 
conjugates.  This was consistent with the optimal reported liposomal size (40 nm) for lymphatic 
uptake after s.c. administration [1]. The 74-kD HA-IR820 conjugate drained at a similar rate to 
both the popliteal and axillary lymph nodes after injections into the footpad and forearm, 
respectively, with a tmax of  ca. 2 hr.  Furthermore, it was found that the HA conjugates are highly 
retained by the lymph nodes with t50% of 6.9, 21, and 15 hrs for the popliteal, iliac, and axillary 
lymph nodes, respectively.  Hyaluronan would be an effective carrier for sentinel lymph node 
drug delivery as the HA-IR820 conjugate is cleared relatively slowly from the axillary and 
popliteal nodes.  
One issue with the development of HA conjugates is due to the increased viscosities 
associated with increasing the MW and concentrated HA solutions, along with the limited drug 
loading degrees due to issues with the solubility and biocompatibility.  Therefore we sought to 
develop a new biodegradable star polymer with variable degrees of anionic charges, to be used as 
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a new lymphatic carrier for imaging and drug delivery.  Rao et al. examined the effect of varying 
the negative charge on the lymphatic uptake of PLGA nanoparticles [2], but this is the first study 
using defined-structure polymers while varying the negative charge . The authors varied the ratio 
carboxylic acid terminated to uncharged polymers in their preparation of nanoparticles and 
determined that an increase in the anionic character of the nanoparticles led to increased 
lymphatic uptake, both in the SLN and cumulative draining lymph nodes.  After fully 
characterizing the star polymer with four degrees of anionic charge, we found that the polymer is 
less toxic in vitro than other polyanionic and polycationic polymers used for drug and gene 
delivery.  Further, the star polymer was significantly less viscous than HA solutions, with 
viscosities similar to that of water (1 Pa!s).  A linear decrease in the zeta potential, with respect 
to the increase in the anionic character, was observed.  Although no significant differences were 
found in the total cumulative drainage of the 40-90 wt% acid star polymers, large differences in 
the elimination half times for the popliteal and iliac lymph node were observed.  Sixty weight 
percent acid conjugation on the star polymer was determined to be the optimal star polymer 
formulation for lymphatic delivery using whole body fluorescent imaging, due to its rapid 
drainage from the popliteal node (t50% = 1.9 hrs) and increased retention in the iliac node (t50% = 
19 hrs).  The results suggest that the 60% wt acid-star polymer would be an ideal candidate for 
deep lymphatic drug delivery to the subsequent lymph nodes.   
After optimizing the star polymer using star-IR820 with in vivo fluorescent imaging, we 
developed a star-geldanamycin analogue (17-HEAG) conjugate, with 15% wt/wt drug loading, 
for the treatment of localized melanoma and breast cancer.  It was found that the release half-life 
of the 17-HEAG from the star-GA conjugate was 4 hr, which is shorter than ideal for sustained 
drug release.  However, the in vitro data suggested that the conjugate along with 17-DMAG 
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exhibited cytotoxicity against the B16F10, A2058, and 4T1.2 Neu cell lines, so we decided to 
proceed with treatment in the in vivo tumor models.  However, the 17-DMAG (i.v.) and star-GA 
formulations did not exhibit any response or a significant tumor regression in all three of the in 
vivo tumor models (B16F10, A2058, and 4T1.2 Neu).  This suggests that either these rapid 
growing tumor models do no respond to HSP90 inhibitors in vivo or the 17-HEAG released too 
rapidly from the star polymer before the star-GA conjugate was able to reach the tumor to elicit a 
sufficient tumor response.    
In conclusion, we optimized both the size and charge of two different carriers for the use 
in intralymphatic imaging and drug delivery.  Further, we developed a new biodegradable, less 
viscous, and water soluble star polymer as a potential carrier for use in lymphatic drug delivery.  
Hyaluronan may be useful for SLN lymphatic drug delivery, whereas the star polymer may be 
more useful for deep lymphatic drug delivery.  Even though our initial studies with the star-GA 
conjugate did not delay the tumor progression in the three in vivo tumor models, promising 
preliminary results show that we may have developed a new multiple dosing treatment option for 
melanoma, which is a fast growing, resistant disease, for which there are little treatment options 
if the tumor is not detected and removed early. 
! 166!
5.2  Future Work 
 
5.2.1 Further Optimization of Lymphatic Carriers and Imaging Agents 
For future multimodal lymphatic imaging and drug delivery, it would be advantageous to 
develop a new NIR dye rather than continue using the IR820 dye utilizing an amino group on the 
linker to displace the chloride (Figures 5.1 A, B, and C).  After developing the series of HA-
IR820 conjugates, we observed red shifts in the UV absorbance post derivatization of the dye, 
leading to suboptimal absorbance and fluorescence wavelengths for in vivo imaging.  Further, it 
was found that at high concentrations (e.g. > 0.1 mg/mL IR820), the IR820 dye has the tendency 
to self-quench leading to reduced fluorescence signals both in vitro and in vivo and limiting the 
detection of the fluorescent conjugates only at low concentrations.  Preliminary work is under 
way to develop a new derivative of the IR820 dye, which utilizes a thiol group (Figure 5.1 D) 
rather than an amine (Figures 5.1 B and C) to replace the chloride (Figure 5.1 A).  The use of the 
sulfur in the linker moiety leads to similar UV absorbance and fluorescence spectra (data not 
shown) as the original IR820, rather than the blue shifts seen for the amino group on the linkers 
used for HA-IR820 and star-IR820.  This is because sulfur is more electron donating, unlike the 
nitrogen, which destabilizes the conjugated system leading to a shift in the UV absorbance and 
fluorescence.  However, the photostability and quenching characteristics of the new thiol IR820 
derivative have not yet been studied.  If the new derivative appears to be photo-unstable or 
quenched, other fluorescent NIR dyes, can be investigated for the use of in vivo fluorescent 
imaging.  One such dye could be the Cy7-NHS ester, which is photostable, easy to conjugate to 
the polymers, and exhibits bright fluorescence in the NIR range (!ex/!em = 750/773 nm, " = 
199,000 cm-1 M-1). 
! 167!
Further, it is likely that the MW/size of the star polymer used in the optimization of the 
anionic charge was not optimal for lymphatic delivery.  The MWs of the star polymers used were 
approximately 54 kD, 63 kD, 72 kD, and 85.5 kD for the 20, 40, 60 and 90% acid-star polymers, 
respectively; however these differences in the MW are due to the addition of succinic acid on the 
sugar moieties along the polymer backbone, which is unlikely to change the overall size 
significantly.  Due to difficulties in optimizing the conditions needed for sizing small particles by 
dynamic light scattering, the accurate size identification was not conducted for the star polymers; 
however, it is likely that similar to the size of 6.4 kD HA (ca. 10 nm) based on similar elution 
times using SEC.  Further optimization of the size of the star polymers would be advantageous, 
in order to maximize the lymphatic uptake of these delivery platforms.  The optimization could 
easily be done in a similar manner as with the IR820-polymer conjugates using whole body 
fluorescent imaging.  However, one limitation to this study is that multiple different MW (at 
least 2 to 3 additional MW) star polymers must first be synthesized prior to the imaging studies. 
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Figure 5.1.  Chemical structures of A) IR820, B) 5-carboxypentyl-amino-IR-820 (used in HA-
IR820), C) 3-aminopropyl-amino-IR820 (used in star-IR820), and D) ethylthiol-IR820. 
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5.2.2  Future Optimization of the Star-GA Conjugates and Dosing Regimens 
Two possible ways to test if an increased exposure to the GA analogue would result in a 
tumor response are to 1) treat animals with multiple doses of the GA analogues, either with 17-
DMAG or the current star-GA conjugate, and 2) develop an actual sustained release formulation 
of the star-GA conjugate by modifying the linker between GA and the star polymer.  To 
determine whether increased exposure to the GA drug would improve the outcome, we 
determined the in vitro toxicity of GA, 17-DMAG, and star-GA at multiple exposure times (24, 
48, and 72 hr) in the B16F10, A2058 and 4T1.2 Neu cell lines.  The preliminary results suggest 
that increased incubation with the GA analogues elicits a greater cytotoxic response, indicated by 
decrease in IC50 values with increased exposure times (Table 5.1).  Some of the IC50 results 
suggest that the analogues are more toxic when incubated for 48 hr compared to 72 hrs, however, 
this study was only conducted once and statistical significance could not be determined.  Further 
repetitions of these cytotoxicity assays may validate the observed trend, however, with the 
limited replicates presented, it is not possible to determine if results are real or experimental error.  
On the other hand, it is clear, that prolonged exposure of more than 24 hrs does result in a higher 
cytotoxic response.   
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 With the promising results from this preliminary study, we decided to determine whether 
multiple i.v. dosing of 17-DMAG would result in a delay in the tumor growth of the two murine 
tumor models, B16F10 and 4T1.2 Neu.  Mice were treated with three weekly doses of 17-
DMAG (5 mg/kg i.v., 1:1 DMSO:PBS), and the tumor growth was measured and compared to 
the tumor growth discussed in Chapter 4 for the non-treated and single dosed i.v. 17-DMAG.  
B16F10 tumor bearing mice (n=2) responded to multiple 17-DMAG dosing (Figure 5.2 A), 
whereas the 4T1.2 Neu tumor bearing mouse (n=1) did not exhibit a different response compared 
to a single dose of 17-DMAG (Figure 5.2 B).  One of the B16F10 tumor bearing mice with 
multiple treatments exhibited a ten-day delay in tumor growth, whereas the other mouse 
exhibited significant tumor regression by doubling its life expectancy (>44 days compared to 19 
days).  The mouse exhibiting increased survival was euthanized since the approved study period 
(45 days) had concluded.   
Further investigation with multiple dosing of the current star-GA formulation, along with 
the use of more animals in the 17-DMAG group is needed.  Treatment with 10 mg/kg (MTD), 
rather than the 5 mg/kg used in this study, in three weekly doses may provide additional tumor 
responses to the observations seen with the 5 mg/kg dose.  The animals in this study were limited 
to three weekly doses with i.v. 17-DMAG, as the mouse’s tail needed at least five days between 
treatments to heal due to the extravasation of the DMSO causing necrosis.  Further, a more 
frequent subcutaneous dosing schedule should be investigated for increased tumor responses, as 
the healing time is not necessary for s.c. injections as with i.v. injections.  Further optimization 
of the linker would be potentially useful also to achieve sustained release of the GA analogue 
while the carrier is localized in the draining lymph nodes.  Since the hydrolysis of the existing 
ester bond between GA and the star polymer results in rapid release of GA (4 h release half-life), 
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future studies may us a long-lived pH-sensitive or tumor activated linker, such as a dihydrazide, 
peptide, or enzymatically cleavable linker.  Dr. Cai in our laboratory has previously employed a 
dihydrazide linker for the sustained release of doxorubicin from HA in which the release half-life 
decreased with decreasing pH, resembling that of the hypoxic tumor environment [3].  
Pathological examination of the tissues of mice treated with the star polymer would provide 
insight as to if these new biodegradable star polymers are indeed less toxic than their dendrimer 
counterparts.  Additionally, since GA is known to induce liver toxicity, pathology studies of the 
animal liver tissues in the 17-DMAG and star-GA treatment groups would determine if the star 
polymer also reduces the liver toxicity associated with GA treatment. 
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Appendix 1.  Synthesis of 4-Arm-Acid-Star Polymers 
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The following sections describe the detailed synthesis of the acid-star polymers 
utilized in Chapters 3 and 4 described in this dissertation.  The MADIX agent was 
synthesized based on the procedure reported previously [1].  The RAFT agent was 
synthesized according to the procedure reported previously [2].  
 
A.1  Materials 
Unless noted otherwise, all reagents and solvents were purchased from Sigma 
Aldrich and used without further purification.  1H-NMR (400 MHz) and 13C-NMR (100 
MHz) spectra were collected on a Bruker DRX 400 spectrometer using compounds 
dissolved in CDCl3, MeOD or D2O.  Chemical shifts were referenced to !7.28 and 77.0 
ppm for 1H-NMR and 13C-NMR spectra, respectively.  High-resolution mass 
spectrometry (HRMS) data were generated after flow injection analysis (FIA) manually 
matching peaks on an Applied Biosystems Mariner TOF spectrometer with a turbo-
ionspray source.  
 
A.2  Synthesis of Acid-Star Polymers 
 
A.2.1  Synthesis of the Bromide Intermediate Compound (Scheme 3.1)[1] 
Pentaerithol (1.36 g, 10 mmol) was dissolved in 25 mL of dry chloroform and 2.5 
mL of pyridine and cooled to 0 oC.  The 2-bromo propionyl bromide (10.01 g, 45 mmol) 
was added dropwise, and the reaction proceeded at ambient temperature (ca. 23°C) for 48 
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hours.  The mixture then was neutralized with aqueous HCl (10 wt %).  Then the organic 
phases were washed with water, sodium bicarbonate solution (5%), and brine, followed 
by drying with sodium sulfate.  Evaporation of the solvent under reduced pressure 
yielded the desired bromide intermediate compound, and the molecular structure was 
verified by 1H-NMR and compared with the reported data.  The reaction yielded 4.89 g of 
the desired bromide intermediate compound was obtained with a yield of 72%.  1H-NMR 
(CDCl3, 400 MHz) !: 1.85 (d, 12 H, J = 7.0), 4.22-4.23 (m, 4H), 4.33-4.39 (m, 4H), 4.41 
(q, 4 H, J = 7.0).  The chemical shifts are consistent with the structure and no impurities 
or unknown peaks were observed. 
 
A.2.2.  Synthesis of the MADIX Agent (Scheme 3.1)  
A solution of the bromide intermediate compound (2.028 g, 3.0 mmol) in 
chloroform (45 mL) was treated with a 10-fold excess of O-ethylxanthic acid, potassium 
salt (5.01 g, 30 mmol).  The mixture was stirred at ambient temperature for 3 days, and 
the resulting suspension was filtered and washed with chloroform.  Evaporation of the 
solvent followed by purification through a flash column on silica gel using 3:7 ethyl 
acetate:hexanes as eluents yielded the desired compound, and the molecular structure was 
verified by 1H-NMR and compared with the reported data. 
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A.2.3.  Synthesis of the RAFT Agent, 1,2;3,4-di-O-isopropylidene-6-O-acryloyl-!-D-
galactopyranose (Scheme 3.2) [2]  
To a 100-mL round bottom flask 1,2,3,4-di-O-isopropylidene-6-O-acryloyl-!-D-
galactopyranose (1.39 g, 5.20 mmol), basic alumina (2.44 g, 23.92 mmol), 20 mL of dry 
acetonitrile, and acryloyl chloride (2.26 mL, 27.04 mmol), were added dropwise.  After 
stirring under argon for 3 days at ambient temperature, the mixture was filtered through a 
thin layer of celite, and the solids were washed with 50 mL of acetonitrile.  The combined 
organic layers were concentrated under reduced pressure.  The resulting pale yellow 
residue was purified through a flash column using 1:2 ethyl acetate:hexanes as eluents, 
and its molecular structure was verified by 1H-NMR and compared with the reported 
data.  The desired RAFT agent was obtained with a yield of 100%.  1H-NMR (CDCl3, 
400 MHz) !: 1.44 (t, 12 H, J = 7.0), 1.60 (d, 12 H, J = 7.2), 4.12-4.22 (m, 8H), 4.44 (q, 4 
H, J = 7.2), 4.66 (q, 8 H, J = 7.0). The peak shifts were consistent with the structure and 
suggested that the compound was pure.  
 
A.2.4.  Synthesis of the Protected Sugar-Star Polymer, poly-(1,2:3,4-di-O-isopropylidene-
6-O-methacryloyl-!-D-galactopyranose) by MADIX/RAFT Polymerization (Scheme 3.2) 
The 1,2,3,4-di-O-isopropylidene-6-O-acryloyl-!-D-galactopyranose (3.11 g, 9.9 
mmol) was treated with basic alumina and 10 mL of dry ", ", "- trifluorotoluene in a 50-
mL round bottle flask.  The RAFT agent (0.054 g, 0.0622 mmol) was added to the 
solution, followed by the addition of AIBN (1.36 mg, 0.00827 mmol), and the reaction 
flask was placed on ice and purged with argon for 30 min.  The flask was then transferred 
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to a thermostatic oil bath at 70 oC for ca. 10 hrs.  The mixture was cooled in an ice bath 
and poured into cold diethyl ether to obtain the precipitate followed by concentration 
under reduced pressure.  The molecular structure and molecular weight of the resulting 
polymer were determined by 1H-NMR and size exclusion chromatography (SEC), 
respectively.  1H-NMR (D2O, 400 MHz) !: 1.29-2.05 (brs, 1 H), 2.17-2.74 (brs, 2 H), 
3.45-4.17 (brs, 6H), 5.26 (brs, 1 H). 
 
A.2.5. Deprotection Reaction to Form the Sugar-Star-Polymer, the Multi-Arm poly-(6-O-
methacryloyl-D-galactose) (Scheme 3.2) 
The poly-(1,2:3,4-di-O-isopropylidene-6-O-methacryloyl-"-D-galactopyranose) 
(500 mg) was dissolved in 100 mL of 90% formic acid. The solution was stirred at 60 oC 
for 24 hours.  The solution then was dialyzed (10 kDa MWCO dialysis tubing, Pierce, 
Rockford, IL) against distilled water for 2 days with water changes every 6 hours to 
remove the acid.  After dialysis, the resulting polymer was lyophilized to obtain the 
desired multi-arm poly-(6-O-methacryloyl-D-galactose) (Scheme 3.2).  1H-NMR (D2O, 
400 MHz) !: 1.29-2.05 (brs, 1 H), 2.17-2.74 (brs, 2 H), 3.45-4.17 (brs, 6H), 5.26 (brs, 1 
H). 
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A.2.6.  Modification of Multi-Arm poly-(6-O-methacryloyl-D-galactose) with Succinic 
Anhydride to Yield the Acid-Star-Polymers 
Polymers with increasing degrees of succination (20%, 40%, 60% and 90%) were 
generated by reacting the star poly-(6-O-methacryloyl-D-galactose) (100 mg) with 
succinic anhydride (20, 40, 60 and 90 mg, respectively) in 20 mL of dry dimethyl 
formaldehyde (Scheme 3.3). The mixtures were stirred at ambient temperature to form a 
homogeneous solution, followed by dropwise addition of 5 mL of dry pyridine.  After 2 
days, the solutions were dialyzed (10 kDa MWCO dialysis tubing) against 50% ethanoic 
water for 1 day followed by absolute ethanol for 1 day, with solvent changes every 6 hrs 
to remove the dimethyl formaldehyde, pyridine, and other small molecule impurities.  
The solvent of the resulting solution was removed under reduced pressure, which led to 
the desired sugar multi-arm polymers with increasing substitution degrees of carboxylic 
acids.  1H NMR (D2O, 400 MHz) !: 1.29-2.05 (brs, 1 H), 2.17-2.74 (brs, 2 H, methylene 
protons from the sugar polymer and the succinic acid portion overlapped), 3.45-4.17 (brs, 
6H), 5.26 (brs, 1 H). 
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